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Abstract 
 Active polymeric materials that alter shape in response to an external stimulus offer 
unique avenues for the design and study of dynamic structures. This research focused on 
developing elastomeric polymer composites with multiple functionalities by exploring the design 
and properties for various applications including controlled drug delivery and shape memory.  
 The first part of this dissertation describes the fabrication and characterization of a soft, 
elastomeric polymeric composite with inherent shape memory properties capable of localized, 
long-term tunable drug release. In Chapter 2, the fibers were loaded with a hydrophilic drug 
model, Rhodamine B, and embedded within a siloxane-based elastomeric matrix to form a 
composite, which is critical to regulating water transport from the environment to the fibers to 
liberate the drug. In vitro drug release studies were conducted in PBS under physiological 
conditions to evaluate the effect of drug concentration, fiber size, fiber crystallinity, drug loading 
and the addition of the crosslinked siloxane. The effect of the microstructural properties of the 
fibrous phase on drug release were explored and tuned through thermal treatment of the 
composite.  
 The findings from Chapter 2 were then applied to Chapter 3 for the development of a 
vascular graft with controlled and sustained nitric oxide (NO) releasing capabilities and suitable 
mechanical properties for the prevention of restenosis. To avoid the unwanted systemic side 
effects associated with a free radical such as NO, our approach delivered NO locally by 
supplying it from the vascular graft material. It was found that reducing the tin catalyst used for 
crosslinking the silicone constituent significantly improved cell viability, however, the NO 
interacted with the catalyst activity, affecting the silicone crosslinking reaction. The NO-
releasing composite was demonstrated to be a strong chemottractant to endothelial cells.  
 The next part of this research focused on the development of a shape memory elastomeric 
composite featuring thermoplastic fibers imbibed by polyanhydride-based elastomer. It was 
determined in Chapter 4 that the polyanhydride elastomer is capable of dynamic covalent 
exchange reactions at elevated temperatures among the network chains that allowed near-
complete reconfiguration of the permanent shape in the solid state. Together, these features were 
combined to create a shape memory elastomer capable of arbitrary programming of both 
temporary and permanent shapes. The degradation properties of this composite were then studied 
in Chapter 5 under in vitro conditions, where it was revealed that the degradation rate of the PAH 
matrix was strongly influenced by the selection of the composition of polymeric fibrous phase. 
The degradation of this composite was found to occur as a modified surface to bulk degradation, 
although the PAH by itself erodes heterogeneously. A hydrophilic model drug was incorporated 
in the fibrous phases and used to study the in vitro controlled release properties of these 
composites, where drug release correlated with the matrix degradation. The shape memory 
properties of these polyanhdride-based compositions were also examined. 
 Lastly, Chapter 6 investigated the design, fabrication, and characterization of a polymeric 
composite composed of oriented semicrystalline polymeric fibers embedded within a crosslinked 
epoxy matrix. This anisotropy enabled the construction of complex three dimensional geometries 
featuring latent mechanical programming. Rather than relying on specific molds to manipulate a 
new shape, this system capitalized on strain conditioning to influence a new structure. 
Additionally, we found that by compressing the oriented fibers of each ply during composite 
cure, the composites constructed from such plies exhibited actuation.  
The shape memory composites studied in this dissertation demonstrated the potential be 
broadly applicable from drug releasing implants, tailorable degradability, and the self-assembly 
of complex shapes. Chapter 7 provides some recommendations for future directions. 
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Chapter 1 
Introduction and Scope of Dissertation   
 
1.1 Polymers and Composites 
1.1.1 Polymers 
 Polymers are non-metallic macromolecules composed of smaller repeating units that 
form long molecular chains resulting in characteristically high molecular weights.
1
  One may be 
more familiar with polymers in its final, processed form, colloquially known as plastics. 
Considering that plastics, and therefore polymers, affect daily life, these materials encompass all 
industries including automotive, textiles, food packaging, electronics, and biomedical, and are 
also produced naturally as part of hair, spider silk, starch, and even DNA. Accordingly, polymers 
comprise a significant subject of research.  
 Polymers are either semi-crystalline or amorphous, a classification that forecasts material 
design and processability. Amorphous polymers do not possess crystallizable regions in their 
molecular arrangement, which is principally due to structural hindrances of the atoms along the 
polymer backbone, or the presence of irregularly ordered side groups that can lead to a 
randomized molecular organization, thus preventing crystallization. Consequently, amorphous 
polymers do not exhibit a melting transition temperature, but instead a glass transition 
temperature (Tg), above which the onset of coordinated chain motion softens the polymer, 
resulting in rubbery to viscous flow behavior; below Tg the polymer vitrifies.
2
 Crystallization of 
polymers occurs when the polymer chains are packed favorably to produce distinct oriented, 
folded lamellae, such as when cooling a polymer from a melt through the melting transition 
temperature (Tm) to below the crystallization transition temperature (Tc). Given that polymer 
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chains are inherently long, any misalignment of the chain folding prevents this regular packing, 
resulting easily into intermediary amorphous regions. In semicrystalline polymers, these regions 
tend to exist between the crystallites and will also exhibit a Tg, in addition to Tm and Tc. 
Intrinsically, the motion of the polymer chains, such as those produced by thermal or mechanical 
stimuli, greatly influence crystallization, and thus ultimately the mechanical behavior, opacity, 
and thermal properties. While crystallization generally occurs during cooling, it may also result 
from solvent evaporation or tensile strain and is further affected by the rate of each these 
variables as well as its molecular architecture.
3,4
   
 Polymers are also classified as either thermoplastic or thermoset, based on their ability to 
be processed thermally. Thermoplastics are those polymers, either amorphous or semi-
crystalline, that can reversibly melt and re-solidify. These types of polymers can also completely 
dissolve in a compatible solvent, which is useful for cast molding or electrospinning. Typical 
thermoplastics include linear polymers or those with simple branching such as polyethylene, 
polypropylene, and polystyrene. Poly(ε-caprolactone) is another example of a semicrystalline 
thermoplastic, whereas poly(vinyl acetate) is an amorphous thermoplastic, both of which are 
studied in more detail in this work.  Thermosets are distinct from thermoplastics in that these 
polymers cannot reversibly become a liquid once solidified following the cross-linking reaction 
of their polymer or monomer precursors, which typically originate in liquid form. Unlike 
thermoplastics, thermosets will not dissolve in a compatible solvent, but instead will swell to a 
maximum expansion governed by the extension of its cross-links. Examples are vulcanized 
rubbers, polyimides, epoxies, and silicones, the latter two, which are studied and discussed in 
further detail in this dissertation. 
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 In any design of a polymeric material, it is important to consider the variables that affect 
the processability, manufacturablity, and final properties of the material. As mentioned above, 
the thermal properties such as the glass, melting and crystallization transition temperatures will 
influence the conditions which will enable microstructural as well as macrostructural changes to 
the polymer, which are critical for determining molding or end-use parameters. Other thermal 
considerations include the temperature at which the polymer degrades, which can lead to 
irreversible damage of the primary covalent bonds and cause failure. In processing the polymer, 
solvent selection is dependent on the chemical properties and molecular weight of the polymer, 
where it is often followed that “like dissolves like”, referring to the similar polarities between the 
polymer and the solvent. Molecular factors include molecular weight and 
hydrophilicity/hydrophobicity. If different polymers are combined at the molecular level, the 
miscibility and resulting morphology are important features to investigate. Other design 
parameters to consider are the mechanical properties such as the Young’s modulus, storage and 
loss moduli, and strain-to-failure, which indicate the elasticity and structural capacities, and are 
also affected by molecular weight, cross-link density, microstructure and morphology. 
1.1.2 Polymer Composites 
 Composites are a class of engineering materials fabricated from a combination of other 
chemically or physically distinct materials such as the coupling of metals, polymers, and/or 
ceramics.
5,6
 Akin to polymers, composites are found in all industries. Some familiar examples 
are the combination of cellulose fibers and lignin that produce wood, and the dispersion of gravel 
and sand in cement that becomes concrete. Composites are especially advantageous when a 
single material cannot meet specific design criteria or when designing such a material requires 
 4 
costly and complicated customization. The goal of composite material development is to achieve 
a set of properties that each material alone cannot provide, offering additional degrees of 
freedom to devise new material properties. Hence, composites accrue new properties not 
observed in either component in isolation, producing a superior material. A polymeric composite 
resolves a major problem within polymer engineering by overcoming the inherent poor 
mechanical properties of polymers compared to metals, while taking advantage of the plethora of 
properties that polymers have to offer.
7
 Additionally, there is a significant benefit and cost-
savings in the ability to use commercially available or existing materials to create new materials 
while avoiding the need to invent new chemistry. 
 Many polymeric composites consist of a matrix and a reinforcing component. The matrix, 
which generally constitutes the largest volume fraction, serves as a continuous phase that encases 
the reinforcing (or dispersed) phase that is typically composed of fibers or spheres or particles.
6
 
As a result of these physical differences, the microstructure of composites are heterogeneous 
with a discrete interface between the continuous and reinforcing phases, often termed interphase; 
here, the transfer of stress from the “weaker” matrix to the “stronger” fibers occurs.
8
 
Additionally, the matrix also provides a protective barrier to the fibrous phase from the external 
environment.
9,10
 Most polymer composites are fabricated from thermoset matrices since the low 
viscosity of these monomers enables ease of traditional molding and greater fiber wetting, 
although thermoplastics matrices have become increasingly utilized.
7
 Some specific variables 
that affect composite properties include fiber or particle size, distribution and orientation. The 
composition of materials as well as the processing methods is a source of study and challenge for 
advanced applications. 
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1.2 Multi-Functional Materials 
 Many materials possess only one function beyond load bearing and often necessitate 
complementary materials or additional components in order to accommodate growing complex 
design requirements. Consequently, many researchers have sought to develop multifunctional 
materials, as these materials can simultaneously perform more than one independent functional 
capability beyond structural, such as self-healing, stimuli-responsiveness, self-cleaning, 
biodegradability, conductivity, biocompatibility, and drug delivery, with some even inspired by 
biology.
11-17 
These types of materials differ from systems containing multiple components in that 
they are more efficient in weight and volume, given that these materials are typically single 
constituents or, in most cases, composites with integrated properties.
18
 Composite materials 
providing multifunctionality can be classified based on the dimensional scale at which 
integration between its constituents occur, ranging from coating or lamination between phases, to 
incorporation at the molecular level. 
19,19
 Polymer composite materials lend themselves well to 
achieving multifunctionality considering they are the result of the synergistic combination of 
differing properties into a single, new material. This demand for multifunctionality has even 
influenced the expanding development of polymer composite materials.
20
 
 As is the case for polymers, the development of multifunctional materials also spans 
many industries including energy storage, healthcare, automotive, communications, and 
consumer goods. For example, to address the multifaceted requirements in healthcare, Neffe et 
al. developed a smart polymer that is thermally deployable to allow for minimally invasive 
surgery, with controlled drug release for infection management, and biodegradability to avoid 
additional surgery for implant removal.
21
 Other examples include incorporating battery function 
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within load-bearing structures, transparent polymer nanocoatings for lenses or windows, wear- 
and scratch-resistance, self-healing materials, and shape memory polymers, which are covered in 
several review articles on the subject.
17,20,22-25 
The following sections briefly describe several 
material functions studied in this dissertation. 
1.2.1 Biocompatibility for Biomedical Applications 
 Given that biological tissues are essentially polymers or composites, it is a natural 
tendency to for many researchers to utilize polymer composite materials for biomedical use.
26,27
 
Since these materials must come into contact with living tissue, whether externally or internally, 
it is crucial that these materials exhibit biocompatibility. A material is considered 
biocompatibility when it does not trigger an adverse biological response from the host cells or 
tissues, whether locally or systemically, under specific circumstances.
28
 Additionally, the 
material must also perform as intended, such that it has a positive therapeutic effect, rather than 
exist simply a non-toxic placement in the body. As such, biocompatibility is affected by the 
biological site selection, the intended function of the material, device size, and treatment 
duration. Several properties make up biocompatibility such as cytotoxicity, hemocompatibility, 
surface compatibility, and mechanical compatibility; these properties are typically first studied in 
vitro to screen new materials.  In polymeric materials, biocompatibility is affected by mechanical 
properties, surface energy, hydrophilicity/hydrophobicity, surface and bulk chemical 
composition, and surface topography, to name a few.
29-31 
Since composites are composed of 
more than one material, it is not sufficient to know the biocompatibility of each material, but to 
demonstrate both as a system.  
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 Biocompatible materials may be classified as biomaterials when used to supplant or 
support the function of human tissues.
32
 One of the biggest challenges in biomaterials research is 
matching the properties of soft tissues such as skin, arteries, cartilage, muscles, organ walls, and 
tendons. Mechanical compatibility with the host tissue of a biomaterial or device is important to 
prevent complications such as stress-shielding or thrombosis.
33,34
 Most biomaterials are polymer-
based, due to their low cost versatility and low modulus.. Polymer composites, such as those 
reinforced with fibers, offer tailorable tensile strength and functional microstructural properties, 
and are closer to mimicking the complex structures of native tissues, where a combination of 
collagen, elastin and fibronectin provide elasticity and tensile strength.
35
 Nevertheless, polymers 
and their composites are still limited in soft tissue applications due to poor strength and 
elasticity.
36
 
1.2.2 Degradation 
Degradable polymers are used in many biomaterials applications such as degradable 
implants, resorbable sutures, and, as further discussed in Section 1.4, a mechanism to control 
drug delivery. These polymers also find utility in environmental applications, where degradable 
consumer goods such as packaging and diapers can reduce environmental impact. Degradable 
polymers contain labile bonds in their chemical structure that upon contact with an aqueous 
environment, undergo hydrolytic cleaving of their chains. Degradation of polymers is classified 
as either surface/heterogeneous or bulk/homogenous degradation. As depicted in Figure 1-1, 
surface degradation occurs when the material loss is localized at the surface and is quicker than 
the rate of water diffusion, resulting in the polymer maintaining its overall geometry during 
degradation.
37
 In contrast, bulk degradation loses material through its matrix as water penetrates 
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through to its interior, and does not maintain its shape during degradation; most polymers are 
bulk eroding.
38
 Typical degradable biomaterials are based on homopolymers or copolymers of 
poly(glycolic acid), poly(lactic acid), polyesters, and  polydioxanones, bacterial-derived 
polymers, polyanhydrides, or natural polymers.
39,40
 Several variables affect the degradation 
properties beyond chemical composition such as whether the degradation products are acidic and 
cause autocatalysis, addition of any drugs or excipients, and even size and shape in the case of 
surface erosion. Chapter 5 further discusses and studies degradation. 
1.2.3 Controlled Drug Delivery 
Drug delivery is the supply and introduction of drugs in the body to treat diseases and is 
one of the most rapidly growing areas of biomedical engineering, encompassing many 
disciplines. A controlled drug delivery system is one where an active molecule is combined with 
a material.
41 
Familiar examples of drug delivery systems include tablets, creams, aerosols, 
liquids, and injections. The ideal drug delivery system would administer a drug at an optimum 
concentration that maximizes the therapeutic outcome without side effects, and maintains this 
efficacious concentration range for the duration of the treatment time.
42
 Toxicity occurs when the 
drug concentration is above the maximum therapeutic range, whereas a concentration below is 
ineffective. The challenge with conventional drug delivery systems, such as ingesting a tablet or 
administering an injection, is that while this enables immediate delivery of a therapeutic dosage, 
multiple administrations are required to maintain its therapeutic effects, particularly for those 
with  chronic conditions, which can be unwieldy, painful, difficult to maintain, and/or expensive, 
and decrease patient quality of life.
43 
Consequently, the study and development of controlled (or 
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sustained or prolonged) drug delivery systems target minimizing dosing frequency by providing 
a therapeutic concentration for an extended period of time.
44
  
Drug release systems are designed and structured as reservoir, hydrogel or matrix 
delivery systems. Reservoir delivery systems are constructed by sandwiching the drug between 
two or more layers of membrane material, typically a non-degradable, hydrophobic polymer.
41
 
Diffusion of the drug through the polymer membrane determines the drug release rate. Hydrogel 
drug delivery systems utilize cross-linked water soluble polymers that contain entrapped drugs 
with a release rate are influenced by the degree of swelling and diffusion of drug through the 
material.
45
 In a matrix delivery system, which is studied in Chapters 2 and 5, drugs are either 
dissolved or dispersed throughout the polymer bulk and rate limited by diffusion. Generally, 
drug release rate is limited by drug diffusion through the polymer and is affected by the diffusion 
coefficient of the drug, the chemical and structural properties of the polymer.  
Drug release systems are also characterized by their drug release profiles, which quantify 
the amount of drug released over time and fall into three main categories: controlled release, 
burst release, or pulsatile (cyclic) release.
44
 Drug release profiles are influenced by the mode of 
drug release and preferably follow zero-order release kinetics in order to maintain a constant 
drug concentration; however, first-order or variable release kinetics are more common and may 
be more desirable in certain applications.
44,46
 Polymer composite materials are a logical choice 
for drug delivery systems as these systems enable custom material property combinations that 
would tailor controlled release. Some of the variables to consider studying drug release include 
drug loading efficiency, ratio of drug to polymer, mechanical properties, surface chemistry, 
morphology, and polymer crystallinity. Polymer degradation can serve as another way to control 
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drug release, with surface erosion widely studied for drug release, since drug release profiles 
tend to be more constant, though in reality, drug diffusion from the bulk can also occur 
independent of the erosion front.
41
 
1.2.4 Shape Memory 
 Shape memory polymers (SMPs) are a category of mechanically active smart materials 
that can memorize a programmed temporary shape and return to its pre-programmed shape in 
response to external stimuli such as heat
47
, electricity
48
, ultrasound
49
, solvent
50,51
 and 
irradiation
52-55
  Thermally induced shape memory is the most widely studied system. SMPs have 
strong potential in biomedical applications such as by allowing bulky devices to become 
deployable following implantation through small incisions, self-tightening sutures in compact 
areas, artificial muscles, self-anchoring stents, and adaptable surfaces to direct cellular traffic, to 
name a few.
56,57 
Other applications include actuators, sensors, dimmable windows,
58,59
 smart 
textiles,
60,61
 and self-peeling adhesives.
62
 Several review articles discuss this topic in depth.
55,63
 
 In order to exhibit shape memory, polymers must contain a combination of molecular 
features such as crosslinks (i.e. covalent, physical, or ionic), which serve to determine and 
“memorize” the original, permanent shape. These crosslinks are typically produced during 
fabrication in a stress-free state and contain some degree of extensibility to enable macroscopic 
shape shifting. The temporary shape “programming” (or “fixing”) of SMPs originates from the 
physical immobilization of the crosslinked network. Specifically, this is accomplished by 
exposing the deformed shape through a thermal transition to enable reversible crystallization or 
vitrification transitions for thermally triggered shape memory systems. The recovery of a fixed 
shape back to its original shape is achieved by exposure to a temperature exceeding its melting or 
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glass transition temperatures to enable the molecular mobility back to its permanent shape. An 
example of one way shape memory is presented in Figure 1-2.  
1.3 Shape Memory Elastomeric Composite 
To address the deficits of many soft smart polymer systems, the Mather Research Group 
previously developed a shape memory elastomeric composite (SMEC).
[Luo 2009] 
The goal of this 
composite was to develop a soft and elastic shape memory material by combining two 
commercially available polymers. Thermoplastic poly(ε-caprolactone) (PCL) was electrospun 
into a porous, non-woven fiber mat. The fibers were then embedded into Sylgard 184, a cross-
linked polydimethylsiloxane matrix, which imparted elasticity and infiltrated the free space 
between the fibers. This system showed excellent shape memory performance, where the 
crystallizable PCL served as the switching phase and the crosslinks of the PDMS would serve to 
“remember” the original shape. This composite is advantageous structurally in that the fibrous 
structure imparts greater strength compared to PDMS due to its load distribution. The versatility 
of this system is that the properties are customizable by simply adjusting the fiber to matrix ratio, 
cross-link density of the matrix, fiber morphology or substituting the fibers or matrix with a 
different polymer with different properties. All of this utilizes much simpler chemistries and 
even commercially available materials. Rodriguez et al. later introduced anisotropy into this 
SMEC system, substituting the fibrous semicrystalline PCL phase with fibrous amorphous 
poly(vinyl acetate) PVAc.
64
 They found that in the case of aligned fibers, shape fixing became a 
function of fiber angle orientation. Onyejekwe studied adding a drug, however undesirable 
shrinkage occurred and the biocompatibility properties were deficient.
65 
In all of these studies, 
controlled drug delivery, biocompatibility, or degradation were not introduced into this system.  
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Outside of our group, several researchers have developed SMPs with additional material 
functionalities, though only few exhibit soft and elastomeric properties. For example, a SMP was 
developed by Wischke et al. to deliver a variety of model drugs that released over several 
months; however the Young’s modulus was greater than that required for soft tissue applications 
such as vascular grafts.
54
 Other drug-releasing SMPs were developed with soft, elastomeric 
properties comparable to native arterial tissue, however these materials have a biodegradation 
profile that falls short of that required for certain vascular applications such as arteriovenous 
access grafts, where mechanical stability is required over years instead of days or weeks.
66
 For 
example, Serrano et al. developed polydiolcitrate based shape memory soft elastomeric films 
capable of controlled drug release of up to 30 days of hydrophobic model drugs, however these 
polymers degraded within two months.
66
 A similar degradation profile was achieved by Kashif et 
al. by using a blended PCL/POSS nanocomposite also capable of shape memory, with controlled 
drug release; however, like others, their modulus was too stiff for soft tissue applications.
67
 In 
addition, these SMP systems do not use commercially available materials and instead require 
laborious custom polymer syntheses. In another instance, Wang and coworkers recognized the 
limited available elastomeric shape memory materials and sought to develop a shape memory 
composite with thermally-trigged self-healing capabilities. This was accomplished by combining 
two commercially available non-degrading materials, however was focused on non-medical 
applications.
68
 
1.4 Scope of Dissertation 
 This dissertation examines the design, development and properties of electrospun 
composites for various applications such as controlled drug delivery and shape memory. In 
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Chapter 2, a hydrophilic drug model is incorporated into an electrospun polyester fiber mat and 
its drug releasing properties were studied relative to the microstructure of the fibers. The drug 
release from these fibers embedded into a siloxane elastomer was also investigated. Chapter 3 
examines the applicability of this composite for use as a biomimetic vascular graft with the 
incorporation of a nitric oxide donor in the fibrous phase. The nitric oxide releasing properties 
were investigated and its impact on cell migration was evaluated. The mechanical and 
biocompatibility properties were studied relative to the design requirements for this medical 
device. Additionally, it was discovered that the tin catalyst affected cell viability and a maximum 
concentration was determined that preserved the mechanical properties. In Chapter 4 (adapted 
from Lawton et al.
69
), a fully degradable shape memory elastomeric composite was developed 
with the ability to reconfigure its original, permanent shape. This composite was composed of a 
simple polyurethane electrospun fibers embedded in a cross-linked polyanhydride matrix. 
Chapter 5 studied the degradation behavior of the polyanhydride-based composite developed in 
Chapter 4, comparing two different fibrous compositions as well as the drug releasing 
properties. Anisotropy of the polyester fibrous phase was introduced into a cross-linked epoxy 
matrix in Chapter 6, where dormant mechanically programmed shapes were investigated and 
reversible actuation was explored. Finally, a summary of the findings and conclusions of this 
work are presented in Chapter 7 with suggested directions for continued research. Additional 
work is included in the Appendix of this dissertation. 
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Figure 1-1. Example of erosion mechanisms in degradable polymers where (A) bulk 
(homogenous) erosion occurs throughout the polymer and (B) surface (heterogeneous) erosion 
degrades at the surface, while the sample maintains its shape and properties but deceases in size. 
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Figure 1-2. One way shape memory depicted (A) quantitatively and (B) morphologically.
53,55
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Chapter 2 
Shape Memory Elastomeric Composite with  
Controlled Drug Release of a Hydrophilic Drug Model  
 
2.1 Synopsis 
 
 In this chapter the fabrication and characterization of an elastomeric polymeric 
construction with inherent shape memory properties capable of localized, long-term tunable drug 
release of a hydrophilic drug model is described. This assemblage was fabricated using an 
electrospinning process to produce a micro-fibrous framework. The fibers were doped with a 
hydrophilic drug model, Rhodamine B, and embedded within a siloxane based elastomeric 
matrix to form a composite, which is critical to regulating water transport from the environment 
to the fibers to release the drug. In vitro drug release studies were conducted in PBS under 
physiological conditions to evaluate the effect of drug concentration, fiber size, fiber 
crystallinity, drug loading and the addition of the siloxane. We found that the integration of this 
elastomer can control the initial burst release commonly observed in many drug delivery devices 
and extend drug release. The effect of the microstructural properties of the fibrous phase on drug 
release were explored and tuned through thermal treatment of the composite. 
2.2 Introduction 
 
 The requirements for prosthetic implants are becoming increasingly more complex in 
order to meet the clinical demand of providing biomimetic materials. One approach has been the 
development of smart materials such as shape memory polymers (SMPs), which have been 
studied to address these needs by providing self-anchoring stents, minimally invasive surgery, 
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and even surfaces that can direct cellular traffic.
1,2 
SMPs are a category of materials that can 
memorize a temporary strain and return to its pre-programmed shape in response to external 
stimuli such as heat, electricity, ionic strength, and irradiation.
3-6 
While several groups have 
developed SMPs that can also provide drug delivery capabilities, only very few exhibit soft and 
elastomeric properties with a long-term, stable degradation profile. For example, a SMP was 
developed by Wischke et al. to deliver a variety of model drugs that released over several 
months, however the Young’s modulus was greater than that required for soft tissue applications 
such as vascular grafts.
78
 Another drug-releasing SMP was developed by Serrano et al., which 
exhibited soft, elastomeric properties comparable to native arterial tissue, however its 
biodegradation profile falls short of that required for certain vascular applications such as 
arteriovenous access grafts, where mechanical stability is required over years.
9 
 
 We have studied poly(ε-caprolactone)  (PCL) as a candidate for a drug carrier while 
imparting mechanical support and shape memory switching. PCL is a semicrystalline polyester 
currently approved by the Food and Drug Administration (FDA) for biomedical devices, with 
long term biodegradation of over two years.
10
  PCL is an attractive option for biomedical 
applications, particularly those requiring drug delivery,
11
 and many groups have studied PCL-
based fibers as a drug delivery vehicle; however typical release times are on the order of hours to 
a few days.
12-14
 Consequently, many efforts have been made to blend or chemically modify PCL 
with other components in an effort to improve the sustained drug release outcome, though these 
materials are limited to drug delivery only and do not also exhibit shape memory functionality.
15-
18
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 Our group has previously studied PCL and its mechanisms in formulating SMPs.  We 
have been able to fabricate soft elastomeric composites with shape memory abilities by pairing 
PCL electrospun fibers with a crosslinked vinyl-terminated polydimethylsiloxane (PDMS) 
matrix.
19
 In this composite, the fibers serve as the shape fixing phase via crystallization while the 
elastomeric matrix memorizes the permanent shape through its crosslinks, while imparting 
elasticity.  The shape memory properties were previously studied in our group and are exploited 
for surgical applications in Chapter 3; however, this composite’s ability to store and release a 
hydrophilic model drug has not been previously studied. 
 We conceived that this PCL/PDMS composite can be useful for soft tissue biomedical 
applications requiring controlled drug release of a hydrophilic drug, such as vascular prosthetics, 
considering that these polymers are stable in aqueous media and no short term degradation is 
expected.
20
 By incorporating a drug in the fibrous phase and then adding an elastomeric barrier, 
we hypothesized that the elastomer will regulate water transport to the drug-loaded fibers and 
control burst release while extending the overall drug release. Rhodamine B (RhB) was selected 
as the hydrophilic model drug to study this drug delivery system since it was easily soluble in 
water and cost-effective to model hydrophilic drug release. In this chapter, the effects of drug 
loading, morphology, polymer matrix, on drug release properties were investigated.  
2.3 Materials and Methods 
2.3.1 Materials 
Poly(ε-caprolactone) (70,000 – 90,000 g·mol–1), Rhodamine B (RhB), chloroform, 
tetrahydrofuran (THF), dimethylformamide (DMF)  and dibutyltin dilaurate were purchased 
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from Sigma Aldrich and used as received. Silanol–terminated polydimethylsiloxane (PDMS) 
(2000 cSt) and poly(diethoxysilane) were purchased from Gelest, Inc. 
2.3.2 Fabrication of RhB-Loaded Electrospun Fibers 
 Fibers were electrospun from PCL solutions ranging in concentration from 10 w/v % - 20 
w/v % homogenously mixed with RhB model drug, where higher concentrations of PCL were 
used to create larger fiber diameters. The RhB/PCL solutions were prepared by first adding 0.5 – 
1.5 wt % RhB relative to the total mass of PCL to a clean glass vial, followed by complete 
dissolution in a 4:1 THF:DMF solvent mixture. No RhB precipitation was observed in the 
polymer solution. The RhB/PCL solution was then transferred to a 10 ml syringe fitted with a 
blunt 22G needle tip. A syringe pump was used to supply a steady flow rate of 1.0 ml ∙ h
-1
 which 
was electrospun onto a grounded 50 mm diameter aluminum drum rotating at 400 rpm, at a 
distance of 7 cm from the needle tip to a negatively charged drum (-500 V) and an applied 
voltage of 11.5 kV. Following electrospinning, all fiber mats were dried at room temperature 
under vacuum (-30 mm Hg) for 48 h to remove any residual solvents prior to further use. 
2.3.3 Preparation of RhB-Loaded Fibrous Elastomeric Composite 
 A pre-polymer elastomer was prepared by mixing silanol-terminated 
polydimethylsiloxane (PDMS) with 3 wt% polydiethoxysilane (crosslinker) and 0.5 wt% 
dibutyltin dilaurate (catalyst). The electrospun RhB loaded PCL fiber mats were then coated by 
the PDMS mixture, followed by exposure to vacuum at room temperature for 15 minutes to 
enable thorough infiltration of PDMS within the fiber mat. Excess PDMS was removed from the 
surface using a spatula followed by a 72 h cure at room temperature in a desiccator. The 
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chemical structures of the composite components and PDMS crosslinking scheme are shown in 
Scheme 2-1. 
2.3.4 Morphological Characterization 
 A JEOL JSM-5600 scanning electron microscope (SEM) was used to visualize the 
samples with an accelerating voltage of 4 – 6 kV. Prior to imaging, samples were sputtered 
coated with gold for 45 s. Fiber diameter measurements were determined by taking a minimum 
of 50 measurements at five different locations using an image analysis software (version 1.46, 
National Institutes of Health). The average diameter and standard deviation were calculated 
using a minimum of 250 total measurements. Statistical significance was determined using a 
one-way analysis of variance (ANOVA) with a significance criterion of p < 0.05, using the 
Minitab software package. 
An Olympus BX51 optical microscope equipped with a hot-stage and temperature 
controller (Instec HCS402) was used to visualize the phase distribution of RhB in the PCL fibers. 
A RhB/PCL fiber mat sample was sandwiched between two glass slides and then placed on the 
hot stage maintained isothermally at 80 C to melt the fibers.  
The porosity (P),  of the electrospun fiber mats was calculated according to Eqn. 2-1 
below, where ρf is the measured density of the sample and ρ0 is the known density of pure PCL, 
which has a value in the literature of 1.145 g∙cm
-3
.
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The density of the fiber mat samples was 
determined by dividing the mass of the sample by its volume. A TA Instruments AR-G2 
rheometer fitted with parallel plates was used to measure the thickness of each sample for 
improved accuracy, given the compressible nature of the samples, where the slightest change in 
force can be readily detected to avoid deforming the sample during the measurement.  
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𝑃 (%) =  1 −
𝜌𝑓
𝜌0
 × 100 % (2-1) 
2.3 5 Thermal Characterization 
Differential Scanning Calorimetry (DSC) was performed using a Q200 manufactured by TA 
Instruments, Inc. Samples weighing 2.5 – 4.0 mg were sealed in Tzero aluminum pans and 
heated from -60C to 120C at 10C ∙ min
-1
. The melting enthalpy was calculated from the first 
heating cycle by integrating the melting peak, and was used to determine the crystallinity of PCL 
in the elastomeric composite in their as-manufactured state according to: 
𝐶(%) =  
∆𝐻𝑚
∆𝐻𝑓
0  × 100 % (2-2) 
where c is the degree of crystallinity, fH  is the heat of fusion measured by DSC and 
0
fH is 
the heat of fusion of crystalline PCL, with a literature value of 139 J ∙g
-1
.
22
 The melting enthalpy 
was calculated from the second heating cycle by integrating the melting peak, and was used to 
determine the fraction of PCL (𝑊𝑃𝐶𝐿) in the elastomeric composite by comparing the degree of 
crystallinity according to: 
𝑊𝑃𝐶𝐿(%) =  
∆𝐻𝑚
∆𝐻𝑚,0
 × 100 % (2-3) 
where Hm  is the melting enthalpy of the composite measured by DSC and Hm,o is the melting 
enthalpy of  pure electrospun PCL, as determined by DSC. 
 For completeness of materials characterization, the thermogravimetric analysis (TGA) 
was conducted by loading samples weighing 5 – 10 mg into a TA Instruments Q500 
thermogravimetric analyzer. The samples were heated to 600 C at 20 C min
-1
 under nitrogen 
purge.  
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2.3.6 In Vitro RhB Release 
  Rectangular samples of 1 cm x 2 cm were placed in a known volume (4 – 10 ml) of 
phosphate buffered saline (PBS, pH 7.4) in sealed glass vials. The vials were placed in a thermal 
shaker at 37C to simulate physiological conditions. At different time intervals, a 150 uL aliquot 
of the PBS media was sampled from the vial and the RhB concentration was measured in a 96-
well plate using spectrophotometry (Biotek® Synergy 2 Microplate Reader) at a wavelength of 
553 nm (peak absorbance for Rhodamine B). The concentration of RhB was determined using a 
standard curve. After each time point, the PBS media was completely replaced with fresh PBS of 
a known volume to simulate in vivo “sink” conditions. Three replicates at each time point were 
used and an average and standard deviation is reported. The cumulative amount of RhB released 
was calculated and plotted as a function of time.  
The theoretical total encapsulated moles of RhB in the fibers, 𝑛𝑇, was calculated for each 
sample according to Eqn. 2-4 below: 
𝑛𝑇  =  
𝑥𝑖𝑚𝑖
𝑀𝑅ℎ𝐵
  (2-4) 
where 𝑥𝑖   is the fraction the RhB mass relative to the PCL mass for sample i, mi is the mass of the 
electrospun fibers containing both PCL and RhB, and 𝑀𝑅ℎ𝐵 is the molecular weight of RhB, 
which is 479.01 g ∙ mol
-1
. The cumulative percent of RhB released (D) was calculated according 
to Eqn. 2-5 below: 
𝐷𝑅ℎ𝐵(%) =  
∑ 𝐶𝑖𝑉𝑖
𝑡
𝑖=1
𝑛𝑇
 × 100 % (2-5) 
where 𝐶𝑖   is the molar concentration of RhB at time point i, 𝑉𝑖 the volume of the release media 
relative at each time point, up to time t.  
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2.3.7 Thermal Treatment to Induce Crystallization 
 Fibrous samples were thermally treated prior to drug release by placing “webs” (non-
woven films) of them in an isothermal oven at 45 C for 10 days. These conditions were selected 
to remain below the melting transition of PCL to preserve the fibrous morphology. Prior testing 
indicated that this longer annealing time enabled considerable changes in the crystalline content. 
The composite samples were subjected to a stepped thermal treatment in an isothermal oven by 
first exposing to 90 C for 20 min, immediately followed by placing in another oven at 50 C for 
1 h. 
2.3.8 Mechanical Properties 
 Tensile mechanical properties were studied by punching samples into a dog bone 
geometry (ASTM Standard D638-03 Type IV, scaled down by a factor of 4), and loading onto a 
Test Resources Model 100P Universal Testing Machine equipped with a 24 N load cell. The 
samples were stretched at a rate of 33 μm s
-1
, and engineering stress-strain curves were used to 
determine Young’s modulus, strain-to-failure, and tensile strength. Five samples of each type 
were tested and an average and standard deviation are reported for each sample type. 
2.4 Results 
2.4.1 Fiber Characterization and Composite Morphology 
 The SEM micrographs in Figure 2-1 reveal that a range of increasing fiber diameters was 
produced by electrospinning with an increasing concentration of PCL in the solvent, as was 
expected. The surface of the fibers appeared smooth and did not appear altered by the presence 
of RhB. The resulting fiber diameters ranged from 0.23 μm ± 0.13 μm to 1.29 μm ± 0.63 μm. All 
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fiber diameter populations shown in Figure 2-1 were statistically significantly different at the 95 
% confidence interval. The porosity of the fiber mats generally increased with increased fiber 
diameter, as was anticipated (not shown). Generally, an optimum porosity is necessary for 
controlled drug release, where if the samples are too porous, too much drug may be released too 
quickly.
23
 No obvious RhB crystals were observed on the surface for any of the fiber samples. 
Figure 2-2 shows that the RhB distribution in the fibers is heterogeneous, as evidenced by 
regions of light and dark pink, indicative of the immiscibility of RhB in PCL. The air bubbles in 
Figure 2-2 formed during melting of the fibers and originated from the empty voids originally 
between the fibers. Figure 2-3(A) shows the SEM micrographs of the surface of PCL fibers 
containing 0.5% RhB and post-infiltration of the PDMS elastomer. The cross-section of the 
composite, as seen in Figure2-3(B), reveals that the PDMS completely encapsulated the fibers, 
while occupying the voids within the fiber mat. Similar results were found for a higher 
concentration of RhB (not reported). 
2.4.2 In Vitro RhB Release from PCL fibers 
Figure 2-4A summarizes the RhB release from various fiber diameters of electrospun 
PCL. Surprisingly, there was no observed correlation between the size of the fiber and burst 
release, duration of release, and drug entrapment (unreleased drug), indicating that another factor 
influenced the drug release characteristics. The total amount of RhB released at 48 h relative to 
fiber diameter and sample porosity is compared in Figure 2-4B, where neither variable 
demonstrated an impact on RhB release. All samples showed a similar release pattern, with an 
initial burst release within the first 3 h, followed by a plateau of either no or very slow release. 
Only the smallest diameter sample of 0.23 μm ± 0.13 μm exhibited near complete release of 
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RhB, with the highest burst release of 93 % at 48 h, whereas the largest diameter of 1.29 μm ± 
0.63 μm showed the slowest and least amount of release at 45 % at 48 h; however, the 
correlation did not continue with the intermediate fiber diameters. 
2.4.3 Thermal Characterization and RhB Release 
A clear melting transition was observed for all RhB/PCL electrospun samples as was 
expected due to the semicrystalline nature of PCL as seen in Figure 2-5A. When compared with 
the results of Figure 2-4, described above, it was observed that the amount of RhB released 
increased with increasing melting temperature and enthalpy, as shown in Figure 2-5B and 
tabulated in Table 2-1. The relative degree of crystallinity based on the first heating cycle, 
showed a positive correlation with the amount of RhB release and no clear trend with fiber 
diameter. The variation seen here may be due to the differences in time on the bench at room 
temperature (aging time) before testing, which was not controlled in this study. This is 
particularly possible since PCL features a subambient glass transition temperature (Tg ~ -60 
o
C). 
The melting transition for RhB was not visible since it occurs at ~211 C, which is also its 
decomposition temperature and therefore its crystalline state in the fibers could not be 
determined thermally. 
2.4.4 RhB Release from Thermally Treated Fiber Mats 
 A separate series of experiments was conducted to promote crystallization, purposefully, 
and study the RhB release from PCL fibers at two drug concentrations, 0.5 % and 2.0 % RhB in 
PCL. In this study, the fiber diameters of the two samples were not significantly different, in 
order to isolate the PCL crystallization effect on drug release. The resulting fiber diameters were 
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1.3 μm ± 0.9 μm and 1.2 μm ± 0.4 μm for the 0.5 % RhB/PCL and 2.0 % RhB/PCL samples, 
respectively. Here, the electrospun fibers were placed in an isothermal oven for 10 days at 45 C 
to promote increasing completion of PCL crystallization while preventing melting of the fibers. 
The results in Figure 2-6 show that applying an annealing treatment to the fibers caused a 
decreasing shift in RhB release, which was more pronounced at the higher RhB concentration, 
where a total of only 25 % of RhB was released following annealing, compared to the 51% level 
for the as-electrospun case. In comparison, the low concentration samples showed only a ~10 % 
reduction of RhB release following crystallization. The DSC thermograms in Figure 2-6B 
verified that the thermal treatment did, indeed, increase crystallinity. It is further interesting to 
note that while the changes were slight, the influence on drug release was significant and 
opposite compared to the trend for as-electrospun samples where differences in crystallinity were 
accompanied by other sample variations. 
2.4.5 RhB Release from PCL/PDMS Composites 
 The RhB release from the PCL/PDMS composite is shown in Figure 2-7 for a 
concentration of 0.5 % RhB and compared to drug release from the parent fiber mat (no PDMS), 
as-electrospun. The PDMS matrix greatly extended the RhB release compared to the quick burst 
release detected for the fiber mats. By 24 h, the fibrous samples had completed release of 66 % 
of the total theoretical RhB concentration. While the fibrous samples contained, apparently, a 
significant amount of entrapped RhB, most of the observed release occurred within the initial 
two hours (60 %). In contrast, the 0.5 % RhB/PCL/PDMS composite extended the burst release 
from 2 h to 48 h and appeared to liberate more RhB from the fibers such that approximately 95 
% of the RhB was released after seven days with near completion at 14 days. We attributed this 
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behavior to the full wetting of the fibers by the PDMS, which created additional pathways for 
diffusion otherwise blocked by trapped air between the fibers. The release of RhB from the fiber 
mats can be followed visually over time by witnessing the color change, which begins a dark 
pink and gradually becomes white as the RhB is leached into the media that in turn absorb the 
pink color (Figure 2-8).  
2.4.6 RhB Release from Thermally Treated PCL/PDMS Composites 
 Following the results in the sections above, a separate series of experiments was 
conducted to investigate the effect of the crystalline properties of PCL on the release of RhB 
from the PCL/PDMS composite. Unlike the fibrous samples, complete melting of the PCL phase 
could be performed in the composite samples since the fibrous morphology would be preserved 
by the surrounding crosslinked PDMS matrix. Thus, a stepped thermal treatment of 90 C / 20 
min followed by 50 C / 1 h – melting the fibers – then cooling to room temperature for 15 min 
was implemented to induce complete recrystallization of the 0.5 % RhB/PCL/PDMS fibrous 
phase; for this experiment, the fiber diameter and fiber content were verified to be constant 
between samples. The resulting RhB release in Figure 2-9A shows that a 0.7 J/g increase (~18% 
increase) in first heat enthalpy of fusion produced a significant decrease in the RhB release from 
the more crystalline composite. In particular, 22 % less RhB was released at 48 h and this 
difference was generally maintained for the remaining four days of the testing period. These 
results are consistent with the thermally treated RhB/PCL fiber mats in Section 2.4.4, where a 
small increase in PCL crystallinity led to a marked decrease in RhB release. The DSC first heat 
thermograms in Figure 2-9B verify the increase in enthalpy of fusion for the melting peak 
following PCL stepped recrystallization. Interestingly, however, the melting point was lowered. 
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This decrease in the melting transition temperature may be due to the formation of more 
homogenously sized distribution of crystallites, and likely smaller average size, following 
recrystallization from the PCL melt, which is further evidenced by the narrower melting peak. 
Detailed x-ray scattering analysis is needed to verify this explanation. 
2.4.7 Mechanical Properties 
 The tensile mechanical properties for the composite are shown in Figure 2-10 and 
summarized in Table 2-2 and compared to its individual components. The addition of the RhB 
did not affect the mechanical properties in any significant manner (tensile data of samples with 
RhB not shown). The Young’s moduli and strain-to-failure of the composite samples ranged 
from 2.7 MPa ± 0.6 MPa to 5.0 MPa ± 0.6 MPa, and 460 % ± 60 % to 640 % ± 120 %, 
respectively, across varying weight fractions of PCL in the composite ranging from 5.9 wt% to 
15.6 wt% (Table 2-2). No correlation was observed between PCL fiber content in the composite 
and the Young’s modulus or strain-to-failure, where both features were between that of the 
cross-linked PDMS film and electrospun PCL, as was expected from a biphasic composite. Only 
the Young’s moduli for the composites containing 7.9 % and 8.5 % fibers showed a statistically 
significant difference (~ 1 – 2.3 MPa) from the rest of the groups. The composites containing 6.6 
% and 15.6 % were not statistically different from each other, but statistically different from the 
5.9 % and 11.4 % groups. The composite samples containing 5.9 % fibers showed a statistical 
increase in strain-to-failure from those groups containing 6.6 % and 7. 9 % fibers, which were 
not statistically different from each other; this difference was by approximately 160 – 180 % 
strain. We observed that the shape of the stress-strain curves of the composite appeared to evolve 
from one that is more linear (Figure 2-10A) to containing a toe region (Figure 2-10D-F).  
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Although the appearance of a toe region became more prominent with increasing PCL fiber 
content, the Young’s moduli and % elongation values did not appear to approach that of PCL 
during this growth. 
2.5 Discussion 
 The motivation of this study was to investigate the controlled release of a hydrophilic 
drug from a soft, elastomeric shape memory composite. Rhodamine B (RhB), was selected as the 
model drug since its hydrophilic character (solubility of ~8 mg/ml)
24
 is akin to another drug 
molecule we are also interested in studying. More specifically, the controlled release from a 
hydrophilic nitric oxide donor molecule incorporated into this composite is later examined in 
Chapter 3. The challenge with any nitric oxide donor is that drug release is typically indirectly 
measured and the nitric oxide itself is highly reactive; therefore the use of a model drug provides 
a low cost alternative to develop this material as a candidate for controlled release of nitric oxide 
as well as other hydrophilic drugs. The ease with which RhB release can be directly quantified 
and visually verified (Figure 2-8) is of great advantage for investigating the impact of different 
processing factors on the hydrophilic drug release from this composite, resulting in translatable 
findings. As such, we aimed to systematically study the effect of drug loading, fiber size, and 
crystallinity on drug release from our composite material. 
 It has been demonstrated that drug release can be extended by increasing the diameter of 
electrospun fibers,
25
 though for semicrystalline drug carriers, the dependence of drug release on 
vehicle size becomes more complex.
24 
In our investigation, the RhB release did not strongly 
correlate with fiber size (Figure 2-4), but showed a strong dependence on PCL crystallinity. For 
untreated electrospun fibrous samples, we observed an emerging trend where more RhB was 
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recovered for those samples exhibiting greater PCL crystallinity (Figure 2-5). We noted that the 
sample with the fastest drug release rate exhibited a double endothermic peak, indicating that in 
addition to greater crystallinity, the crystalline microstructure likely contained various lamellar 
thickness populations, though additional testing is required to determine the impact of crystallite 
polydispersity on drug release.
26,27 
The crystallinity of a polymeric vehicle is an important factor 
in drug delivery as it can limit the diffusion of water transport into the polymer bulk and hence, 
the drug release and drug retention within the fibers.
28
 Specifically, water transport through PCL 
occurs through the amorphous regions of the polymer, thus circumventing the crystalline areas, 
which has been used by others as a strategic advantage for controlled release.
13
 Nonetheless, the 
crystallinity of PCL is an important feature for the shape memory polymer feature of this 
composite.
19
 In light of these observations, we postulated that the growing crystalline front 
during electrospinning expelled the RhB toward the fiber surface during fiber formation, thereby 
enabling faster and more complete leaching of RhB. We did not directly observe RhB crystals on 
the fiber surface. This may be due to small crystal size, unresolved by light microscopy, or due to 
the drug being buried just beneath the surface and therefore easily accessible to the diffusing 
external aqueous media.  
 Polymer fibers have been shown to exhibit distinct morphological differences across the 
fiber cross-section, such that a “skin-core” structure is formed.
29,30
 In this configuration, the 
microstructure of electrospun semicrystalline fibers, such as PCL, tend to organize such that the 
amorphous phase is contained within the fiber core enveloped by a crystalline “skin” or sheath. 
Here, decreasing the fiber diameter results in increasing the crystallinity.
31 
We hypothesized that 
the addition of a hydrophilic molecule, such as RhB, to the PCL fiber would result in phase 
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separation, and drive the dispersion of RhB beneath this crystalline sheath toward an amorphous 
core, as depicted schematically in Figure 2-11. We further theorized that increasing this sheath 
thickness, such as by a post-electrospinning heat treatment, would reduce the rate and 
completeness of RhB release. Additionally, we postulated that the presence of trapped air 
between the fibers limited the diffusive pathways that promoted drug entrapment. 
 To test this hypothesis, we conjectured that by annealing the fiber mats, to just below the 
melting transition (to maintain the fibrous structure), the RhB release could be controlled by 
altering the PCL crystalline microstructure. Following heat treatment, the fiber mats showed an 
increase in the melting enthalpy for two different RhB concentrations. Consistent with our 
hypothesis, we observed that increasing the crystallinity of the RhB doped fibers substantially 
decreased both the immediate burst and overall drug release. This effect was more pronounced in 
the fibers containing a greater concentration of RhB, where not only was the total amount of 
RhB released halved, the increase in crystallinity following annealing was also greater, despite 
exhibiting a lower initial melting enthalpy. These results suggest that the fiber crystallinity is 
potentially a much greater influence on hydrophilic drug release from PCL than fiber diameter. 
Furthermore these results indicate that there must be a critical RhB concentration in the fibers 
below which the influence of thermally induced crystallization becomes negligible, and a high 
recovery of drug can be expected, similar to the effect of decreasing fiber diameter. A separate 
study would be required to determine this critical concentration by testing drug release from a 
series of RhB concentration in electrospun PCL. Considering that the polymer/drug solution is 
supplied as a single, homogeneous phase during electrospinning, we assumed the differences in 
the surface energy of hydrophilic (higher surface energy in air) RhB would likely position the 
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drug in the more amorphous core of the hydrophobic PCL fibers during phase separation. We 
suspected that the dispersion of RhB in the fiber core is more uniform at lower concentrations, as 
enhanced molecular dispersions between the drug and polymer tend to occur in the amorphous 
regions.
32
 We also note that any entrapped drug would be liberated long term (over two years) 
due to the hydrolysis and enzymatic degradation of the PCL chains in vivo, although partial 
release does not necessarily indicate inadequate bioactivity.
33,34
 
 The addition of the PDMS elastomeric matrix to the PCL fibers served to prolong and 
increase the totality of RhB release. Comparing the drug release of the composite to that of the 
bare fibers, sustained drug release was extended by approximately 16 days, where most of the 
RhB discharge occurred within approximately two hours. The PDMS matrix provided a 
diffusion-limited water transport from the external aqueous environment to the drug loaded 
fibers, thus preventing immediate dissolution of RhB to the aqueous media. Although PDMS is 
hydrophobic, it is also permeable to water.
35
 When compared to the fibrous samples, the PDMS-
based composite did not exhibit a quick, spontaneous release; rather a sustained initial release 
which was steadily extended from 2 h to 48 h. We observed that the final cumulative total RhB 
released was greater in the composite than in the fibrous samples. We hypothesized that the 
wetting of the fibers by PDMS displaced air that may otherwise block RhB release thus enabling 
further release of any RhB buried within the PCL fibers, though further investigation is merited. 
 Taking into account the large of effect of the PCL microstructure on RhB release, we 
contemplated complete recrystallization of PCL within the PCL/PDMS composite. This was 
possible since the crosslinked PDMS would retain the percolating channels of the electrospun 
fibers following melting of PCL, which is one of the central principles of imparting shape 
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memory behavior to this material. We observed that following slow recrystallization after 
complete melting of PCL, the RhB release was significantly less for the more crystalline 
samples, which was consistent with what we observed for the annealed fibrous study described 
above (Figure 2-6), consequently providing another strategy in addition to fiber diameter to 
control RhB release, and further supporting our skin-core microstructural assumption. 
 As has been studied in previously in our group, the combination of PCL and PDMS 
provide unique properties not present in either constituent alone. The percolating PCL fibers 
impart significant strength not present in the PDMS elastomer, which is ideal for load bearing 
applications, while the PDMS imparts elasticity, allowing for the ability to match the Young’s 
modulus of soft tissues such as skin, blood vessels, muscle and cartilage.
36
 The emergence of a 
toe region, which produced “J-shaped” stress-strain curves, is an interesting feature resonant of 
native soft tissues containing hierarchical components, differing from hard tissues.
37
 Analogous 
to our composite material, soft tissues are fiber-reinforced, composed primarily of collagen and 
elastin, which are the load-bearing and elastic components of soft tissues such as tendons, 
ligaments, arteries.
38,39
 Considering that the fibrous PCL phase is also load bearing, we postulate 
that at low strains the stress corresponds to macroscopic stretching of the PDMS crosslinks and 
slippage of the PCL fibers past each other in the toe region. Upon additional stress, the fibers 
begin to orient in the tensile direction and elongate, until plastic deformation sets in at higher 
strains and rupturing of the PDMS crosslinks, leading to ultimate failure. We observed that the 
toe region became more apparent with an increase in percentage of the PCL phase, where 
samples featuring 8 % or more of PCL exhibited this exponentially shaped curve. 
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2.6 Conclusions 
An elastomeric shape memory composite containing a hydrophilic model drug was 
successfully prepared by embedding drug loaded semicrystalline PCL fibers within a crosslinked 
PDMS elastomer. Controlled drug releasing properties were demonstrated, where it was 
determined that the crystallinity of the fibrous phase had a greater effect on drug release than did 
fiber diameter. The crystallization mechanism determined whether the microstructural properties 
increased or decreased drug release. We postulated that growing crystalline front during fiber 
pushed the drug toward the fiber surface leading to quicker and total release, whereas post-fiber 
formation crystallization was distinct and served to drive the hydrophilic drug toward more 
amorphous fiber core, away from the growing crystalline sheath. This migratory behavior of the 
hydrophilic drug within the hydrophobic semicrystalline PCL fibers was explained to be a result 
of phase separation. Moreover, the tensile mechanical properties demonstrated that this 
composite was an excellent candidate for soft tissue applications due to its elasticity, low 
modulus, and biomimetic multi-stage load bearing response typically associated with native soft 
tissues. 
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Scheme 2-1. Chemical structures of (A) poly(ε-caprolactone) and (B) Rhodamine B, and (C) 
synthesis of cross-linked silanol-terminated PDMS. 
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Figure 2-1. Scanning electron microscopy micrographs of PCL fibers containing 0.5 wt % RhB 
with an average fiber diameter of A) 0.23 μm ±  0.13 μm, B) 0.41 μm ± 0.23 μm, C) 0.50 μm ± 
0.24 μm, D) 0.61 μm ± 0.34 μm, E) 0.91 μm ± 0.40 μm, and F) 1.29 μm ± 0.63 μm.  Fiber 
diameter are reported as mean ± standard deviation for n > 250 fibers (p < 0.05). 
 
  
10 μm
A B C
D E F
Fiber Diameter ( m)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
C
o
u
n
t
0
50
100
150
200
250
Fiber Diameter ( m)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
C
o
u
n
t
0
50
100
150
200
250
Fiber Diameter ( m)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
C
o
u
n
t
0
50
100
150
200
250
Fiber Diameter ( m)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
C
o
u
n
t
0
50
100
150
200
250
Fiber Diameter ( m)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
C
o
u
n
t
0
50
100
150
200
250
Fiber Diameter ( m)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
C
o
u
n
t
0
50
100
150
200
250
 46 
 
 
Figure 2-2. Optical microscopy at two magnifications of 2 % RhB/PCL fibers melted at 80 C. 
Letters denote areas of light (L) and dark (D) pink regions indicating low and high 
concentrations of RhB.  White regions are air pockets formed during melting, as marked by an 
asterisk. 
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Figure 2-3. Representative scanning electron microscopy micrographs of RhB/PCL-PDMS 
composite showing the (A) surface and (B) cross-section. 
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Figure 2-4. (A) Cumulative RhB release from electrospun 0.5 % RhB/PCL fibers of various 
diameters and (B) a comparison of the cumulative RhB release at 48 h with fiber morphology. 
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Figure 2-5. First heat DSC thermograms of various fiber diameters of electrospun PCL 
containing 0.5% RhB in comparison to amount of RhB released at 48 h. 
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Table 2-1. DSC thermograms of various fiber diameters of electrospun PCL with 0.5 wt % RhB. 
 
Fiber 
Diameter 
(μm) 
RhB 
Release at 
48 h (%) 
H
m,1
a
 H
m,2
b
 T
m,1
a
 T
m,2
b
 H
c,1
a
 T
c,1
a
 χ
1
a
 
 
(%) (J/g) (J/g) (°C) (°C) (J/g) (°C) 
1.29 45.3 61.1 51.4 58.0 56.5 48.7 33.1 44.0 
0.41 50.7 68.5 52.9 60.8 57.7 50.3 32.2 49.3 
0.61 66.5 69.6 54.6 60.0 59.8 50.1 32.0 50.1 
0.50 79.4 69.9 50.2 60.9 57.7 51.2 32.3 50.3 
0.91 82.7 69.7 46.3 61.2 58.9 48.6 32.0 50.1 
0.23 93.3 72.4 54.3 60.7 58.6 52.5 31.7 52.1 
a
Determined from the first heating cycle. 
b
Determined from the second heating cycle. 
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Figure 2-6. (A) Controlled RhB release results and (B) thermal characterization comparing drug 
release performance following annealing of two concentrations of RhB electrospun in PCL 
fibers. 
Time (h)
0 10 20 30 40 50
%
 C
u
m
u
la
ti
v
e
 R
h
B
 R
e
le
a
s
e
0
20
40
60
80
100
2% RhB/PCL (As electrospun) 
2% RhB/PCL (Heat treated)
0.5 % RhB/PCL (As electrospun)
0.5 % RhB/PCL (Heat treated)
H
m
 = 64.0 J/g 
H
m
 = 67.9 J/g 
H
m
 = 59.8 J/g 
H
m
 = 67.1 J/g 
A
Temperature (
o
C)
-40 -20 0 20 40 60 80 100
H
e
a
t 
F
lo
w
 (
E
x
o
 U
p
)
2 % RhB/PCL (As electrospun) 
0.5 % RhB/PCL (As electrospun)
2 %RhB/PCL (Heat treated) 
0.5 % RhB/PCL (Heat treated)
1 W/g
10 
o
C min
-1
T
m
 = 58.1 
o
C
T
m
 = 58.0 
o
C
T
m
 = 61.6 
o
C
T
m
 = 67.5 
o
C
B
 52 
 
 
Figure 2-7. Comparison of RhB release from 0.5 % RhB/PCL (fibers only) and 0.5 % 
RhB/PCL/PDMS (composite) in PBS at 37 C for samples fabricated from the same parent fiber 
mat. 
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Figure 2-8. Representative samples of (A) 1.5 % RhB/PCL fiber mat and (B) 1.5 % 
RhB/PCL/PDMS composite after several time points of drug release in PBS at 37 C. Color loss 
is due to the release of RhB from the fibers into the surrounding media. 
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Figure 2-9. (A) Controlled RhB release results and the (B) corresponding thermal 
characterizations comparing drug release performance following thermal treatment of the 
PCL/PDMS composite. 
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Figure 2-10. Tensile  stress-strain curves for the PCL/PDMS composite at various fiber fraction 
values. 
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Table 2-2. Summary of tensile mechanical properties of the PCL/PDMS composite. 
 
Sample 
Fiber 
Content  
(%)
a
 
Young’s 
Modulus 
(MPa) 
Elongation 
(%) 
PCL/PDMS 5.9 2.7 ± 0.6 640 ± 120 
6.6 3.8 ± 0.9 460 ± 60 
7.9 5.0 ± 0.3 480 ± 70 
8.5 5.0 ± 0.6 580 ± 120 
11.4 3.4 ± 0.9 610 ± 110 
15.6 4.2 ± 0.6  500 ± 30 
Electrospun PCL 100 7.1 ± 2.9 1300 ± 140 
PDMS N/A 0.4 ± 0.01 330 ± 50 
  a
Determined by DSC 
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Figure 2-11. Phase separation between hydrophilic model drug Rhodamine B within the PCL 
fiber. 
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Figure 2-12. Thermogravimetric characterizations of the (i) 0.5 % RhB/PCL, (ii) 1.5 % 
RhB/PCL, (iii) PDMS, and (iv) 1.5 % RhB/PCL/PDMS composite. 
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Chapter 3 
Nitric Oxide Releasing Shape Memory Elastomeric Composite  
for Vascular Graft Applications 
 
3.1 Synopsis 
 
The development and characterization of a soft, elastomeric composite with controlled 
and sustained nitric oxide (NO) releasing capabilities for the prevention of restenosis is presented 
in this chapter. To avoid the unwanted systemic side effects associated with a free radical such as 
NO, our approach delivers NO locally to the injured site by supplying it from the vascular graft 
material. Under in vitro physiological conditions, the production of NO from the composite was 
studied for several weeks, demonstrating that the addition of elastomeric matrix PDMS and 
adjusting the drug content served to best produce controlled and sustained release. The 
composite material exhibited suture retention strength comparable to native human arterial tissue 
and sustained elevated internal pressures in excess of physiological levels. The performance of a 
vascular graft implant is also dependent on its biocompability. Accordingly, a cytocompability 
study was conducted on the NO-releasing composite materials developed in Chapter 2, 
revealing that reducing the tin catalyst used in crosslinking PDMS significantly improved cell 
viability; however, the NO interacted with the catalytic activity, influencing the silicone 
crosslinking reaction. The NO-releasing composite was a strong chemottractant to endothelial 
cells. This material is a good candidate for vascular prosthetics. 
3.2 Introduction 
 End-stage renal disease affected approximately 350 million people in 2013 in the United 
States alone.
1
 Given the limited availability of kidney transplants, hemodialysis is the most 
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common treatment for kidney failure in order to support the affected patient’s life. During 
hemodialysis,  blood is drawn from and returned to the patient through a vascular access site 
typically formed in the patient’s non-dominant upper extremity such as between the radial artery 
and cephalic vein in the wrist, where an arteriovenous (AV) graft is surgically implanted.
2
 The 
clinical gold standard for an AV access is to use an AV fistula, a surgically created direct 
connection between an artery and a vein; however, over 20% of hemodialysis patients, such as 
those who are diabetic or elderly, are not suitable candidates for AV fistulas due to inadequate 
diseased veins, and therefore synthetic grafts are the best option in these cases.
1,3
 
Current commercially available prosthetic AV grafts are typically composed of 
polyethylene terephthalate (Dacron®), or expanded polytetrafluoroethylene (PTFE) (Gore-
Tex®) and have a high rate of low patency for small diameter grafts (defined as sized at or below 
6 mm in diameter) due to the progression of thrombosis and neointimal hyperplasia. These 
complications result in a diminished average device lifespan of about two to three years for these 
devices.
4-7 
In turn, additional surgical interventions are required and associated treatments total in 
excess of $1 billion per year.
1
 More specifically, over 70% of AV graft failures are due to 
stenosis that evolve into thrombosis at or within 3 cm of the vein to graft anastomosis.
8
 The 
current clinical approach to mitigate these risks includes administration of anti-platelet and 
anticoagulation drug regimens such as dypiridamole, sulfinpyrazone, ticlopidina, combined 
aspirin and heparin, which have their own side effects and are not able to maintain full patency 
long-term, thus simply delaying graft failure.
9-11
 
Consequently, a great deal of research has been conducted to improve the performance of 
synthetic vascular grafts. For example, efforts have been made to immobilize heparin, a 
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commonly used anticoagulant, by such mechanisms as covalent bonding or surface adsorption, 
either as a polymeric surface coating or within the bulk of PTFE-based grafts; however, the 
results are a modest improvement at best.
12,13 
Other strategies include controlled release of anti-
proliferative agents from the graft material to limit smooth muscle cell migration and 
proliferation growth on the graft luminal surface that cultivates intimal hyperplasia. For example, 
Owen et al. developed an injectable thermosensitive degradable polymer gel that can be loaded 
with paclitaxel, dipyridamole, and/or sirolimus.
14
 While the advantage of this approach is that the 
drug can be replenished, it would require administering ultrasound-guided injections on a weekly 
basis, with a risk of the gel migrating from the targeted location. Furthermore, the results of this 
research did not show that neointimal hyperplasia in vivo was significantly reduced in the 
porcine model studied. Following a similar approach, Baek and coworkers found that dip coating 
ePTFE grafts with sirolimus still resulted in neointimal hyperplasia formation following 
implantation in pigs, though at a slower rate than the untreated control group.
15
 Others have tried 
directly seeding endothelial cells onto ePTFE grafts for enhanced performance, as yet another 
approach.
16-18
 While these modifications to PTFE show some potential, the long term clinical 
performance is unknown and expediently obtaining these cells on demand remains a challenge. 
In addition, these strategies do not address incompatible mechanical properties that also often 
plague synthetic AV grafts.  
Compliance mismatch is a physical problem that also needs to be addressed concurrently 
with material thromboresistance for an artificial AV graft to successfully function long term. 
Current synthetic grafts are poorly matched to the native blood vessel, where the Young’s 
modulus of PTFE and Dacron® polyester grafts has been reported to be as high as approximately 
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0.5 GPa and 14 GPa, respectively, making them significantly stiffer than that of 0.12 – 3.7 MPa 
reported for native blood vessels.
19-23
 As a result, this critical compliance mismatch enables 
intimal hyperplasia and the ensuing turbulent flow, adding to the reduced graft patency.
24,25
 
Controlled delivery of nitric oxide (NO) from a synthetic graft can potentially resolve the 
issue of thrombogenicity of prosthetic vascular implants biomimetically. NO is a diatomic 
molecule naturally produced by endothelial cells (ECs) that is vital to maintaining vascular 
homeostasis and thromboresistance of the endothelium.
26
 Integration of NO into the vascular 
graft material has the added benefit of actively recruiting ECs, suppressing smooth muscle cell 
(SMC) proliferation and migration, and even inhibiting leukocyte chemotaxis, all which 
harmoniously work to impede thrombosis and neointimal hyperplasia.
9,27
 
Exogenous NO production can be replicated by incorporating NO donors into vascular 
graft materials; these donors are synthetic compounds that are capable of decomposing into NO 
under specific conditions.
28
 There are several classes of NO donors; however, the most studied 
are N-diazeniumdiolates and S-nitrosothiols due their ease of releasing NO under physiological 
conditions.
29,30 
N-diazeniumdiolates are synthesized by reacting primary, secondary amines, or 
polyamines with NO under high pressure, yielding two moles of NO per amine functional 
group.
9
 These types of donors dissociate into NO and its corresponding amine in the presence of 
water, as shown in Scheme 3-1, with its decomposition decreasing with increasing pH.
31
 The 
structure of an amine-functionalized NO donor molecule influences the half-life of the donor at 
physiological conditions, ranging from a few seconds to 20 h for diethylenetriamine nitric oxide 
adduct (DETA-NO).
32
 The other major class of NO donors, S-nitrosothiols, are synthesized by 
reacting a thiol with NO or nitrogen oxides
28,33
 which then release NO following exposure to 
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UV, heat, oxides, and transition metal ions.
34
 In light of the nature of the triggers for these types 
of NO donors, these substances are more useful for applications such as topical patches for 
wound healing or antimicrobial medical tubing, where external switching is advantageous
35
 
rather than as implants under aqueous flow conditions, unless further modification is done to 
incorporate the NO release trigger within the delivery vehicle.
36   
In general, use of any type of NO donor by itself does not provide long term efficacy due 
to its high reactivity in blood,
37
 and also does not provide targeted therapy. Given these limiting 
conditions, many researchers have studied incorporating these molecules into a polymeric 
vehicle to control the drug release properties. For example, Zhang et al. studied covalently bound 
NO donor to silicone rubber and demonstrated tunable release by altering the NO donor loading 
and polymer formulation.
38
 This silicone rubber exhibited in vitro NO release up to 20 d and had 
some improved thromboresistance in rabbit models, though these results still fall short of the 
long term patency goals of years. Another group investigated fabricating core-shell fibers where 
the outer “shell” layer of the polymer fibers was composed of either poly(ε-caprolactone) (PCL) 
or heparin and the inner “core” layer of the fibers were composed of a PCL/NO donor mixture, 
allowing for NO donor encapsulation and controlled NO release.
39
 The investigators showed that 
the NO release profile for the core shell samples exhibited a steadier release than the control 
groups containing only solid fibers. Additionally, it was found that NO release sustained for just 
55 h and involved a significant burst release, which is too short for significant therapeutic effect. 
Considering that near complete endothelialization of  prosthetic surfaces has been reported to 
vary between a period of 4 – 12 weeks, this time frame is too short to provide adequate 
therapy.
40-44 
Although that material demonstrated enhanced mouse fibroblast (3T3) proliferation 
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after several days, it would have been more significant to the intended application to study the 
NO release on human aortic endothelial cells (HAECs) proliferation and migration. Other 
researchers turned to making coatings for cardiovascular devices that would provide the same 
NO releasing benefit, with sustained release even up to 30 d
45
; however, these strategies didn’t 
address the physical/mechanical limitations of current implants that can also result in thrombosis 
and NO release is typically up until 24 h.
46
 
 Composite materials with drug releasing capabilities, such as the drug releasing 
PCL/PDMS composite introduced in Chapter 2, have the potential to meet these multifaceted 
demands for developing vascular grafts. In the Mather research group, controlled NO release was 
previously investigated by incorporating donor molecule DETA-NO into a composite composed 
of a commercially available polydimetheylsiloxane (PDMS) (Sylgard 184) and polyvinylacetate 
(PVAc).
47,48
 This combination of materials exhibited controlled NO release over several weeks; 
however the effect of NO donor loading in the composite was not studied. Furthermore, the 
focus of that research was the use of amorphous poly(vinyl acetate) as the fibrous phase, which 
led to significant shrinkage of the composite dimensions by up to 50% when hydrated, thus not 
making it an ideal candidate for use as vascular graft.
49
 In Chapter 2, a custom cross-linked 
PDMS chemistry was developed and combined with electrospun PCL fibers to form a composite 
that demonstrated mechanical properties suitable for vascular graft applications and controlled 
release of a hydrophilic model drug, which can mitigate these challenges. Therefore, the goal of 
this work was to investigate the ability of that PCL/PDMS composite to controllably release NO 
from a hydrophilic donor molecule. We further assessed the suitability of this composite’s 
mechanical properties in an application specific relevant manner by evaluating the suture 
 66 
retention and burst pressure strengths. The cytocompatibility of the composite was studied with 
systematic improvements by altering the PDMS crosslinking chemistry. Lastly, the in vitro 
migratory responsiveness of endothelial and smooth muscle cells in the presence of the NO 
releasing composite was evaluated. 
3.3 Methods 
3.3.1 Materials 
Poly(ε-caprolactone) (70,000 – 90,000 g·mol–1), tetrahydrofuran (THF), anhydrous 
dimethylformamide, and dibutyl tin dilaurate were purchased from Sigma Aldrich and used as 
received. Dietheylenetriamine NONOate (DETA-NO) was purchased from Cayman Chemicals. 
Silanol–terminated polydimethylsiloxane (2000 cSt) and poly(diethoxysilane) were purchased 
from Gelest, Inc. 
3.3.2 Fabrication of NO-Loaded Electrospun Fibers 
NO-loaded fibers were prepared by first dissolving 13 w/v% PCL in 4:1 THF:DMF 
solvent mixture. NO donor compound DETA-NO was separately mixed with 0.2 ml anhydrous 
methanol per 10 mg DETA-NO until a homogenous suspension was observed. The DETA-NO 
suspension was then added to the PCL solution under constant stirring conditions, such that the 
targeted concentration of DETA-NO was obtained  relative to the mass of PCL in the final 
solution. The DETA-NO/PCL solution was then transferred to a 10 ml syringe fitted with a blunt 
22 gauge needle tip. A syringe pump was used to supply a steady flow rate of 1.0 ml ∙ h
-1
. The 
solution was electrospun onto a grounded 3 mm – 50 mm diameter aluminum drum rotating at 
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400 rpm, at a distance of 7 cm from the needle tip and an applied voltage of 11.5 kV. Following 
electrospinning, all fiber mats were dried at room temperature under vacuum (-30 mm Hg) for 48 
h to remove any residual solvents prior to further use and stored at -18 C in a dessicated 
container. 
3.3.3 Preparation of NO-Loaded Fibrous Elastomeric Composite 
 A pre-polymer elastomer was prepared by mixing silanol-terminated 
polydimethylsiloxane (ST-PDMS) with 3 wt% polydiethoxysiloxane (crosslinker) and 0.5 wt% 
dibutyl tin dilaurate (catalyst) similar to what was previously done by others.
50
 The electrospun 
drug-loaded PCL fiber mats were then coated by the PDMS mixture, followed by exposure to 
vacuum at room temperature for 15 min to enable thorough infiltration of PDMS within the fiber 
mat. Excess PDMS was removed from the surface using a spatula followed by a 72 h cure at 
room temperature in a desiccator.  
3.3.4 Morphology 
 A JEOL JSM-5600 scanning electron microscope (SEM) was used with an accelerating 
voltage of 4 – 6 kV. Samples were sputter-coated with gold 45 s prior to imaging. Fiber diameter 
measurements were determined by taking a minimum of 50 measurements at five different 
locations using ImageJ software (version 1.46, National Institutes of Health). The average 
diameter and standard deviation were calculated using a minimum of 250 total measurements. 
Statistical significance was determined using a one-way analysis of variance (ANOVA) with a 
significance criterion of p < 0.05, using the Minitab software package. 
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3.3.5 Thermal Characterization 
Differential scanning calorimetry (DSC) was performed using a Q200 manufactured by TA 
Instruments, Inc. Samples weighing 2.5 – 4.0 mg were sealed in Tzero aluminum pans and 
heated from -60C to 120C at 10C ∙ min
-1
. The melting enthalpy was calculated from the first 
heating cycle by integrating the melting peak, and was used to determine the crystallinity of PCL 
in the elastomeric composite according to: 
𝐶(%) =  
∆𝐻𝑚
∆𝐻𝑓
0  × 100 % (3-1) 
where c is the degree of crystallinity, fH  is the heat of fusion measured by DSC and 
0
fH is 
the heat of fusion of crystalline PCL, with a literature value of 139 J ∙g
-1
.
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 The melting enthalpy was calculated from the second heating cycle by integrating the 
melting peak, and was used to determine the fraction of PCL (𝑊𝑃𝐶𝐿) in the elastomeric 
composite by comparing the melting enthalpies according to: 
𝑊𝑃𝐶𝐿(%) =  
∆𝐻𝑚
∆𝐻𝑚,0
 × 100 % (3-2) 
where Hm  is the melting enthalpy of the composite measured by DSC and Hm,o is the melting 
enthalpy of  pure electrospun PCL, as determined by DSC. 
3.3.6 In Vitro NO Release 
 Samples of 1 cm x 2 cm were placed in a known volume (4 – 10 ml) of phosphate 
buffered saline (PBS, pH 7.4) in sealed glass vials and placed in a thermal shaker at 37 C to 
simulate physiological conditions. Nitric oxide was indirectly measured using a commercially 
available Griess reagent assay (Promega Corp.), a widely used technique that 
 69 
spectrophotometrically measures the concentration of nitrite in the media.
52
 Since NO reacts 
with oxygen in water to produce nitrite, a stable, non-volatile compound, the total nitrite in PBS 
was assumed to be due to NO decomposition from the donor compound, where one mole of 
DETA-NO can release two moles of NO (Figure 3-1). The Griess reagent assay process entails 
first diazotizing the nitrite in the sample buffer with 1% sulfanilamide in 5% phosphoric acid 
(SA) followed by azo coupling with aqueous 0.1% N-1-naphthylethylenediamine 
dihydrochloride (NED). The resulting chromophore formed by the reaction with NED has an 
absorbance maximum at 540 nm, which using a plate reader (Biotek® Synergy 2 Microplate 
Reader). The detection limit for the Griess assay is 125 pmol, which is well below the target NO 
(nitrite) release concentration. A calibration curve was first prepared for all measurements using 
known concentrations of nitrite. The NO flux from the samples was determined by converting 
the measured concentration value to into mass (moles) and dividing by the surface area of the 
sample and plotting versus time (min). The slope of a linear regression revealed the flux (mol 
cm
-2
 min
-1
).  All testing was conducted in triplicate at each time point, and an average and 
standard deviation are reported.  
3.3.7 Suture Retention Strength 
Suture retention strength of the composite was conducted in accordance with 
ANSI/AAMI/ISO 7198: 1998/2004 “Cardiovascular implants – Tubular vascular prostheses” 
standard using a tensile tester (Test Resources, Model 100P).
53
 Samples were cut into rectangles 
of 2.0 cm by 1.2 cm. One end was secured using a single throw of a commercially available 
monofilament polypropylene suture of size 5-0 looped once (5-0 Prolene, Ethicon, Piscataway, 
NJ) into a single loop at 2 mm from the edge and knotted a minimum of five times. The 
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unsutured end was fastened by the stage clamp while the opposing clamp mounted to transducer 
was gripped onto the knotted end of the suture. The suture was pulled from the sample at a rate 
of 50 – 120 mm ∙ min
-1
 until the suture completely ripped through the sample wall resulted in 
failure. The peak force required to pull the suture through the sample is reported as the suture 
retention strength (N). An average and standard deviation are reported for a total of five samples. 
3.3.8 Burst Pressure 
 Burst pressure testing was performed on tubular graft samples with an inner diameter of 6 
mm consistent with other studies.
53-55
 The graft tubes were each cut to a minimum length of 3 
cm, in accordance with ANSI/AAMI/ISO 7198,
 53
  and were fitted over a custom testing platform 
that allowed both ends to be secured, as shown in Figure 3-8A. The sample was pressurized with 
water and air bubbles expelled at room temperature using a syringe pump to supply water at 20 
mL min
-1
 until failure, as has been reported by others.
56,57
 The internal hydrostatic pressure was 
measured over time using an in-line pressure gage while the graft diameter was actively 
measured using a linear laser positioned at a fixed distance and projected onto a screen. The gap 
or shadow in the projected laser line due to the graft was used to determine the diameter (Figure 
3-8A). Prior to testing, a standard curve was constructed using known diameter measurements 
from which the actual external diameter calculated with an accuracy of 0.5 mm. All captured 
images were calibrated using reference lines of known dimension and analyzed using ImageJ 
software. The pressure at which the sample bursts was reported as the burst pressure. A sample 
size of three was used and an average and standard deviation are reported. The hoop stress (𝜎𝐻) 
for a thin-walled tube was calculated using Eqn. 3-3 below, where P, d, and t refer to the internal 
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pressure, tube diameter, and tube wall thickness, respectively. A thin wall assumption was used 
since the ratio of the radius to tube thickness was greater than ten. 
𝜎𝐻 =
𝑃𝑑
2𝑡
 (3-3) 
The compliance (C) was calculated using the burst pressure data and according to Eqn. 3-4 
below, where d0 refers to the initial, unpressurized diameter. 
𝐶 =
∆𝑑
𝑑∆𝑃
 (3-4) 
 
3.3.9 Kink Resistance 
A tubular PCL/PDMS sample was fitted over a flexible, kink-free wire support of 
diameter 5.9 mm. Shape fixing was conducted by heating the sample above the melting transition 
of PCL at 60 C and then deforming the sample into a bend of radius of 0.8 cm or until just 
before a kink formed, followed by quenching in a freezer at -18 C to recrystallize the PCL 
fibers. The sample was then removed from the wire support and a fixed shape was observed and 
the fixed bend radius was measured. Shape recovery was then triggered by placing the sample in 
an oven at 60 C to melt PCL, and enabling the PDMS crosslinks to recover the previously 
permanently memorized, strain-free shape. The radius of curvature of the recovered shape was 
then measured. A kink in the tube was defined visually as a large scale buckling in the outer 
surface of the tube wall at the point of bending.
58 
The radius of curvature of the fixed sample 
measured using ImageJ image analysis software and compared to the deformed sample before 
removal from the bent wire support. The fixing ratio, 𝑅𝑓, was calculated using Eqn. 3-5 below, 
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where 𝑟𝑑 is the radius of curvature of the targeted deformed shape (while on the wire support) 
and 𝑟𝑓 is the radius of curvature of the resulting fixed shape. 
𝑅𝑓(%) =
𝑟𝑑
𝑟𝑓
× 100% (3-5) 
The recovery of the straight tube was assessed according to the recovery ratio below: 
𝑅𝑟(%) =  (
𝑟𝑓 − 𝑟𝑟
𝑟𝑓 −  𝐿0
) × 100% (3-6) 
where L0 is the original length, and 𝒓𝒓 is the recovered length following heating. The reciprocal 
value of the radius of curvature was used to describe the curvature of the sample. The critical 
curvature is the curvature value limit before a kink will occur with increased bending. The 
critical curvature, shape fixing ratio and standard deviation of three samples per test group was 
reported. 
3.3.10 Cytotoxicity 
 Sample preparation was conducted according to ISO 10993-5 and ISO 10993-12, where a 
non-contact extraction-based method was used to determine cytocompatibility.
59,60
 Samples were 
cut into pieces in order to maintain an extraction ratio of 3 cm
2
 ∙ ml
-1
 of sample surface area to 
extract media. All samples were sterilized by ultraviolet light for 1 h per side. Sterilized samples 
were then incubated in media for a specified sample extraction time (24 – 72 h). Following 
extraction, the sample media was used to incubate L929 cells for 24 h at 37 C in 95% 
humidified air containing 5% CO2. Cytotoxicity was quantified using the CCK-8 assay to 
colorimetrically measure mitochondrial activity, an indicator of cell viability. The cell culture 
media was replaced with 100 uL of 10% (v/v) CCK-8 solution in media was incubated for 4 h. 
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The absorbance of the samples was measured at 450 nm using a plate reader (Biotek® Synergy 2 
Microplate Reader). Cell viability was calculated by dividing the absorbance values of the 
sample by the absorbance value of the positive control and reported as a percentage of the 
positive control. A minimum cell viability of 70% or greater was used to determine 
cytocompatibility.
58
 All testing was conducted in triplicate and a mean and a standard deviation 
are reported.   
3.3.11 Mechanical Characterization 
 Tensile mechanical properties was studied by punching samples into a dog bone 
geometry (ASTM Standard D638-03 Type IV, scaled down by a factor of 4), and loading onto a 
Test Resources Model 100P Universal Testing Machine equipped with a 24 N load cell. The 
samples were stretched at a rate of 33 μm s
-1
, and engineering stress-strain curves were used to 
determine Young’s modulus, strain-to-failure, and tensile strength. Five samples of each type 
were tested and an average and standard deviation are reported. 
3.3.12 Cell Migration Assay 
 The cell migration was performed in a modified Boyden chamber
61
 using 24-well 
Transwell plates (Corning™ Transwell, 8 μm pore size). All samples were sterilized by 
ultraviolet light for 1 h per side. Samples punched into 6.5 mm diameter discs were placed in the 
bottom compartment and allowed to soak in media for 48 h prior to cell seeding to ensure full 
water uptake through the sample and initiation of NO release. Bovine aortic endothelial cells 
(BAECs) or bovine smooth muscle cells (BSMCs) from passages 5 and 6, respectively, were 
cultured for 72 h prior to cell seeding. The cells were suspended in media containing 10% fetal 
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bovine serum (FBS), 1% GlutaMAX, and 1% penicillin/streptomycin and Dulbecco’s modified 
Eagle’s medium (DMEM). The Transwells were then seeded with 10,000 cells in the upper 
compartment and placing the sample in the bottom compartment with 600 uL of cell culture 
media. Both the cell culture media and a solution containing 10 μM of DETA-NO in media were 
used separately as positive controls. The DETA-NO control was prepared just prior to cell 
seeding due to its high reactivity and sterilized by filtration (0.20 μm, Corning®). Serum-
reduced media containing 1% FBS was used as the negative control. The assembled migration 
chambers were incubated for 48 h in a humidified incubator at 37 C with 5% CO2 to allow cells 
to migrate through the Transwell filter. After the migration period, the cells were fixed using 4% 
formaldehyde in PBS and stained with Alexa Fluor 647 conjugated phalladium (1:40 dilution, 
Life Technologies) for actin cytoskeleton visualization and Systox Green (1:10000 dilution in 
PBS, Life Technologies) for nucleus staining. Non-migrated cells in the seeding (upper) chamber 
were removed using a cotton swab, leaving only the migrated cells on the obverse filter surface 
for analysis. The stained cells were imaged using a Leica DMI 4000B inverted fluorescence 
microscope equipped with a Leica DFC 340FX camera using a 10X/0.22 NA objective. 
Pseudocoloring was applied to the images using ImageJ software. The total number of migrated 
cells from three representative areas per well were quantified using Automated Contour-based 
Tracking for In Vitro Environments (ACTIVE) software.
62,63 
Each assay test condition was 
conducted in triplicate wells, and an average and standard deviation are reported.  
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3.4 Results 
3.4.1 Fabrication 
 PCL fiber mats containing DETA-NO were prepared by electrospinning with an average 
fiber diameter of 0.91 μm  ± 0.51 μm and 0.46 μm ± 0.24 μm for fiber mats loaded with 0.5% 
and 1.5% DETA-NO, respectively. No drug crystals or particle aggregation were observed on the 
fiber surfaces, though it may be too small for the SEM resolution limit of the equipment used 
(Figure 3-1A-B).The fiber mats were then successfully imbibed with PDMS, which occupied the 
interstitial space between the PCL fibers, as shown in Figure 3-1C-D. Tubular composite 
samples (Figure 3-1E) were also fabricated by electrospinning the fibers onto a smaller diameter 
mandrel and were used for burst pressure and shape memory kink testing.  
3.4.2 Thermal Characterization 
 The thermal properties of the NO releasing PCL/PDMS composites are presented in 
Figure 3-2 and Table 3-1, and compared with their respective components. Both composites are 
composed of mostly PDMS, comprising approximately 8 – 10% based on a comparison of the 
melting enthalpies between the fibers and the composites in the second heating cycle. Some 
variation in the local composition of the composite was expected given that the PDMS 
deposition and infiltration process is manually performed. The melting endotherm of DETA-NO 
was not visible in the thermograms. 
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3.4.3 NO Release 
The in vitro cumulative drug release profiles of the PCL/PDMS composites doped with 
two NO donor concentrations were compared to NO release from the non-encapsulated fibers 
and presented in Figure 3-3. Consistent with the drug delivery results in Chapter 2, the addition 
of the crosslinked PDMS elastomeric matrix to the PCL fibers served as a water-regulating 
composite that suppressed the initial burst release for 0.5% DETA-NO/PCL/PDMS composite, 
which was reduced from approximately 12% to 9% drug release within the first 3 h. The burst 
release was not substantially different between the 1.5% DETA-NO/PCL/PDMS composite and 
its corresponding fiber mat, since both exhibited a 4 % cumulative release by 3 h. 
Notwithstanding quantitative differences attributed to DETA-NO loading, both composites 
continued releasing NO long after the fibrous samples stopped and with greater total NO 
released, also consistent with the drug delivery results in Chapter 2.  
In general, increasing the concentration of the NO donor in the samples resulted in 
decreased total NO released over time on a percentage basis, by approximately 16% of 
theoretical stored NO between composites, and 11% for the fiber mats. After 72 d, the 0.5% 
DETA-NO/PCL/PDMS composite had released approximately 27% of the theoretical NO, 
whereas the 1.5% DETA-NO/PCL/PDMS composite had released approximately 12%. Both 
composites also showed drastically reduced release rates at that time point. In contrast, both fiber 
mat samples no longer released significant amount of drug after approximately 2 – 3 d, with total 
concentrations well below their respective composite analogs, totaling to 86% and 94% 
unreleased drug remaining for the 0.5% DETA-NO/PCL and 1.5% DETA-NO/PCL samples, 
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respectively. These trends are consistent with what was observed for Rhodamine B release from 
the same materials discussed in Chapter 2. 
To assess the physiological relevance of these NO release results, the profile values were 
converted into flux values by plotting the NO release (mol ∙ cm
-2
), normalized by the sample 
surface area, alongside the release time (in minutes), and divided into four stages, each 
composed of a linear trend. The slope of best-fit linear regression of each stage revealed the flux 
in Figures 3-4 and 3-5.  The flux values both NO concentrations in the composite were observed 
to progressively decrease over time, as tabulated in Table 3-2, however, both composites 
exhibited sustained NO release for over eight weeks.  
3.4.4 Suture Retention 
 The suture retention strength of the DETA/NO-PCL-PDMS composite was quantified 
according to ANSI/AAMI/ISO 7198
64
 using a single throw of 5-0 Prolene sutures using a tensile 
tester as shown in Figure 3-6. The suture retention strength was 2.0 N ± 0.4 N for the composite 
when tested at 50 mm ∙ min
-1
. This average value reduced slightly when tested at faster speeds, 
resulting in suture retention strengths of 1.6 N ± 0.4 N and 1.7 N ± 0.4 N for pull speeds of 100 
mm ∙ min
-1 
and 120 mm ∙ min
-1
, respectively (Figure 3-7 and Table 3-3). These differences due 
to pull speed were not statistically significantly different at the 95% confidence interval. 
3.4.5 Burst Pressure 
 The burst pressure of the PCL/PDMS composite was tested using a custom testing 
platform shown in Figure 3-8.  The average burst strength was 1508 mm Hg ± 284 mm Hg, 
which was over 12 times greater than the physiological pressure of human arteries of 120 mmHg 
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which was specified by ANSI 7198.
41
 The estimated hoop stress (Eqn. 3-3) based on the burst 
pressure value was 11,310 mm Hg (1.5 MPa), which was slightly lower than average tensile 
strength of the PCL/PDMS composite of approximately 7 MPa reported in Chapter 2. The 
resulting compliance, based on the burst pressure data was determined to be approximately 0.028
 
% mm Hg
-1
 ± 0.005
 
% mm Hg
-1
, which was lower than the value of approximately 0.44
 
% mm 
Hg
-1
 reported for the saphenous vein.
65
 Since compliance is dependent on sample thickness, a 
reverse calculation (assuming a Young’s modulus of 3.85 MPa reported in Chapter 2) estimated 
that decreasing the sample thickness to between 0.1 to 0.2 mm would achieve the literature 
reported value for saphenous veins. The failure of the composite sample under high hydrostatic 
pressure progressed as localized plastic deformation, where whitening (akin to crazing of 
amorphous polymers undergoing fracture) of the composite was observed at the site where water 
leaked from the graft sample, as shown in Figures 3-8B and 3-9B. A linear relationship was 
observed between the internal pressure and diameter expansion until the diameter expansion was 
approximately 130 – 150% of its original diameter, at which point continued inflation did not 
substantially increase the internal pressure before failure occurred.  
3.4.6 Kink Resistance 
 The results of fixing tubular samples of the composite into a kink-free, looped shape of 
varying tube diameters and wall thickness are presented in Figures 3-10 and 3-11. The two wall 
thicknesses tested for 3 mm graft samples were: 0.19 mm ± 0.05 mm (“thin”) and 0.34 mm ± 
0.07 mm (“thick”). The two wall thicknesses for the 6 mm graft samples were: 0.17 mm ± 0.09 
mm (“thin”) and 0.47 mm ± 0.01 mm (“thick”). The permanent (original) shape of this sample 
was a straight tube, which was then deformed into a kink-free bend as described in Section 3.3.9. 
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All samples exhibited full shape recovery within seconds of stress-free exposure to 60 C in an 
isothermal oven, as can be seen in Figure 3-10. For two graft sizes, the critical curvature 
increased when the wall thickness was increased, particularly for the 6 mm graft, as shown in 
Figure 3-11A. The 6 mm graft displayed some wrinkling on the surface when the wall thickness 
was decreased. Reducing the clearance between the fixing wire support and the sample aided in 
limiting wrinkle formation; however some wrinkle formation occurred for the 3 mm grafts with 
thicker walls. These wrinkles were local surface features much smaller than the tube diameter, 
unlike a kink, which is a large-scale occlusion of the tube lumen, caused by mechanical buckling 
during tube flexure. The shape fixing ratio, presented in Figure 3-11B, increased for both the 3 
mm and 6 mm samples when the wall thickness decreased.  
3.4.7 Cytotoxicity 
 The cell viability results of the NO releasing composite and its individual components 
shown in Figure 3-12(A). The electrospun PCL, both with and without DETA-NO, 
demonstrated cytocompatibility at 125% ± 20% and 124% ± 11%, respectively, with no 
significant difference due to the addition of DETA-NO after 24 h of material extraction. 
Additional extraction time in media slightly decreased viability to 96% ± 0.2% for electrospun 
PCL and 92% ± 0.1% electrospun PCL with DETA-NO, which was well above the 70% 
threshold for cytocompatibility. When PCL was combined with PDMS to form the composite, 
the resulting cell viability was 22% ± 3% cell at 24 h, which was not significantly different than 
cast PDMS films, which had a cell viability of 23% ± 3.   
 Based on the above results, it was hypothesized that the source of toxicity was residual 
tin catalyst (DBTDL) used to synthesize crosslinked PDMS. To test this hypothesis, PDMS was 
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then synthesized using different concentrations of DBTDL. The resulting cell viability in Figure 
3-12(B) showed that increasing the DBTDL concentration from 0.25% up to 1% resulted in poor 
cell viability ranging from 25% ± 7% to 39% ± 6%, with slightly greater viability at lower 
catalyst concentration. Cell viability significantly improved to 98% ± 9% when PDMS was 
synthesized using 0.1% DBTDL. These findings were then used to improve the 
cytocompatibility of the NO-releasing composite by crosslinking PDMS using a lower DBTDL 
level; however, it was discovered that while the SMEC containing 0.1% DBTDL had no issues 
curing, the addition of DETA-NO prevented complete cure of the PDMS, even after 14 d at 50 
C, which is more than sufficient to crosslink PDMS (data not shown). Figure 3-12(C) shows 
the cell viability results of drug-loaded and neat composite at different DBTDL concentrations. 
Consistent with the cell viability results for PDMS in Figure 3-12(B), only the composite 
containing 0.1% catalyst was similarly cytocompatible with a cell viability of 94% ± 11%. Since 
the DETA-NO containing composite could not be tested using a DBTDL concentration of 0.1% 
due to poor cure, only the cell viability results for DBTDL concentrations of 0.25%  and 0.5% 
are shown.  The cell viability significantly improved when DETA-NO was added to the 
composite by up to 60% for the composite containing 0.25% DBTDL, and 26% for composite 
containing 0.5% DBTDL.  Based on these results, it was postulated that DETA-NO possibly 
counteracted the catalytic activity of DBTDL, which may explain why at very low levels of 
DBTDL, the DETA-NO releasing composite was unable to cure even at aggressive conditions. 
Furthermore, this may explain why these samples exhibited better cytocompatibility at higher 
concentrations compared to the composite without DETA-NO. The DETA-NO/SMEC 
containing 0.25% was determined to be cytocompatible based on a cell viability of 73% ± 6% 
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relative to the positive control. Given that reducing the catalyst concentration further affected the 
ability for PDMS to cure, this DBTDL composition (0.25%) was selected for chemotaxis studies 
described in Section 3.3.10.  
 Figure 3-12(D) showed that the cell viability for DETA-NO concentrations of 0.1 μM  to 
100 μM in cell media was significantly greater than 70%, with values ranging from 94% ± 19% 
to 117% ± 18%, indicating cytocompatibility and even cell growth; only a DETA-NO 
concentration of 1000 μM showed strong cytotoxicity, which was comparable to the negative 
control. Based on these results, a 10 μM DETA-NO solution was selected to use as a second 
positive control in the chemotaxis study described in Section 3.4.10. The tensile testing results in 
Figure 3-13 and Table 3-4 showed no significant differences in the mechanical properties of the 
crosslinked PDMS at catalyst concentrations between 0.1 wt% to 1.0 wt%. 
3.4.8 Migration Assay 
 The in vitro migration of BAECs and BSMCs was evaluated in the presence of the 0.5% 
DETA-NO/PCL/PDMS composite and summarized in Figure 3-14. Following 48 h of cell 
migration, there was significantly greater cell migration toward the NO-releasing PCL/PDMS 
composite, which was not significantly different than the DETA-NO positive control for both 
cell types. The BSMCs also migrated in response to NO, independent of NO source, whether 
from the composite or positive control, though with highly variable results, as indicated by the 
large error bars for the BSMCs in Figure 3-14. The PCL/PDMS composite without drug 
exhibited significantly less BAEC and BSMC migration than the doped composite. The least 
overall amount of migration activity was observed for both the media and the serum-reduced 
media controls, with no significant difference in cell count between the two media conditions. In 
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general, there was no statistical difference between the cell migration populations of the BAECs 
and the BSMCs in all the test conditions, as both cell types migrated in similar patterns. The 
morphology of the migrated BAECs and BSMCs shown in Figures 3-15 and 3-16 were 
consistent healthy ECs and SMCs. 
3.5 Discussion 
 PCL and PDMS have each been widely studied for use in medical devices owing to their 
excellent biocompatibility properties.
66,67
 The combination of these two materials to form a drug-
releasing elastomeric composite with controlled release of a hydrophilic model drug was studied 
in Chapter 2. This chapter served to further study this composite material for a vascular graft 
application, this time incorporating an NO-releasing molecule, considering that the composite 
also demonstrated good mechanical properties to substitute human blood vessels, as discussed in 
Chapter 2.  
 In healthy blood vessels, the endothelial lining of the luminal surface of prevents 
restenosis due to the continuous EC release of NO that provides a non-thrombogenic blood-
contacting surface.
68 
To mimic this effect, DETA-NO was selected as the NO donor to integrate 
into the PCL/PDMS composite due to its relatively long half-life of 20 h in aqueous solution at 
37 C. The addition of the PDMS elastomeric matrix served to sustain NO release due to its 
water-regulating properties, while although hydrophobic, is semi-permeable to water.
69
 The 
spontaneous release initially observed within the first few hours is likely due to NO donor 
readily accessible at the surface and was greatly reduced by the addition of the PDMS matrix, 
which served to shield the NO donor from instant dissociation in water. We attribute subsequent 
release of NO donor to diffusion from the bulk of the PCL fibrous framework. We had 
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hypothesized that increasing the NO donor concentration would increase both the total amount 
released (on a percentage basis) and the accompanying release rate; however, the opposite trend 
occurred. This result occurred despite the composite with lower drug loading exhibited slightly 
more PCL crystallinity and larger fiber diameters, both which may act as a hindrance to drug 
release as was determined in Chapter 2. We surmise that this may be due to added entrapment 
of drug within the fiber core. This type of indirect correlation between drug loading and release 
has been observed in other controlled drug release systems, particularly in drug encapsulated 
micro- and nanospheres, where it was suggested that above a particular concentration the drug 
dispersion throughout the polymer matrix becomes heterogeneous, thus impeding release.
70-73
 In 
systems where drug has poor miscibility in the polymeric carrier, the drug may be crystalline or 
appear as aggregates, rather than exist as a molecular dispersion within the matrix, and may 
require an additional step of first being dissolved by the external aqueous environment prior to 
beginning diffusion out of the polymer, thus resulting in reduced release at higher loading.
74 
The 
crystallinity of PCL would also provide domains that would impede water penetration and thus 
drug diffusion out, which is what we found in Chapter 2, where the PCL/PDMS composite also 
showed less release as the loading of a hydrophilic model drug Rhodamine B increased.  
Considering that a suspension of DETA-NO in PCL was electrospun, the resulting fibers likely 
did not contain uniform drug dispersion throughout the cross-section and this is more evident as 
the concentration is increased.
 
Since the solubility of the DETA-NO solution in the 
electrospinning solution was limited, it is likely that phase separation between DETA-NO and 
PCL occurred while the electrospinning solvent evaporated during fiber formation and that the 
recrystallization of PCL during this stage further encased the drug within the fiber core. This was 
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supported by the observation that the 0.5% DETA-NO samples were slightly more crystalline 
than the 1.5% samples and still released more, further supporting the notion that the observed 
drug release pattern was a result of phase separation. Additionally, the differences in total drug 
release between the fibrous samples and the composites was consistent with that observed in 
Chapter 2, where the composite samples released more total drug. We postulate that this 
difference may be due to trapped air in the fiber mats that may block drug diffusion into the 
aqueous media, which is not present in the composite, where PDMS wets the surfaces of fiber 
and media, displacing the air that may otherwise block release. 
 NO release of the native endothelium has been reported to be within 0.05 – 0.1 nmol cm
-2
 
min
-1
.
75
 The 0.5% DETA-NO/PCL/PDMS composite was found to release within this order of 
magnitude during the first 3 d in PBS at 37 C (Figure 3-4 and Table 3-2). The initial burst and 
ensuing NO release during this period may be critical to preventing restenosis by SMC migration 
and proliferation, which can occur approximately 24 h following surgical intervention that 
triggers vascular injury, with maximum activity at 48 h.
76
 The subsequent long-term sustained 
NO release is necessary for continued suppression of SMC proliferation while supporting 
endothelialization for ultimately building confluency, which generally occurs within of 4 – 12 
weeks following implantation.
40-44
 Host body responses to synthetic vascular grafts occur 
immediately upon contact with blood, beginning with  protein adsorption, platelet adhesion 
within several hours, followed by EC and SMC migration.
77,78
 It has been reported that up to 
18% of synthetic vascular grafts for dialysis fail due to thrombosis within the first 3 weeks;
79
 
ideally, a vascular graft would last for the life of the patient with no need for additional surgeries 
to replace with another graft, though such a synthetic option currently does not exist. Compared 
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to those options, our composite material is an improvement since it has demonstrated the 
potential for continuous mediation of EC advancement through NO release for over two months. 
Although the NO flux in the later stages (Table 3-2) was found to be below NO release by native 
endothelial cells, this can potentially be improved by implementing a thermal treatment to the 
composite to reduce the PCL crystallinity, as determined in Chapter 2, and may even be 
sufficient when combined with the endothelial cell based NO release. 
 In order to be successful as a vascular graft implant, the material must be able to support 
sutures under tension during and after surgery. The suture retention strength is an indicator of 
anastomotic strength, which is can also be affected by suture needle thickness, needle shape, and 
the material and thickness of the suture; these factors are typically not controlled or 
standardized.
80,80
 The suture retention strength of human saphenous veins using the same suture 
has been reported to be 1.92 N ± 0.02 N, which was comparable to that for our composite 
material.
81,81
 Generally, researchers use an approximate value of 2.0 N as the minimum 
acceptable strength for prosthetic vascular graft materials, though the testing tensile speeds used 
are not standardized in the field.
82-85 
Since the ANSI procedure calls for a wide range of 50 –  
200 mm ∙ min
-1
, our composite was tested at three different speeds, with no statistical significant 
difference in the suture retention strength between the speeds, though the strength decreased 
slightly with increasing pull speed. We postulated that this strength can be improved by 
optimizing the volume fraction and crystallinity of PCL fibers in the composite. 
 Healthy human arteries can withstand systolic blood pressures of approximately 120 mm 
Hg.
86 
Our PCL/PDMS composite material demonstrated an average burst pressure of 1508 mm 
Hg ± 284 mm Hg,  which was more than twice that of the currently acceptable commercial 
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options, such as non-elastomeric ePTFE which has a reported burst pressure of ~ 600 mm Hg,
21
  
and over 12 times greater than blood pressure. Although the clinical requirement for vascular 
graft prosthetics is approximately 2000 mm Hg (38.7 psi), this is in order to ensure that it 
performs beyond any expected physiological thresholds and is based on the incredible burst 
strength of the human saphenous vein, but is also in great excess of systolic pressure, as has been 
pointed out by others.
57,87
. Burst pressure strength of graft materials have been shown to be 
dependent on the rate of inflation, where higher inflation rates lead to lower burst pressure 
results.
88
 In this study, the PCL/PDMS composite material was tested using an aggressive rate 
and was still able to achieve a high value, which demonstrated the robustness of this material. 
The nonlinear behavior of the graft under high pressures was suggestive of irreversible plastic 
deformation and has been referred to as the aneurysmal point in the vascular graft.
88
The point of 
failure of the graft consistently occurred central to the clamped areas and presented as small 
punctures or slits in the material, surrounded by “crazed” (or whitened) areas (Figure 3-9B). 
Unlike other vascular substitutes, our samples did not exhibit perspiration of water during 
pressurization,
88
 indicating good adhesion between the fibrous and elastomeric phases during 
dilation since no pores were formed. It is likely that any minor defect in the fiber/matrix 
distribution from the manual fabrication process attributed to a compromised region for stresses 
to concentrate; optimizing the graft fabrication and testing at a lower inflation rate would likely 
improve the burst strength and reduce the variation in the average values. Burst pressure is also 
inherently higher for smaller diameters and greater wall thicknesses, and considering that we 
only tested the largest diameter for a small graft, we anticipate that the strength will only 
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improve. In any case, our composite greatly exceeded physiological pressures and showed great 
potential to meet the preferred clinical target and is an adequate substitute for blood vessels. 
 Kink resistance of the composites was studied to assess the potential to form a loop for 
precision surgical placement as is typical of many arteriovenous procedures.
89
 Failure to prevent 
kinking of the graft during surgical placement can impede blood flow and lead to graft failure. In 
this work, the shape memory properties of the PCL/PDMS composite were exploited to provide 
tailorable loop configurations, which were quantified by measuring the bend radius before a kink 
appeared with additional applied stress. The larger graft size was prone to surface wrinkling as 
the wall thickness decreased. For both sizes, increasing the wall thickness improved kink 
resistance by enabling tighter loops to be formed without kink development. It is likely that the 
thicker tube walls resisted the wall thinning associated with tube bending that predisposes it to 
wrinkling and kinking.
90
 Reducing the clearance between the fixing wire support and the sample 
aided in limiting wrinkle formation; however some wrinkle formation occurred for the smaller 
grafts with thicker walls. These particular wrinkle formations (Figure 3-10H) were local surface 
features on the outer surface of the bend, much smaller than the diameter, and unlike a kink, 
which is a large-scale occlusion of the tube lumen caused by mechanical buckling during tube 
flexure.  This wrinkling behavior dependence on thickness and diameter are consistent with what 
has been reported for bending hollow aluminum alloy tubes.
90
 We also observed that the fixing 
ratio for tube bending was improved for samples with thinner walls, regardless of diameter. We 
postulate that this may be due to an imbalance of contributing forces between the fixing fibrous 
and elastomeric phases, and that future optimization of these volume fractions can improve this 
result. Unlike other biomedical materials, this graft material will maintain its looped 
 88 
configuration upon release of the load due to its inherent shape memory effect, thereby being 
more likely to maintain its shape during the desired application. The looped formation can be 
reformed by simply heating the sample above 60 C to recover its original straight shape, and the 
shape programming cycle can be reactivated as needed. The programming temperatures are well 
above physiological temperatures and accidental recovery of the shape will not occur post-
implantation. 
 Many polymers commonly used for biomedical applications, such as polyurethanes and 
silicones, rely on the use of heavy metal catalysts such as DBTDL or stannous octoate in their 
syntheses or crosslinking reactions.
91 
Given that these organotin catalysts are known to be 
cytotoxic, some researchers have sought to avoid employing these types of catalysts
92,93 
while 
others have demonstrated cytocompatibility of their materials.
94 
More specifically, the 
polycondensation or room temperature vulcanization of siloxanes frequently utilize organotin 
catalysts such as DBTDL.
50,95,96 
In this study, we identified that the cytotoxicity of the tin 
catalyst could be mitigated by reducing the concentration of the catalyst in the cross-linking 
reaction of PDMS, as demonstrated in Figure 3-12(B); this approach has been similarly 
employed by others. For example, Zhang and coworkers developed an NO-releasing silicone 
rubber that employed comparable polycondensation chemistry to crosslink PDMS, using 
DBTDL as the catalyst.
38
 While they determined that catalyst levels of 0.03% to 0.5% was 
sufficient to cure PDMS, no cytotoxicity was reported in this study. It is also unlikely that they 
would have observed any NO interference with PDMS curing since the films were cured prior to 
diazeniumdiolation of the pendant amine groups. In another study, Pretti and coworkers studied 
the ecotoxicology of PDMS coatings, also synthesized using similar chemistry.
97
 Here, they 
 89 
compared a tin catalyst (dibutyltin diacetate) to a bismuth-based one (bismuth neodecanoate) and 
found that  after 14 d of leaching in seawater, only the tin-based crosslinked PDMS exhibited 
toxicity to the marine organisms studied using a concentration of 0.1%. In contrast, Zhu et al. 
developed a PDMS-based polyurethane copolymer membrane that showed good cell viability 
using 0.1 wt% DBTDL as the catalyst concentration, which was consistent with our results.
94
 In 
our study, we also observed that the addition of NO donor DETA-NO to the composite appeared 
to interfere with the PDMS crosslinking reaction at a very low catalyst concentration, such that 
only those composites fabricated without the NO donor were able to cure at this concentration. 
We hypothesized that the NO donor may be poisoning enough of tin catalyst to prevent the 
crosslinking reaction at low catalyst concentrations. Furthermore, since the NO-releasing 
composite became more cyctocompatible with the addition of DETA-NO, we also postulated 
that the NO possibly counteracts the catalytic activity of DBTDL. In light of this, a catalyst 
concentration of 0.25 wt% was selected for further cell culture testing of the NO releasing 
composite due to the favorable cytocompatible results and ability to cure. Additionally, the 
mechanical properties of PDMS at varying catalyst concentrations showed no compromise in 
strength or elasticity. 
 The ability of the NO-releasing composite material to attract endothelial cells and deter 
smooth muscle cell migration was evaluated in vitro using a modified Boyden chamber 
migration assay. Following vascular surgery, SMCs  migrate  from the cut edges of the adjacent 
artery and are available to participate in the neointima formation along the luminal surface of a 
synthetic graft, whereas in native vessels, the ECs are already present to repair the endothelium, 
thus preventing undesired SMC luminal proliferation.
98
 We separately tested the migration of 
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BAECs and BSMCs in the presence of the NO releasing PCL/PDMS composite, using a 48 h 
migration period as had been done by others.
99
 The strikingly strong endothelial cell chemotactic 
response to the NO releasing PCL/PDMS compared to the undoped PCL/PDMS composite and 
control groups demonstrated the ability of the composite to provoke a positive biological 
response and thus the potential to generate new endothelial lining on the synthetic surface in 
vivo. To our surprise, the BSMC responded similarly to the BAECs, where BSMC migration was 
also promoted by the NO releasing PCL/PDMS composite. This effect has been observed before 
by others, where vascular smooth muscle cell (VSMC) chemotaxis was found to be highly 
dependent on NO donor concentration. In that study, Seymour et al. had hypothesized that the 
combination of DETA-NO with a statin would provide an additive inhibitory effect on vascular 
VSMC migration
.100
 Instead, they observed that the NO donor counteracted the statin activity 
and VSMC chemotaxis was increased at high concentrations of DETA-NO. Their findings 
confirmed a previous study, where the same authors had observed VSMC stimulation at high 
concentrations of DETA-NO over long term exposure (> 18 h).
101 
Interestingly, our selected 
DETA-NO concentration was well below what Seymour et al. had observed to stimulate VSMC 
migration; however, the duration of exposure to DETA-NO in our study was considerably longer 
than what the authors examined (48 h versus 20 h) and may have also contributed to SMC 
stimulation. An improvement on this assay would be to co-culture the ECs and SMCs into a 
single migration assay to better simulate physiological conditions, as the presence of ECs may 
aid in preventing or considerably reducing SMC proliferation.
76
 The graft produces a favorable 
environment for endothelialization. Overall, the results of this migration study demonstrated that 
the NO release from the composite (Figure 3-4) sufficed to stimulate the endothelial cell 
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migration necessary for luminal surface remodeling and may even be too high given that smooth 
muscle cells were negatively stimulated. Since this was conducted in vitro, it is also possible that 
the required concentration of exogenous NO may be different to induce a similar in vivo 
biological reaction.
99
  
3.6 Conclusions 
 An elastomeric shape memory composite comprised of electrospun PCL embedded 
within a crosslinked PDMS elastomer and doped with an NO donor drug was successfully 
prepared and demonstrated controlled release of NO for over ten weeks. Increasing the DETA-
NO concentration escalated the phase separation effect between the DETA-NO drug and the 
PCL fibers and resulted in reduced drug release as more drug molecule was trapped within fiber 
interior. This composite exhibited good suture retention comparable to native blood vessels and a 
burst pressure strength that exceeded commercially available options. The NO-releasing 
composite demonstrated good cytotoxicity when using a reduced concentration of the the tin 
catalyst used to crosslink the PDMS matrix, with no impact on the tensile mechanical properties. 
The addition of the NO donor compound counteracted both the catalytic activity and cell toxicity 
caused by the catalyst. Lastly, the NO-releasing composite promoted significant endothelial cell 
migration. We expect that this composite material is a good candidate for blood vessel 
prosthetics such as AV or bypass grafts where long term mechanical and anti-thrombogenic 
properties are desired. 
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Scheme 3-1. The decomposition of diethylenetriamine nitric oxide donor (DETA-NO) upon 
exposure to water. 
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Figure 3-1. SEM micrographs of electrospun DETA-NO loaded PCL fibers showing the (A) 0.5 
% DETA-NO/PCL fiber mat,  (B) the 1.5 % DETA-NO/PCL fiber mat, (C) the fiber mat surface 
following following PDMS infiltration, (D) the cross-section of the DETA-NO/PCL/PDMS 
composite, (E) the composite in tubular form, and (F) the cross-section of the tubular composite. 
The micrographs in C - D are shown for 0.5% DETA-NO donor concentration. 
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Figure 3-2. DSC thermograms comparing melting transitions of NO releasing PCL/PDMS 
composite and fibrous components at two NO donor concentrations. Solid lines denote second 
heating cycle and dashed lines denote first heating cycle. 
  
Temperature(
o
C)
-20 0 20 40 60 80
H
e
a
t 
F
lo
w
 (
E
x
o
 U
p
)
0.5 % DETA-NO/PCL/PDMS
1.5 % DETA-NO/PCL/PDMS
0.5 % DETA-NO/PCL
1.5 % DETA-NO/PCL
0.5 W/g
10 
o
C / min
 104 
Table 3-1. Thermal properties of the NO releasing PCL/PDMS composite and fibrous 
components at two NO donor concentrations. 
 
 
H
m,1
a
 
(J/g) 
H
m,2
b 
(J/g) 
T
m,1
a
  
(°C) 
T
m,2
b 
 
(°C) 
χ
1
a 
 
 
(%) 
PCL Content
b
 
 
(%) 
0.5 % DETA-NO/PCL/PDMS 7.9 5.0 59.7 55.5 5.7 10.0 
1.5 % DETA-NO/PCL/PDMS 6.1 4.0 60.7 55.6 4.4 7.9 
0.5 % DETA-NO/PCL 57.9 50.0 56.5 55.9 N/A N/A 
1.5 % DETA-NO/PCL 62.2 56.6 57.4 56.1 N/A N/A 
a
Determined from the first heating cycle. 
b
Determined from the second heating cycle. 
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Figure 3-3. (A) Overall cumulative NO profiles comparing electrospun fibers and as fibers 
embedded in the PDMS matrix for two NO donor concentrations. The plots in (B) and (C) are 
magnified views of (A). 
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Figure 3-4. (A) Cumulative NO release of 0.5% DETA-NO/PCL/PDMS composite divided into 
five stages. A magnified view of the release pattern in stages I and II are shown in (B). A linear 
regression (dashed line) was used to calculate the flux in each of NO release phase.  
 
 
 
Time (days)
0 10 20 30 40 50 60 70
C
u
m
m
u
la
ti
v
e
 R
e
le
a
s
e
 (
m
o
l 
/ 
c
m
2
)
0
5.0x10-9
10-8
1.5x10-8
2.0x10-8
2.5x10-8
I - II
III IV
A
Time (days)
0.00 0.05 0.10 0.15 0.20 0.25
C
u
m
m
u
la
ti
v
e
 R
e
le
a
s
e
 (
m
o
l 
/ 
c
m
2
)
0
2x10-9
4x10-9
6x10-9
8x10-9
10-8
III
B
 108 
 
 
Figure 3-5. (A) Cumulative NO release of 1.5% DETA-NO/PCL/PDMS composite divided into 
five stages. A magnified view of the release pattern in stages I and II are shown in (B). A linear 
regression (dashed line) was used to calculate the flux in each of NO release phase.  
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Table 3-2. Linear regression parameters of NO release profiles used to calculate the flux. 
 
Sample   
Slope of Cumulative 
Release vs. Time 
(mol ∙ cm
-2
 ∙ min
-1
) 
Y-Intercept  
(mol ∙ cm
-2
) 
R-squared 
(%) 
0.5% DETA-NO/PCL/PDMS 
Stage I 10
-10
 0 94.2 
Stage II 8 x 10
-12
 5 x 10
-9
 91.9 
Stage III 8 x 10
-13
 9 x 10
-9
 95.9 
Stage IV 5 x 10
-14
 2 x 10
-8
 99.6 
1.5% DETA-NO/PCL/PDMS 
Stage I 4 x 10
-10
 0 94.2 
Stage II 3 x 10
-11
 2 x 10
-8
 91.2 
Stage III 9 x 10
-13
 3 x 10
-8
 95.7 
Stage IV 2 x 10
-13
 6 x 10
-8
 97.8 
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Figure 3-6 (A) Suture retention testing set-up and  (B) representative force-displacement plot for 
the composite using a tensile speed of  50 mm ∙ min
-1
. The suture retention strength is denoted by 
an asterisk. 
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Figure 3-7 Average suture retention strength for the composite at three different tensile speeds. 
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Table 3-3 Average suture retention strength for the composite at three different tensile speeds. 
 
# Samples Tensile Speed (mm/min) Peak Strength (N) 
17 50 2.0 ± 0.4 
6 100 1.6 ± 0.4 
8 120 1.7 ± 0.2 
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Figure 3-8 (A) Burst pressure testing set-up and (B) representative images of sample dilation 
and failure. 
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Figure 3-9 Results of burst pressure testing showing (A) representative pressure-diameter and 
hoop stress displacement curves and (B) representative sample following high pressure burst 
failure. The arrow indicates the area where point of failure occurred. 
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Figure 3-10 Kink-free bends for surgical placement using thermal shape programming feature 
showing (A) the radius measurement and the (B) supporting substrate used to fix a looped shape. 
Representative fixed shapes are shown for the 6 mm graft in (C) and (D), with respective 
recovered shapes in (E) and (F). Representative fixed shapes for the 3 mm graft are shown in (G) 
and (H), with respective recovered shapes in (I) and (J). The wall thickness classification is 
denoted on the photos. 
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Figure 3-11 Results of kink resistance testing demonstrating (A) the critical curvature, which 
was the curvature value limit before a kink will occur with increased bending, and (B) shape 
fixing ratio dependence on graft tube wall thickness and diameter. 
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Figure 3-12. Cell viability of L929 fibroblast cells cultured in extracts from (A) the NO 
releasing PCL/PDMS composite and its components at different extraction times, (B) the PDMS 
elastomer with various catalyst concentrations, (C) the composite, both with and without NO 
donor, fabricated using different PDMS catalyst concentrations (% w/w), and (D) varying 
concentrations of the NO donor DETA-NO in cell culture media. The results for (B) – (D) were 
measured following 24 h of incubation in media. The results of the doped composite in (C) 
containing 0.1 % DBTDL could not be tested due to NO donor interference with PDMS 
crosslinking. All testing was conducted in triplicate. Dashed line indicates acceptable 
cytocompatibility level of 70 %.  
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Figure 3-13. Mechanical properties of crosslinked PDMS using different concentrations of 
DBTDL catalyst showing (A) representative engineering tensile stress-strain curves,  (B) 
Young’s moduli, and (C) strain-to-failure. 
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Table 3-4. Summary of mechanical properties of PDMS crosslinked using different DBTDL 
concentrations. 
 
DBTDL 
Concentration 
(wt %) 
Young’s Modulus 
(MPa) 
Strain-to-Failure  
(%) 
0.1 0.41 ± 0.02 316 ± 30 
0.5 0.37 ± 0.01 309 ± 40 
1.0 0.40 ± 0.02 333 ± 139 
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Figure 3-14. Effect of NO release from the 0.5 % DETA-NO/PCL/PDMS composite on BAEC 
and BSMC migration. Comparisons were made to the positive controls (media and DETA-NO in 
media) and negative control (serum-reduce media). The data shown are the mean and standard 
deviation of three experiments. 
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Figure 3-15. Representative micrographs of stained BAECs on the lower surface of the 
Transwell membrane taken with fluorescence microscope (10 X magnification). The cells visible 
on this surface are a result of migration over 48 h. The various conditions are (A) serum-reduced 
media, (B) media only, (C) 10 μM DETA-NO in media, (D) PCL/PDMS, and (E) 0.5 % DETA-
NO/PCL/PDMS composite. The cells were stained for nuclei (green) and cytoskeleton (red), and 
the arrow points to the open pores on the Transwell membrane. The scale bar represents 50 μm. 
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Figure 3-16. Representative micrographs of stained BSMCs on the lower surface of the 
Transwell membrane taken with fluorescence microscope (10 X magnification). The cells visible 
on this surface are a result of migration over 48 h. The various conditions are (A) serum-reduced 
media, (B) media only, (C) DETA-NO in media, (D) PCL/PDMS, and (E) DETA-
NO/PCL/PDMS composite. The cells were stained for nuclei (green) and cytoskeleton (red), and 
the arrow points to the open pores on the Transwell membrane. The scale bar represents 50 μm. 
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Chapter 4 
Anhydride-Based Reconfigurable Shape Memory  
Elastomeric Composite1 
4.1 Synopsis 
Soft shape memory polymers typically embody a permanently memorized geometry that 
cannot be altered, and therefore a new sample must be fabricated each time a new structure is 
required. In this chapter, a shape memory elastomeric composite featuring thermoplastic fibers as 
a fixing phase and a polyanhydride-based elastomer as the permanent, elastic phase is developed 
and characterized. It was discovered that the elastomer is capable of dynamic covalent exchange 
reactions at elevated temperatures (T > 50 °C) among the network chains that allowed near-
complete reconfiguration of the permanent shape in the solid state. Together, these features were 
combined to create a shape memory elastomer capable of arbitrary programming of both 
temporary and permanent shapes. 
4.2 Introduction 
Shape memory polymers (SMPs) are mechanically active materials featuring at least two 
primary attributes: “memory” of a stress-free permanent configuration (or shape) and 
“programming” of a temporary shape through a combination of heating and molding.
1
 
Deployment from the programmed to permanent shapes is triggered by heat, light, solvent-
exposure, or other means. At the molecular and nanoscale levels, memory is afforded by 
crosslinks (covalent or physical) established at a stress-free state during processing, while 
                                                 
1 The work in this chapter was originally published in Lawton, M. I., Tillman, K. R. & Mohammed, H. S. 
Anhydride-based reconfigurable shape memory elastomers. ACS Macro Letters 5, 203 (2016). 
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programming (or “fixing”) is accomplished by kinetic trapping of a deformed and stressed shape 
by means of crystallization, vitrification, secondary crosslinking, or even plastic deformation. 
These physical transformations act to immobilize the constituent network chains, translating to 
macroscopic shape fixing. There are four (4) major classifications of such SMPs were identified 
and the interested reader is referred to that paper
2
 and other recent reviews
3-7
 for more details. 
The systems described above achieve shape fixing in a manner that engenders high 
macroscopic stiffness due to the positive impact of either vitrification or crystallization on 
modulus. Soft shape memory with lower tensile modulus even in the fixed state is needed for 
SMPs to be useful as seals, gaskets, stamps, and some surgical devices. Addressing this need, 
many have reported on liquid crystalline elastomers,
8,9
 POSS-grafted biopolymers,
10,11
 PEO-
based epoxy networks,
12
 and hydrogen-bonded networks
13
 that have both softness and shape 
memory. Alternatively, soft shape memory polymers, or SM elastomers, can be achieved by an 
elastomeric composite approach wherein an elastomer is reinforced with a percolating fixing 
phase.
14
 Such shape memory elastomeric composites (SMECs) can be achieved by imbibing an 
electrospun fixing phase with an elastomeric matrix precursor, followed by crosslinking of the 
matrix,
15
 or by dual-electrospinning of a fixing polymer and a thermoplastic elastomer.
16
 This 
SMEC approach to soft shape memory is applied in the present work. 
Reports of soft shape memory polymers to date have all featured a permanent, 
memorized shape whose geometry either cannot be altered (covalent networks) or cannot be 
altered without traversing a fluid state by remolding (thermoplastic SMPs).  As a practical 
matter, this leads to shapes that are usually limited to flat films – a natural geometry for casting 
and molding processes. To prepare an SMP article with a new configuration or with a non-flat 
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shape, a new sample must be made and this is both time-consuming and inefficient. Thus, we 
were motivated for the present work to design a covalently bonded elastomeric matrix for use in 
a SMEC configuration capable of permanent shape reconfiguration by facile thermomechanical 
means. Such a matrix composition would allow for fine-tuning of sample geometry, prototyping 
of devices, recycling, versatility in shape memory “target” shape, and possibly self-healing.  
In contemplating the dynamic covalent chemistry needed for the envisioned soft 
reconfigurable SMP, we considered the recent advances in the fields of self-healing polymers
17,18 
and photo-responsive polymers.
19
 In one class of self-healing polymers, reversible covalent 
bonds have been exploited to reform bonds following crack-induced damage to the materials. 
Wudl and colleagues pioneered use of Diels-Alder chemistry in this manner, utilizing 
diene/dienophile pairs; e.g., furan/maleimide, that proved to be very effective in allowing bond 
reconfiguration and crack-rebonding by application of heat during external crack closure. 
Meanwhile, Bowman and colleagues have reported on photoactive “covalent adaptive networks” 
that undergo interchange reactions during exposure to light, reconfiguring the deformed 
networks toward a stress free state apparently without macroscopic fluidization. This general 
concept was appealing to us for our purposes, but the requirement of light illumination during 
processing was deemed to be cumbersome and limiting. 
In separate studies, Shipp et al. introduced biodegradable elastomers utilizing thiol-ene 
“click” chemistry and incorporating hydrolytically labile anhydride groups.
20
 For our present 
study, we postulated that the anhydride groups of the elastomeric matrix might enable desired 
exchange reactions for thermal reconfiguration based on limited (and often old) literature that 
indicated such exchange reactions occur in solution, though no prior report testing this notion in 
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solid or rubbery materials could be found to support our conjecture.
21-25
 In this report, we present 
the synthesis and characterization of a new soft, shape memory elastomer that is thermally 
reconfigurable, termed Re-SMEC.  
4.3 Methods 
4.3.1 Materials  
 4-Pentenoic anhydride (PNA), pentaerythritol tetrakis(3-mercaptopropionate) (PETMP), 
azobisisobutyronitrile (AIBN), chloroform, N,N-dimethylformamide (DMF), trimethylolpropane 
diallyl ether (TMPDAE), 1,6-hexanedithiol (HDT), 1-hydroxycyclohexyl phenyl ketone (99%), 
anhydrous dichloromethane (DCM), anhydrous diethyl ether (≥99%, DEE), and tetrahydrofuran 
(HPLC-grade, ≥99.9%, THF).were purchased from Sigma-Aldrich and used as received. 
Thermoplastic polyurethane PCL (PCL PU) was synthesized using 3,4-dihydroxy-1-butene 
(DHB), hexamethylene diisocyanate (HDI), toluene and poly(ε-caprolactone) diol (Mn ~2000 g 
mol
-1
), which were purchased from Sigma-Aldrich and dried prior to synthesis. Tin-POMS was 
used as a catalyst and purchased from Hybrid Plastics and dried prior to use. 
4.3.2 Thiol-ene Elastomer Syntheses 
PAH was synthesized by reacting PNA with PETMP using a stoichiometry of one allyl 
per thiol functional group, and 1 wt% AIBN, and cast on glass slides with a 0.25 mm Teflon 
spacer, followed by UV cure for 30 min. Similarly, TMPDAE-based elastomer was reacted with 
PETMP using the same stoichiometry and concentration of AIBN. Poly(TMPDAE) was UV 
cured for 1 h followed by a thermal post-cure at 70 C for 1 h to be consistent with the 
conditions to cure the PAH/PCL PU composite. 
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 4.3.3 Polycaprolactone Polyurethane Synthesis 
 PCL-based polyurethane (PCL PU) was synthesized by Wenbin Kuang, a graduate 
student in the Mather Research Group. PCL diol was combined with HDI as the urethane linker 
and small molecule DHB (molar ratio of 3:6:2.1) with 1 wt% tin POMS catalyst and was reacted 
in toluene under nitrogen at 100 C for 12 h. The polymer was then precipitated in excess hexane 
and washed with DI water several times and vacuum dried at room temperature prior to use.  
4.3.4 Electrospinning 
The PCL PU of Section 4.3.3 was electrospun from a 20% (w/v) solution prepared by 
dissolving 2 g PCL PU in chloroform/DMF (volume ratio = 2:1). PCL PU fibers were produced 
using a flow rate of 1 mL h
-1
, a voltage of 16 kV, and a needle to collector distance of 12 cm 
onto a rotating and translating cylindrical collector with a diameter of 5 cm. 
4.3.5 PAH/PCL PU Composite Fabrication 
The polyanhydride monomer was applied onto the surface of the electrospun PCL PU 
fiber mat and vacuum was utilized at room temperature for complete infiltration of the monomer 
into the PCL PU fiber mat, followed by removal of excess monomer on the surface.  PAH/PCL 
PU was photocured for 30 min exposed on both surfaces using a 365 nm (2.5 W) ultraviolet light 
source at a distance of 15 cm from the sample to the light source. This irradiation cure step was 
followed by a thermal post-cure at 70 C for 1 h to complete cure of the PAH matrix, as the PCL 
PU fibers can prevent the absorption of UV below the surface. 
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4.3.6 Morphology 
 A JEOL JSM-5600 scanning electron microscope (SEM) was used with an accelerating 
voltage of 4 – 6 kV. Samples were either sputtered with gold or gold palladium for 9 – 45 s prior 
to imaging. 
4.3.7 Differential Scanning Calorimetry 
 A TA Instruments Q200 differential scanning calorimeter (DSC) was used to study the 
melting and glass transitions and enthalpies. All samples were first cooled to -60 C, followed by 
heating at 10 C min
-1
 to 100 C. Only the second heating cycles are reported to remove any 
effect from variable thermal histories. The glass transition was selected from the inflection point 
of the step transition, and the maxima were taken as the melting transition point. The melting 
enthalpy was calculated from the second heating cycle by integrating the melting peak, and used 
to determine the fraction of PCL in the elastomeric composite by comparing the degree of 
crystallinity according to: 
𝐶(%) =  
∆𝐻𝑓
∆𝐻𝑓0
 × 100 % (4-1) 
where c is the degree of crystallinity, Hf   is the heat of fusion measured by DSC and Hfo is the 
heat of fusion of  pure electrospun PCL, as determined by DSC. 
4.3.8 Thermomechanical Characterization 
 A TA Instruments Q800 dynamic mechanical analyzer (DMA) was used in 
multifrequency strain mode to measure the storage and loss moduli and tan delta. All samples 
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were first cooled to -60 C, followed by heating at 10 C min
-1
 to 90 C. Samples were cut into 
rectangular strips, maintaining a ratio of length to width of 5:1.  
4.3.9 Tensile Testing 
 A Test Resources mechanical tester equipped with a 24 N (5.6 lbf) load cell was used in 
the tensile mode to generate stress-strain curves. Samples were punched by a dog bone cutter 
(ASTM D63 Type IV, scaled down by a factor of 4) and were stretched at a rate of 33 μm s
-1
 
until failure, at room temperature.  
4.3.10 Stress Relaxation 
 A TA Instruments Q800 dynamic mechanical analyzer (DMA) was used in stress 
relaxation mode to measure the iso-strain, time dependent response at a constant temperature. 
The stress relaxation time reported was zeroed to when the stress is applied. Strain values of 1 – 
5% were used. The data was fit to a conventional Arrhenius equation to describe the temperature 
dependence of stress relaxation is expressed in Eq 4-2 below, where τ is the stress relaxation 
time, τ0 is the reference time, Ea is the activation energy of the reaction, A is the reaction factor, 
R is the gas constant, and T is the absolute temperature (K).
26
 Eq 4-2 was rearranged to calculate 
the activation energy from the slope, as shown in Eq 4-3. 
𝜏 (𝑇) =  𝐴𝑒−𝐸𝑎/𝑅𝑇 (4-2) 
ln 𝜏 = 𝑙𝑛 𝜏0 +
𝐸𝑎
𝑅𝑇
 (4-3) 
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4.3.11 Qualitative Shape Memory and Reconfiguration Testing 
 A rectangular strip was deformed by wrapping in foil and arbitrarily molding the foil into 
a wave pattern then placing in water heated to 40 C to melt the PCL PU fibers; the sample was 
held submerged for 1 min, followed by immediate quenching in an ice bath for several seconds 
to recrystallize PCL PU to set the temporary, fixed shape. This fixed shape was then placed back 
in the warm water to examine recovery, qualitatively. In a separate experiment designed to 
mechanically program the permanent shape, the permanent shape of a Re-SMEC was 
reprogrammed by deforming and fastening the sample around a cylindrical rod and placed in an 
oven at a higher temperature of 80 C for 20 min followed by cooling to RT. The reconfigured 
shape was tested for permanency by placing in the warm water bath for 20 min and observing 
whether any shape change occurs. A new shape memory cycle was conducted again using same 
methods described here, using a different temporary shape. The cumulative exposure of the 
sample to the water bath was kept to less than 1.5 h, to prevent significant degradation of the 
samples.
27
 
4.3.12 Quantitative Shape Memory and Reconfiguration Testing 
 The shape memory and permanent shape reconfiguration of the composite were 
quantified using the DMA. The DMA was used in controlled force mode to stretch a dog bone 
sample at 40 C to a 15% strain by ramping the force at 0.05 N min
-1
. The temperature was then 
decreased at 3 C min
-1
 to -40 C and held isothermal for 10 min to fix the temporary shape. The 
force was then unloaded at 0.25 N min
-1
 until it reached the preload force of 10
-3
 N. The 
permanent shape was recovered by heating at 2 C min
-1
 to 40 C, and holding isothermal for 10 
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min. The permanent shape was then reprogrammed by changing the DMA mode to stress 
relaxation and holding a strain of 5.0 % and an isothermal temperature of 90 C for 5 min 
followed by a recovery time of 20 min. To run a second shape memory cycle, the DMA was 
immediately switched back to controlled force mode and a new shape memory cycle was 
executed using the parameters described above. To test consecutive shape memory cycles 
without shape reconfiguration, the DMA was set to the controlled force mode and the shape 
memory cycle described above was repeated three times. The degree of shape fixing (Rf) and the 
degree of shape recovery (Rr) were quantified for each cycle using the following equations: 
𝑅𝑓(%) =  (
𝜀𝑓𝑖𝑥𝑒𝑑
𝜀𝑑𝑒𝑓𝑜𝑟𝑚𝑒𝑑
) × 100 % (4-1) 
𝑅𝑟(%) =  (
𝜀𝑓𝑖𝑥𝑒𝑑 −  𝜀𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑
𝜀𝑓𝑖𝑥𝑒𝑑 −  𝜀0
) × 100 % (4-2) 
where ε0 is the original strain (at the beginning of each cycle), εdeformed is the deformed strain that 
occurs after cooling while still under a load, εfixed is the fixed strain that results following 
unloading, and εrecovered is the recovered strain following heating. 
4.4 Results   
4.4.1 Thiol-ene Elastomer Synthesis 
 Similar to a previous report, the polyanhydride elastomer (PAH) was synthesized using 
commercially available materials to yield a crosslinked, degradable polyanhydride (Scheme 4-
1A).
28
 Using the same materials and methods, another diene monomer, trimethylolpropane 
diallyl ether (TMPDAE), was substituted to yield a non-anhydride elastomer for comparison of 
shape reconfiguration performance (Scheme 4-1B). 
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4.4.2 PAH/PCL-PU Composite Fabrication and Morphology 
 Poly(ε-caprolactone)-based polyurethane (PCL PU) was synthesized as shown in Scheme 
4-1B to serve as the shape fixing phase via crystallization with a resulting molecular weight of 
157,000 g mol
-1
, as determined by gel permeation chromatography (data not shown). This PCL 
PU was electrospun to create a nonwoven fiber mat and the reactive PAH monomer mixture was 
then imbibed into the PCL fiber mat and cured as shown in Scheme 4-1C. The morphology of 
the PAH/PCL composite was observed using scanning electron microscopy (SEM), where the 
electrospun PCL exhibited a fibrous morphology (Scheme 4-1D) that was completely infiltrated 
by PAH, as indicated by the absence of cavities (Scheme 4-1E). 
4.4.3 Thermal Properties 
 The thermal properties of the composite were characterized using differential scanning 
calorimetry (DSC). A comparison of the second heating and first cooling cycles of electrospun 
PCL PU and neat PAH shows that the thermal transitions of both components are also detected 
in the composite at the same temperatures as in the individual components, with electrospun PCL 
PU exhibiting a relatively low melting transition at 30.3 C  (Figure 4-1A,B). By dividing the 
enthalpy of fusion of the composite by the enthalpy of fusion of electrospun PCL PU, it was 
estimated that the composite contained 23% PCL. The thermal properties of the PAH and 
pTMPDAE elastomers are shown in Figure 4-1 and Figure 4-3A, respectively. Based on these 
data, the glass transition temperatures for PAH and pTMPDAE were determined to be -31.5 C 
and -21.0 C, respectively. 
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4.4.4 Thermomechanical Properties 
 The thermomechanical properties of the composite were characterized using dynamic 
mechanical analysis (DMA). Consistent with DSC results, the tensile storage modulus of the 
composite exhibited transitions corresponding to its individual components (Figure 4-1A). 
Specifically, the composite exhibited a drop in storage modulus around -30 C that can be 
attributed to the glass transition of PAH, as can be seen from the loss modulus maximum in 
Figure 4-2B, and a second storage modulus drop around 30 C attributed to the melting of PCL 
PU, which was used for exploiting shape memory. The storage modulus of the PAH/PCL PU 
samples was observed to be between that of its components, PCL and PAH, for T < Tm. 
4.4.5 Mechanical Properties 
 Uniaxial tensile mechanical properties at room temperature were determined by 
performing tensile testing on dog bone samples. The resulting engineering stress-strain curves 
shown in Figure 4-4 and summarized in Table 4-1 reveal that the composite mechanical 
properties are between that of the individual components. The Young’s modulus of the 
PAH/PCL PU composite was 5.6 MPa ± 1.4 MPa and was not significantly different from that of 
the PAH elastomer, at 4.5 MPa ± 0.5 MPa. The strain-to-failure of 160 % ± 40 % and tensile 
strength of 4.2 MPa ± 0.9 MPa of the composite increased dramatically, compared to PAH alone, 
which was 25 % ± 5 % and 1.1 MPa ± 0.1 MPa, respectively.  
4.4.6 Stress Relaxation 
The shape reconfiguration potential of the polyanhydride elastomer component prior to 
the addition of PCL was investigated by studying its stress relaxation response for a range of 
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temperatures. Figure 4-5 shows that only the PAH elastomer exhibited stress relaxation, whereas 
the elastomer lacking anhydride groups, such as when substituting PAH with pTMPDAE 
(Scheme 4-1A), it featured no time-dependent reduction in stress. Stress relaxation testing was 
also conducted at increasing temperatures for the same sample of PAH, which revealed that 
stress relaxation occurred a meaningful (and increasing) rate for temperatures above 40 C, with 
stress decaying exponentially for all temperatures (Figure 4-5B). Increasing the temperature 
enabled faster completion of shape reconfiguration, from approximately 9 min at 90 C to greater 
than 4 h at 50 C.  
4.4.7 Qualitative Shape Reconfiguration 
To examine the shape reconfiguration of the PAH elastomer qualitatively, samples of the 
PAH- and TMPDAE-based elastomers were heated and deformed around a cylindrical rod and 
the resulting shape was observed. As shown in Figure 4-6, only the anhydride-based (PAH) 
elastomer maintained the newly configured curved shape, whereas the TMPDAE-based 
elastomer returned immediately to its original, flat shape upon removal of the load.  
4.4.8 Qualitative Shape Memory and Reconfiguration 
 The top row of Figure 4-7A demonstrates that the composite can exhibit basic one way 
shape memory behavior, beginning as a flat strip programmed into a serpentine form at 40 °C, 
which then recovers back to its original flat form upon being thermally trigger. The ability of this 
composite to reconfigure its shape is demonstrated in the bottom row of Figure 4-7A, where the 
composite is heated to 80 C while deformed into a circular bend, that does not recover to its as-
cured flat shape under the same conditions used to trigger shape recovery (Figure 4-7A iii – iv). 
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The newly reconfigured permanent shape can undergo additional shape memory cycles, which 
are demonstrated by again heating to 40 C and deforming indiscriminately into a coil that is 
then recovered to the reconfigured permanent, circular shape.  
4.4.9 Quantitative Shape Memory and Reconfiguration 
 The shape memory and reconfiguration cycles were quantified and shown in Figures 4-
7B and Figure 4-8.  Figure 4-7B first demonstrates one way shape memory by programming a 
temporary elongated shape and recovering to its as-fabricated length. The permanent shape was 
then reconfigured to a new length by implementing a stress relaxation cycle (between time 
markers 105 min and 125 min); this was followed by another one way shape memory cycle, 
which was recovered to the reconfigured length. The results in Figure 4-8 verify that the 
composite is capable of traditional one-way shape memory, repeatable for three consecutive 
cycles. Based on this, the shape fixing ratios were determined to be 87 %, 86 %, and 86 % for 
cycles 1, 2, and 3, respectively, and did not significantly diminish with each additional cycle. 
The additional elongation of the sample upon cooling during the fixing cycle is likely due to PCL 
crystallization.
29
 The shape recovery ratios were calculated to be 84 %, 93 %, and 78 % for 
cycles 1, 2, and 3, respectively. While these recovery ratios are modest in quality, the results 
indicate, collectively, significant and reproducible shape memory behavior in addition to the new 
reconfigurability. 
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4.5 Discussion 
   In this chapter, we identified the dynamic covalent bond exchange properties of a 
cross-linked polyanhydride elastomer and its temperature dependence, and subsequently used 
these features to develop a reconfigurable shape memory elastomeric composite (Re-SMEC).  
 Embedding the PCL PU fibers within a cross-linked PAH elastomeric matrix resulted in a 
composite with thermal and mechanical properties between its individual components, as 
expected, with the exception of Young’s modulus, which was similar to that of the PAH 
elastomer. This is not surprising, given that the composite was determined to be composed of 
approximately 87% PAH. The PAH elastomer has a lower strain-to-failure than would be 
expected from other soft elastomers such as PDMS (see Chapter 3); however, the addition of the 
PCL PU fibers significantly improved these properties six-fold, expanding this material’s 
potential applications. 
 The time- and temperature-dependent relaxation properties of the polyanhydride 
elastomer component, prior to combining with PCL to form a composite, were studied and 
compared with pTMPDAE, a similarly structured cross-linked thiol-ene elastomer lacking the 
anhydride bridging group needed for bond reconfiguration reactions. As shown in Figure 4-5A, 
only the PAH elastomer exhibited stress relaxation, whereas pTMPDAE featured no time 
dependent reduction in stress. This supports our hypothesis that the bond reconfiguration in the 
solid state of the PAH elastomer is due to dynamic covalent exchange reactions involving the 
anhydride groups, as depicted by following the color-coded elements in Scheme 4-2 We 
postulate that this mechanism may be concerted or involve a free acid group. To our knowledge, 
exchange reactions of anhydride groups have been reported to occur for small molecules in the 
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liquid state.
21-25
 About six decades ago, Hurd et al. studied using a ketene agent to prevent mixed 
anhydrides from exchanging during purification, thus simplifying the process.
25 
More recently, 
Tarcha et al. found that sebacic anhydride had a tendency to disproportionate into methacrylic 
anhydride and oligomers of poly(sebacic acid)  during storage, while in the liquid state, and this 
reaction can be stabilized by decreasing the temperature.
22
 These studies all involved anhydride 
monomers in liquid form and not polymerized anhydride in the solid state.  
 As seen in Figure 4-5B, the temperature dependence of the PAH tensile stress relaxation 
was found to enable faster completion of shape reconfiguration at higher temperatures, as is 
evidenced by the significant change in relaxation time from 4 h to 9 min. Arrhenius’ law is often 
used to provide insight into the temperature dependence of chemical reactions such as 
polymerizations, diffusion of molecules and degradation, to name a few. We observed that the 
temperature dependence of the associated relaxation time of the PAH elastomer followed an 
Arrhenius behavior, with an activation energy of 7.7 kcal/mol (Figure 4-9). This activation 
energy is lower than what has been observed in other exchange reaction systems, allowing for 
more efficiency and responsiveness in the design of a smart material. For transesterification-
based exchange reactions, others have reported activation energies within the range of 19 – 33 
kcal/mol.
30-32
 Denissen et al. reported a relatively low activation energy of 14 kcal/mol for their 
vinylogous polyurethane vitrimers, with quick stress relaxation times of 550 s to 85 s, though 
these were at high temperatures of 130 C to 170 C.
33
 At temperatures of 180 – 210 C, Aden et 
al. observed activation energies of 11 kcal/mol of the ester-ester exchange of poly(ethylene 
terephthalate) using a ethyl benzoate catalyst
34 
It was also observed that the initial modulus of 
PAH increased slightly with temperature (Figure 4-10). While a theory for elasticity of 
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thermally reconfigurable networks has not yet been developed, to our knowledge, we attribute 
this observation to the prediction from conventional rubber (entropy) elasticity theory that the 
elastic modulus increases proportionally with temperature as E ~ nkT, where n is the crosslink 
density. 
 To visually demonstrate the shape reconfiguration of the PAH elastomer, a qualitative 
shape reconfiguration test was conducted and compared with similarly synthesized pTMPDAE 
elastomer. The deformed shape following thermally activated stress and strain around a 
cylindrical rod is shown in Figure 4-6. Interestingly, only the anhydride-based (PAH) elastomer 
maintained the newly configured curved shape, whereas the TMPDAE-based elastomer returned 
immediately to its original, flat shape upon removal of the load, as expected of an elastomer. 
Moreover, when the deformed PAH was heated back to 80 C in the stress-free state, it did not 
return to its original shape, but remains deformed (not shown), further supporting that this new 
shape is permanent, as a result of the rearrangement of the anhydride bonds.  
 In light of these thermally reconfigurable properties, a shape memory system was then 
designed with thermal triggers below 50 C as this would prevent overlap of operating regimes 
with the PAH shape reconfiguration that was shown to occur above this temperature. To 
fabricate a shape memory composite capable of permanently changing its original shape, a low-
melting poly(ε-caprolactone)-based polyurethane (PCL PU) was synthesized to serve as the 
shape fixing phase via crystallization (Scheme 4-1B). A shape reconfiguration temperature of 80 
C was selected due to the reasonably short time requirement. The top row of Figure 4-7A 
demonstrates that the composite can exhibit basic one way shape memory behavior, and the 
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ability of this composite to reconfigure its shape is demonstrated in the bottom row of Figure 4-
7A, and was demonstrated to undergo additional shape memory cycles.  
 This shape memory observation was also quantified (Figure 4-7B) where a stress 
relaxation cycle was implemented to produce a reconfigured shape between shape memory 
cycles. Like other shape memory systems, the permanent shape for this composite is established 
by the polyanhydride crosslinks, which served to recall the permanent shape, and is governed by 
the geometry under which it was polymerized.
35
 Unlike other systems, this original shape can be 
reprogrammed by rearrangement of these crosslinks so that the shape memory performs relative 
to this newly reconfigured permanent shape. While others have developed reconfigurable shape 
memory systems, few are biocompatible and to our knowledge, none are fully biodegradable 
which can be used to tailor geometry-specific implantable medical devices capable of controlled 
drug delivery.
 36-38
 Additionally, this composite enables shape recovery to occur at physiological 
temperatures, which can potentially be used for designing medical devices that require this action 
in the body and with timed degradation. 
4.6 Conclusions 
 In conclusion, a new shape memory composite with the ability to reconfigure its 
permanent shape was developed. This biocompatible and fully degradable composite provides 
benefits over other reconfigurable systems in that this material can also provide temporary shape 
programming and recovery without interference with its permanent reconfiguration encoding. 
Additionally, since shape memory occurs at physiological temperatures, the potential exists for 
many biomedical applications such as degradable implants with deploying mechanisms, self-
healing applications, and dynamic surfaces for tissue engineering. 
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Figure 4-1. (A) Differential scanning calorimetry (DSC) second heating curves, and (B) first 
cooling curves of (i) neat PAH elastomer, (ii) PAH/PCL PU composite, and (iii) electrospun 
PCL PU. 
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Figure 4-2. Dynamic mechanical analysis (DMA) (A) storage modulus curves and (B) loss 
modulus curves of (i) neat PAH elastomer, (ii) PAH/PCL PU composite, and (iii) electrospun 
PCL PU.  
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Figure 4-3. (A) Differential scanning calorimetry first cooling and second heating results and 
(B) dynamic mechanical analysis of pTMPDAE-based elastomer. 
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Figure 4-4. Representative engineering stress-strain curves of (i) PAH elastomer, (ii) the PAH-
PCL PU composite, and (iii) electrospun PCL PU, where the composite and its components are 
shown in (A). More details of the  PAH elastomer and the composite are shown in (B). 
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Table 4-1. Summary of mechanical properties for the PAH/PCL PU elastomeric composite. 
 
Sample 
Young's Modulus 
(MPa) 
Strain-to-Failure 
(%) 
Tensile Strength 
(MPa) 
PAH 4.6 ± 0.5 26 ± 5 1.1 ± 0.1 
PCL PU 1.1 ± 0.4 1400 ± 70 17.6 ± 1.7 
Composite 5.6 ± 1.4 160 ± 40 4.2 ± 0.9 
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Figure 4-5. Shape reconfiguration as measured by stress relaxation. The relaxation modulus 
versus time are shown for: (A) varying the network composition at 80 
o
C for (i) PAH and (ii) 
TMPDAE, and (B) varying reconfiguration temperatures for the PAH elastomer. 
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Figure 4-6. Shape reconfiguration response of elastomers synthesized using: (a) anhydride 
(PAH) and (b) TMPDAE diene monomers, in the flat configuration (left) and resulting shape 
following shape reconfiguration at 80 °C (right).  
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Figure 4-7.  Shape memory and reconfiguration behavior of PAH/PCL PU polyurethane 
composite. (A) Images of qualitative study demonstrating one way shape memory where (i) a 
temporary shape is fixed and then (ii) recovered to the original shape, followed by (iii) 
reconfiguration of the permanent shape; (iv) the reconfigured shape does not recover to the 
original geometry. (B) Quantitative shape memory and shape reconfiguration cycles for the 
PAH/PCL PU composite. 
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Figure 4-8. Shape memory stress-temperature-strain plot for PAH/PCL PU composite.  
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Scheme 4-2.  Dynamic covalent exchange activated thermally and involving rearrangement of 
adjacent anhydride groups.  
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Figure 4-10. Isothermal tensile storage modulus of the PAH elastomer as temperature is 
increased in a stepwise manner.  
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Chapter 5 
Biodegradable Shape Memory Elastomeric Composites  
with Controlled Release of a Model Drug 
5.1. Synopsis 
The degradation and drug release properties of polyanhydride (PAH) based elastomeric 
shape memory composites developed in Chapter 4 were studied. Under in vitro physiological 
conditions, the degradation rate of the PAH matrix was strongly influenced by the selection of 
the polymeric fibrous phase. Based on the gravimetric, thermal and morphological properties, 
degradation was significantly faster for the composite containing poly(-caprolactone) (PCL) 
fibers compared to composites with poly(vinyl acetate) (PVAc) fibers. An erosion mechanism 
was found to occur as a modified surface to bulk degradation in the composite, although the 
PAH by itself erodes heterogeneously. A hydrophilic model drug was incorporated in the fibrous 
phases and used to study the in vitro controlled release properties of these composites. For the 
PCL-based composite, drug release correlated with PAH matrix degradation. In contrast, the 
drug release for the PVAc-based composite proceeded more steadily and slowly increased over 
time, which was attributed to plasticization by PAH degradation products and water. Lastly, the 
shape memory properties were examined for both composites. The PCL/PAH composite was 
capable of preserving arbitrary fixed shapes during and for months after matrix degradation. 
While the PVAc/PAH composite could not maintain a fixed shape in aqueous media due to 
significant shrinkage, it proved capable of one way shape memory independent of the 
reconfiguration properties of the PAH matrix. 
 
5.2. Introduction 
 Degradable materials generally have two major applications: (1) ecological, where a  
biodegradable packaging can minimize the environmental impact of consumer products, and (2) 
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biomedical, where, for example, a resorbable prosthesis eliminates the need for retrieval 
surgeries and circumvents long-term foreign responses.
1,2
 These multifaceted, broad range of 
applications for degradable materials translates to complex requirements for device development, 
ranging from rapid degradation for short-term use to long-term maintenance of mechanical 
integrity, among other prerequisites. In the biomedical domain, degradable materials are required 
to subsist in the relatively aggressive environment of the human body, while also providing 
organ function, or substituting for or repairing a specific tissue. Biodegradation is required to 
occur in such a manner that degradation matches the material replacement by native cells.
3
 
Ideally, the material should promote cell attachment and proliferation, with means for cellular 
nutrient and waste transport that facilitates tissue regeneration, and the degradation rate of a 
material must be engineered to accommodate this.
4
 Aside from tailoring the degradation rate, 
other factors must be considered when designing biodegradable materials such as material 
processability, mechanical properties, shelf life, biocompatibility during degradation with safe 
elimination from the body, as well as material properties during degradation.
5
 The challenges 
with developing degradable biomaterials are that degradation is also dependent on morphology, 
hydrophilicity, crystallinity, additives (such as drugs, salts or plasticizers) molecular weight, size, 
shape, and whether degradation was studied in vivo or in vitro.
6-8
 Consequently, the advancement 
of degradable materials is dependent on multiple research fronts and disciplines.
 
 Degradation of a polymeric material proceeds according to two main mechanisms: 
surface/heterogeneous or bulk/homogenous degradation. The mechanisms of degradation are 
generally either hydrolytic, enzymatic, or oxidative in nature. These materials are discernable by 
their hydrolyzable bonds, with the chemical interaction between the labile bond and water 
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dictating the hydrolysis rate.
9
 Polymers that undergo surface erosion maintain their geometry 
during degradation while the material loss occurs at the surface, where it is exposed to its 
environment; the material loss generally proceeds at a constant rate. A bulk eroding polymer 
loses material through its matrix as water penetrates through its volume, and its erosion rate 
depends on the amount of available material at a given time point.
10
 Typical  degradable 
biomaterials are based on homopolymers or copolymers of poly(glycolic acid), poly(lactic acid), 
polyesters, and  polydioxanones, bacterial-derived polymers, polyanhydrides, or natural 
polymers.
11,12
  
 As mentioned earlier, biomaterials are tasked with meeting complex, application-driven 
requirements for placement in dynamic environments. As such, it is not adequate for a material 
to solely possess tunable degradability, since this will still fall short of meeting other constraints. 
Supplementing these materials with additional functionality such as mechanical toughness, shape 
memory for minimally invasive surgery, and controlled drug release for infection management, 
can greatly extends its scope to numerous applications, which is why many researchers 
endeavored to achieve these goals, as revealed by several review articles.
13-14
 Neffe et al. 
recognized this technological gap, and sought to combine three functions into one material by 
cross-linking drug-loaded oligo[(ε-hydroxycaproate)-co-glycolate]dimethacrylates.
15 
By varying 
the glycolate and n-butylacrylate content, the degradation rate of this copolymer was greatly 
varied. Serrano et al. developed a degradable shape memory elastomer capable of both controlled 
release and tunable degradation by synthesizing cross-linked polydiolcitrate polyesters.
16
 
Through alteration of the molar ratio of hydroxyl to carboxyl groups in the synthesis reaction, as 
well as by the addition of a hydrophilic monomer, the authors were able to shift the degradation 
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from approximately 90% to 40% degraded at 8 w, and show good shape memory with drug 
release of a model molecule up to approximately 20 d. Nagahama et al. synthesized custom 
cross-linked branched oligo(caprolactone) networks also capable of one way shape memory and 
controlled drug release.
17
 The polymer degradation was tuned by the addition of ε-caprolactone 
monomer during synthesis to influence crystallinity in the sample. The degradation of these 
materials was slow, with the samples retaining over 96% of its initial weight for 120 d, at which 
point the different degradation profiles became apparent. The authors demonstrated controlled 
drug release; however the release rate was not different between differing samples. These 
studies, like others,
 18-19
 achieved multifunctional degradable materials that rely on customized 
chemical synthesis methods, which are time-consuming, specific, and more expensive for scale-
up and manufacturing. Zhang et al. observed this challenge and aimed to address the need for a 
more cost-effective multifunctional material by combining commercially available materials to 
create a shape memory composite with tunable degradation.
20
 The authors showed that a 
combination of poly(lactic acid) fibers and a cross-linked poly(trimethlylene carbonate) matrix 
exhibited good shape memory and a high mechanical moduli, which is not suitable for tissue 
engineering of soft tissues.  Moreover, this study did not examine or verify the claim of tunable 
degradation of these materials and therefore it is unclear how it performs as a multifunctional 
biomaterial. As such, there remains an opportunity to develop a more cost-effective, 
manufacturing-friendly multifunctional material with tailorable degradation, particularly with 
low moduli. 
 Another approach to meet the challenging requirement of multifunctionality is to blend 
existing materials to form composites. Polymeric composites offer versatility of material 
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properties and hold the potential of designing materials that meet multiple requirements. 
Composites have an added commercial benefit in that the simple regulation of the ratio of its 
individual components, such as homopolymers, results in a diversity of material properties. The 
blending of polymers to form a composite is scalable and cost-effective, particularly when using 
commercially available materials, and even more so if the material has been previously used in 
FDA-approved devices.  On the other hand, composite materials introduce challenges of 
reproducibility of microstructure and often a large impact of the fiber/matrix interface on 
macroscopic properties. Our research strategy in this chapter was based on the integration of 
commercially available biocompatible materials to form multifunctional, degradable composites. 
 One polymer of interest to us was poly(-caprolactone) (PCL), a degradable, 
semicrystalline polyester with proven biocompatibility that has been widely studied as a platform 
for new products due to its ease of manufacture, and long-term degradability. PCL has been 
studied extensively in vivo and is FDA approved for use in a number of biomedical devices 
including sutures and drug delivery vehicles
.21,22
 PCL is commercially available in a range of 
molecular weights, and easy to manufacture given its ability to dissolve in many common 
organic solvents and its relatively low melting transition of approximately 54 – 60 C for melt 
processing. Degradation of PCL occurs after about 2 - 4 y via hydrolysis of the ester groups and 
occurs in two main stages beginning with a reduction in molecular weight, which is likely 
dominated by bulk erosion that can be accelerated in the presence of lipase.
4,23,24
 PCL by itself, 
however, does not meet many biomedical needs beyond biocompatibility. To extend its range of 
application, many have combined it with another polymer or material.
25-26
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 In Chapter 4 we presented a study of the shape memory and shape reconfiguration 
properties of a new elastomeric composite that combined PCL with cross-linked polyanhydride 
(PAH). However, the degradation properties of this new composite had not been investigated. 
PAH is a hydrophobic polymer that undergoes surface erosion by hydrolysis of the anhydride 
groups. Further, it is distinguished from other materials undergoing hydrolytic reactions, such as 
esters and amides, in that it has a much shorter half-life due to the relative instability of the 
anhydride linkage in many types of aqueous environments.
27
 PAH has been demonstrated to be 
biocompatible and has been approved in some forms by the FDA in devices to treat brain 
cancer.
28,29 
Due to these properties, PAH-based materials are primarily studied for drug delivery 
applications given their predictable degradation profile. The PAH used in this studied was 
developed by the Shipp et al., where a thiol-ene chemistry was used to create cross-linked, 
elastomeric polyanhydrides with tailorable properties and was shown to undergo in vitro surface 
degradation over a period of approximately three days.
30
  
 Prior work in the Mather research group focused on developing soft, elastomeric shape 
memory composites using electrospun fibers with a distinct thermal transition embedded in an 
elastomeric matrix. Both Luo et al. and Robertson et al. developed shape memory composites 
combining electrospun PCL embedded in a non-degradable matrix such as  polydimethylsiloxane 
or a polyurethane, each termed a shape-memory elastomeric composite (SMEC).
31,32
 These 
composites were limited to shape memory and the drug-releasing properties of these composite 
configurations were not studied. In the present work, we utilized a degradable elastomeric 
matrix, where we sought to understand the influence of the fiber hydrophobicity on matrix 
degradation. We hypothesized that embedding a semicrystalline, hydrophobic percolating fibrous 
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phase, such as PCL, will increase the degradation rate of the surrounding PAH matrix relative to 
using another polymer, such as polyvinyl acetate (PVAc), due to the decreased water interaction 
with PCL relative to PVAc, therefore enabling greater aqueous availability for PAH degradation. 
We anticipated that by substituting the fibrous phase with another polymer in the composite, the 
degradation rate and drug release from the fibers could be modulated. We also examined the 
mechanical and shape memory properties during degradation. 
   
5.3. Materials and Methods 
5.3.1 Materials 
 Poly(ε-caprolactone) (PCL) (Mn ~80,000 g mol
-1
), 4-Pentenoic anhydride (PNA), 
pentaerythritol tetrakis(3-mercaptopropionate) (PETMP), azobisisobutyronitrile (AIBN), 
chloroform, N,N-dimethylformamide (DMF), phosphate buffered saline (pH of 7.4), and 
tetrahydrofuran (HPLC-grade, ≥99.9%, THF) were purchased from Sigma-Aldrich and used as 
received. Poly(vinyl acetate) (PVAc, Mn ~350,000 g mol
-1
) was purchased from Scientific 
Polymer Products and was used as received. 
5.3.2 Electrospinning of PCL 
 Poly(ε-caprolactone) (PCL) was electrospun from a 20% (w/v) solution prepared by 
dissolving 2 g PCL in THF/DMF (volume ratio = 2:1). PCL fibers were produced using a flow 
rate of 1 mL h
-1
, a voltage of 11 kV, and a needle to collector distance of 7 cm onto a grounded 
rotating and translating collector. Following electrospinning, the PCL fiber mat was vacuum 
dried at room temperature for 24 h.  
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5.3.3 Electrospinning and Thermal Treatment of PVAc 
 Poly(vinyl acetate) (PVAc) was electrospun from a 20% (w/v) solution prepared by 
dissolving 2 g of PVAc in methanol/DMF (volume ratio  = 7:3). PVAc fibers were produced 
using a flow rate of 1.0 mL h
-1
, a voltage of 11 kV, and a needle to collector distance of 7 cm 
onto a grounded rotating and translating collector. Following electrospinning, the PVAc fiber 
mat was vacuum dried at room temperature for a minimum of 24 h. The PVAc fiber mat was 
maintained secured on the aluminum foil substrate used in electrospinning, which was used to 
aid in anchoring the fibers during thermal treatment to relieve residual stresses incurred during 
electrospinning. A post-electrospinning thermal treatment of 50 C for 24 h, while the fiber mat 
remained constrained on the aluminum foil used to deposit fibers during electrospinning, was 
implemented to minimize fiber shrinkage. 
5.3.4 PAH Monomer Preparation 
 The polyanhyride (PAH) monomer preparation and synthesis conditions are the same as 
those used in Chapter 4 of this thesis and described in Section 4.3.2. 
5.3.5 PCL/PAH Composite Fabrication 
 The methods of vacuum infiltration of electrospun PCL with PAH monomer and curing 
are the same as those used in Chapter 4 of this thesis and detailed in Chapter 4.3.5. 
5.3.6 PVAc/PAH Composite Fabrication  
 To minimize shrinkage of the PVAc fibers upon contact with the PAH monomer or 
water, as a result of residual stresses accrued during the electrospinning process, the PAH 
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monomer was allowed to slowly pre-cure for 19 h – 20 h at 1.6 C (in a standard refrigerator) 
prior to vacuum infiltration of the PAH monomer into the PVAc fiber mat. It was determined 
that slowly pre-curing the PAH monomer under refrigeration combined with thermally treating 
the PVAc fibers enabled reproducible fabrication of the PVAc/PAH composite. The PVAc/PAH 
was photocured for 30 min exposed on both surfaces using a 365 nm (2.0 mW cm
-2
) ultraviolet 
light source at a distance of 15 cm from the sample to the light source. Although the former step 
led to complete matrix cure, the irradiation cure step was followed by a thermal post-cure at 70 
C for 1 h to be consistent with PCL/PAH curing conditions. 
5.3.7 Thermal Characterization  
 Differential scanning calorimetry (DSC) was performed using a TA Instruments Q200 
apparatus. Samples weighing 2 – 5 mg were sealed in Tzero aluminum pans and were from -60 
C to 120 C at 10 C
.
min
-1
. The characteristic thermal transitions for all samples were 
determined using the second heat for glass transition or first heat for crystallization. The glass 
transition was selected from the inflection point of the step transition, and the maxima were 
taken as the crystallization transition point.  
 For the PCL/PAH composite, the crystallization enthalpy (Hc) was used to determine 
PCL content of the composite, as it is directly related to crystallinity. The crystallization enthalpy 
was calculated from the first heating cycle by integrating the crystallization peak, and used to 
determine the fraction of PCL in the elastomeric composite by comparing the degree of 
crystallinity according to: 
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𝑊𝑃𝐶𝐿(%) =  
∆𝐻𝑐
∆𝐻𝑐,0
 × 100 % (5-1) 
where c is the degree of crystallinity, Hc  is the heat of crystallization of the composite 
measured by DSC and Hc,o is the heat of crystallization of  pure electrospun PCL, which was 
determined by DSC to be 60.6 J g
-1
. 
 For the PVAc/PAH composite, the change in heat capacity at Tg (Cp) was used to 
determine the PVAc content of the composite, as it is directly related to its glass transition. The 
heat capacity was calculated from the step change using the TA Instruments Universal Analysis 
software (version 4.5A) during the second heating cycle, and used to determine the fraction of 
PVAc in the elastomeric composite by comparing the degree of amorphousness according to: 
𝛼𝐴(%) =  
∆𝐶𝑝
∆𝐶𝑝,0
 × 100 % (5-2) 
where αA is the percentage of material (PVAc) having the Tg under isolated analysis, Cp, is the 
change in heat capacity of the composite measured by DSC, and Cp,o is the heat capacity change 
of the corresponding pure electrospun PVAc, which was determined by DSC to be 0.62 J g
-1
°C
-1
. 
5.3.8 In Vitro Degradation  
 The in vitro degradation of the PAH-based composites was carried out by cutting samples 
into 1 cm x 1 cm squares and immersing separately in phosphate buffered saline (PBS, pH of 
7.4). All samples were placed in an isothermal shaker (New Brunswick Scientific, Model C24) 
under a constant temperature of 37 C and agitating at 60 rpm for up to 14 days. A minimum 
ratio of 2 mg of sample per mL of PBS was used and the acidity of the dissolution media was 
monitored daily and changed every few days to maintain a pH of 7.4. At a scheduled time point, 
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three samples were removed from PBS, rinsed with DI water and dried at room temperature in 
vacuo. The mass loss was calculated by comparing the mass at a given time point (Mt) with the 
initial mass (M0) prior to degradation, as shown in Eqn. 5-3 below. Each mass loss determination 
was conducted in triplicate and an average and standard deviation are reported. 
𝑀 (%) =  100 % × (1 −
𝑀0 − 𝑀𝑡
𝑀0
) (5-3) 
The thermal, morphological, and mechanical properties of the samples were also evaluated at 
different degradation times using DSC, SEM, and tensile testing. The composition of the samples 
during degradation was analyzed by comparing the DSC thermograms of the degraded samples 
to that of its individual, unaltered components, as detailed in Section 5.3.7. 
5.3.9 Mechanical Properties 
 Tensile mechanical properties was studied by punching samples into a dog bone 
geometry (ASTM Standard D638-03 Type IV, scaled down by a factor of 4), and loading onto a 
Test Resources Model 100P Universal Testing Machine equipped with a 24 N load cell. The 
samples were stretched at a rate of 33 μm s
-1
, and engineering stress-strain curves were used to 
determine Young’s modulus, strain-to-failure, and tensile strength. Five samples of each type 
were tested and an average and standard deviation are reported. 
5.3.10 Morphology 
 The surface features of the samples were microscopically visualized using a JEOL JSM 
5600 scanning electron microscope (SEM) and an accelerating voltage of 5 kV. The samples 
were sputter coated with gold for 45 s prior to imaging. 
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5.3.11 Qualitative Shape Memory 
 
 Shape memory was performed for the PVAc/PAH composite only, as the glass transition 
temperature of the composite (~30 C) enabled one way shape memory without activation of the 
PAH reconfiguration, unlike the PCL/PAH composite (Tm ~ 60 C), as discussed in Chapter 4. 
A rectangular strip was deformed into a temporary shape by wrapping around a Teflon rod of 
known diameter and securing in place by wrapping in foil. The sample was then placed in an 
isothermal oven at 45 C for 10 min followed by immediate placement in a freezer (-18 C) for 
10 min; the sample was then removed from the rod to observe the fixed shape.  Shape recovery 
was triggered by placing the sample in the isothermal oven at 45 C in the stress-free state.  
5.3.12 Quantitative Shape Memory 
  
 The shape memory of was quantified using the DMA based on a four-step sequence.
33
 
The DMA was used in controlled force mode to stretch a dog bone sample at 40 C to a 15% 
strain by ramping the force at 0.02 N min
-1
. The temperature was then decreased at 3 C min
-1
 to 
0 C and held isothermal for 5 min to fix a temporary shape. The force was then unloaded at 0.05 
N min
-1
 until it reached the preload force of 10
-3
 N. The permanent shape was recovered by 
heating at 10 C min
-1
 to 40 C, and holding isothermal for 5 min. The shape memory loop 
described above was repeated three times. The degree of shape fixing (Rf) and the degree of 
shape recovery (Rr) were quantified for each cycle using the Eqns. 5-4 and 5-5 below, where ε0 
is the original strain (at the beginning of each cycle), εdeformed is the deformed strain that occurs 
after cooling while still under a load, εfixed is the fixed strain that results following unloading, and 
εrecovered is the recovered strain following heating. 
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𝑅𝑓(%) =  (
𝜀𝑓𝑖𝑥𝑒𝑑
𝜀𝑑𝑒𝑓𝑜𝑟𝑚𝑒𝑑
) × 100 % (5-4) 
𝑅𝑟(%) =  (
𝜀𝑓𝑖𝑥𝑒𝑑 −  𝜀𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑
𝜀𝑓𝑖𝑥𝑒𝑑 −  𝜀0
) × 100 % (5-5) 
5.3.13 Fixed Shape during Degradation 
Here, we sought to measure the ability of the composites to retain a fixed shape during 
degradation. For that, samples were prepared by arbitrarily deforming a rectangular strip into a 
spiral, a curve or a wave pattern. The samples thus deformed were placed in an isothermal oven 
at 70 C and held there for 10 min, melting the constituent PCL crystals, followed by transferring 
to freezer maintained at -18 C for 10 min, recrystallizing the PCL to fix the temporary shape. 
The newly fixed shape was then placed buffered PBS at 37 C, agitated at 60 rpm, as described 
in Section 5.3.8, to begin in vitro degradation and photographed at different time points for 
visual assessment and comparison to the original fixed shape and equilibrium (flat) shape. Shape 
fixing during degradation was not performed on the PVAc/PAH samples since the PVAc shrinks 
considerably upon PAH degradation and subsequent exposure to water and therefore cannot 
maintain a fixed shape while immersed in water. 
5.3.14 In Vitro RhB Release 
Controlled drug release of hydrophilic model drug Rhodamine B (RhB) from the PAH-
based samples was conducted using the methods established in Chapter 2 (Section 2.3.6). 
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5.4. Results 
5.4.1 Fabrication of PAH-based composites 
 The fabrication process of PAH-based composites followed a similar method used for the 
fabrication of the PCL-PU/PAH composite discussed in Chapter 4, using either commercially 
available PCL or PVAc electrospun into fibers. Scheme 5-1 summarizes the chemical structures 
for the PAH, PCL, and PVAc components. The cross-linking of the PAH elastomer proceeded 
using same scheme as in Chapter 4, using the vacuum infiltration process previously described 
to combine the fibers with the monomer to form a composite; only the PVAc-based composite 
required an additional thermal treatment to prevent significant shrinkage during the PAH curing 
step, as a result of residual stresses accrued during the electrospinning process. Figure 5-1 
summarizes the effect of applying a thermal treatment to electrospun PVAc, where significant 
shrinkage occurs without heat treatment following exposure to water (Figure 5-1C), and 
dissolution of the PVAc fibers occurs when combined with PAH monomer (Figure 5-1A). It was 
determined that slowly pre-curing the PAH monomer under refrigeration combined with 
thermally treating the PVAc fibers enabled reproducible fabrication of the PVAc/PAH composite 
with visually distinct phases. 
 The thermal and thermomechanical properties of PAH-based composites are presented in 
Figure 5-2, and compared with their respective individual components. Figure 5-2A shows that 
both composites display two distinct thermal transitions corresponding with their individual 
components. The PCL/PAH composite shows a melting transition at 54.3 C and a glass 
transition temperature of -21.4 C; the melting temperature of electrospun PCL, itself was 54.8 
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C, and the glass transition of neat PAH was -21.2 C. Using Eqn. 5-1, the PCL/PAH composite 
contained approximately 18% PCL. The PVAc/PAH exhibited glass transition temperatures of    
-31.3 C and 30.1 C; the glass transition temperature of neat electrospun PVAc was 44.7 C. 
Using Eqn. 5-2, the PVAc/PAH composite comprised of approximately 16% PVAc. Given, 
however, the evident plasticization of PVAc by PAH monomers, this estimate of PVAc 
incorporation level is dubious. Figure 5-2B shows that at 25 C, the PCL/PAH and PVAc/PAH 
had a storage moduli of 14.9 MPa and 304.1 MPa, respectively. The storage modulus for 
electrospun PVAc decreased from 491 MPa to 408 MPa at 25 C following heat treatment, 
which we attributed to a lower of the molecular orientation in the constituent fibers. Both 
composites showed the presence of a rubbery plateau between 50 C and 80 C, which is due to 
the presence of PAH.  
 The morphologies of both the surface and cross-sections are shown in Figure 5-3, which 
verified complete infiltration of the PAH through the thickness of both samples, as presented in 
Figures 5-3B and 5-3E, where the surfaces are smooth, likely due to film formation of PAH. 
The cross-sections of both composites, as shown in Figures 5-3C and 5-3F, reveal an absence of 
voids due to the PAH occupying the space between the fibers. In addition, the electrospun PVAc 
maintained a fibrous morphology following thermal treatment (Figure 5-3D). 
 The mechanical properties of the PAH-based composites are summarized as engineering 
stress-strain curves in Figure 5-4 and Table 5-1. The average Young’s modulus for the 
PCL/PAH composite was 7.5 MPa ± 0.9 MPa, which is slighter greater than that of PAH of 4.5 
MPa ± 0.4 MPa and not significantly different than that of electrospun PCL at 7.1 MPa ± 3.0 
MPa. The strain-to-failure of the composite was determined to be 80% ± 40% and was 
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significantly less than that of electrospun PCL of 1300% ± 140% and much closer to that of PAH 
at 30% ± 5% indicating that the crosslinked PAH dominated the mechanical properties and 
limited the composite elongation before failure, as it comprised approximately 83% of the 
composite and testing was conducted above the PVAc glass transition temperature. 
 Applying a thermal treatment to the electrospun PVAc fibers resulted in a significant 
increase in Young’s modulus for the PAH composite, from 63.5 MPa ± 11.3 MPa to 157.1 MPa 
± 15.2, with no significant difference in strain-to-failure. This increase in elastic modulus was 
discernible when handling the sample. The PVAc/PAH composite exhibited a Young’s modulus 
of 2.9 MPa ± 0.5 MPa, which was significantly less than each of the PAH and PVAc individual 
components, indicating a potential interaction between the two components. The strain-to-failure 
of PVAc/PAH was 60% ± 7% and was slightly greater than that of PAH and PVAc, although 
these were not statistically significantly different (p > 0.05).  
5.4.2 In Vitro Degradation Mass Loss 
 The mass loss profiles of the PAH-based composites in PBS at 37 C are shown in 
Figure 5-5. The composites exhibited distinct degradation rates. The PCL-based composite 
showed the greatest mass loss within the shortest time period. Specifically, within the first 10 h, 
PCL/PAH rapidly lost about 55% of its original mass, whereas the PVAc/PAH lost only 13% of 
its original mass during this time. The mass loss for PCL/PAH ceased at about 24 h, with no 
significant decrease in mass from 24 h to 14 d and remaining at 29.0% ± 1.4%. The mass 
remaining for PCL/PAH at time points 24 h, 48 h, 72 h, 4 d, and 14 d were not significantly 
different. In contrast, the PVAc/PAH composite lost mass more steadily, reaching about 50% 
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mass loss between 48 h and 72 h. The PVAc/PAH mass loss rate followed a decreasing 
exponential pattern, and approached a % mass remaining of 25.6% ± 3.7% at 20 d.  
5.4.3 Morphology  
The surfaces and cross-sections of the composites were examined following different 
degradation times using scanning electron microscopy. As shown in Figure 5-6A, after 5 h of 
degradation, the smoothness of the surface manifested into wrinkled features, which appear 
consistent with the surface topology of the underlying PCL fibers.  The formation of craters and 
pores appeared after approximately 24 h of degradation and progressed into connected channels 
by 48 h. The cross-sections shown in Figure 5-6B revealed that degradation initially occurred at 
the surface and that by 24 h, channels formed on the surface, and traveled through the cross-
section. By 72 h, the PCL fibers became exposed at both the surface and cross-section, with 
small, random regions of PAH matrix becoming visible on the fibers. The PAH matrix was no 
longer visually evident past 96 h. The dense horizontal linear artifact noticeable in both the 72 h 
and 96 h micrographs was an artifact from the sectioning process of the samples with a razor 
blade. Visually, the PCL/PAH samples maintained their macroscopic size and shape throughout 
degradation with no notable swelling or other geometrical changes. 
As shown in Figure 5-7, the PVAc/PAH composite degraded at a slower rate than the 
PCL/PAH composite. No significant changes to the surface are visualized within the first 10 h of 
degradation, where the surface appeared smooth. The micrograph shown in Figure 5-7A at 10 h 
reveals a crater consistent with a bubble formed at the surface during the cross-linking of PAH. 
At 24 h, cracks and wrinkles began to form on the surface, and by 48 h, pores were formed that 
became interconnected channels by 72 h of degradation. Like the PCL-based composite, the 
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PVAc fibers became noticeable at 72 h, as seen on the both the surface and cross-sections 
(Figure 5-7A,B); however, unlike PCL/PAH, a predominantly fibrous morphology does not 
occur until 8 d instead of 72 h. The change in fiber morphology when compared to the original 
(as electrospun) may be due shrinkage that occurred – driven by the PVAc fibers undergoing 
hydration-triggered contraction
34
 as the PAH degraded and no longer provided mechanical 
support. In contrast to the PCL/PAH composite, the PVAc/PAH samples began to visibly shrink 
and lose their rectangular geometry during degradation, folding onto itself after 24 h of 
degradation; it was also observed that at this degradation time, the samples became tacky. 
Interestingly, the PVAc/PAH composites continued to contain PAH, even after 14 d of 
immersion in an aqueous solution, as indicated by the DSC data in Table 5-3, and discussed 
further in the next section. 
5.4.4 Thermal Properties 
Differential scanning calorimetry was used to determine the changes in thermal 
properties, and by inference composition, the PAH-based composites during degradation. 
Figures 5-8 and 5-9, and Table 5-2 summarize the changes in crystallization enthalpy for the 
PCL/PAH composite at various degradation times. Over the course of the degradation period, the 
peak area corresponding to PCL crystallization increased, indicating an increase in crystallinity 
due to the increasing fraction of PCL in the composite, as the PAH degradation products receded 
into the buffered media.  A rapid growth in the crystallization enthalpy is apparent at 10 h and 48 
h, where the PCL fraction quadruples. The glass transition of PAH is no longer evident after 24 
h, and the PCL Tc shifts by about 2 C and became aligned with that of electrospun PCL (Tc ~ 32 
C). After 48 h, the increase in melting enthalpy became significantly slower, particularly 
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between 4 and 14 d, when there was less than a 4% increase in PCL content. By the 14 d, the 
sample had become composed of approximately 96% PCL, indicating the presence of a small 
amount of residual PAH. Using DSC to determine the thermal transitions may be more sensitive 
to compositional changes than by calculating the mass loss. Although mass loss data in Figure 5-
5 showed no significant degradation beyond 24 h, the micrographs in Figure 5-6 and the 
thermograms in Figure 5-8 both support that this is closer to 4 d.  
A comparison of the heat capacity changes at Tg of the PVAc component was used to 
calculate the fraction of PVAc in the composite using Eqn. 5-2, and the results are summarized 
in Figure 5-10 and Table 5-3. Figure 5-11 plots the time-evolution in glass transition 
temperature (Tg) corresponding to PVAc phase in the composite, along with mass loss due to 
PAH degradation. As shown in Figures 5-10 and 5-11, the initial Tg of the PVAc component in 
the composite, prior to degradation, was approximately 30 C, which is about 15 C lower than 
that of pure electrospun PVAc (Tg ~ 45 C), indicating that the PAH may have had a plasticizing 
effect on the PVAc fibers. During degradation, the PVAc Tg remained stable until about 24 h, 
when it decreased rapidly from 20.3 C and continued to rapidly decrease between 24 h and 72 h. 
After 72 h, the Tg increased from 0.9 
o
C to 29.5 C at 96 h, after which it continued to increase, 
but at a much slower rate from 29.5 C to 36.7 C at 14 days. We attributed the Tg recovery to 
the degradation of the PAH within the PVAc fibers, which would also be limited by diffusion of 
the degradation products from the fibers. At 14 d, the remaining mass approached 20% PVAc, 
which was slightly more than the 16% fraction determined by DSC in the composite prior to 
degradation. Both of these results indicate that at 14 d, some residual PAH remains. A 
comparison of the rate of increasing fiber content during degradation for both the PCL/PAH and 
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PVAc/PAH composites are plotted in Figure 5-12, showing that the PAH matrix degraded faster 
for the PCL/PAH composite than the PVAc/PAH composite. 
5.4.5 Tensile Mechanical Properties 
The tensile mechanical properties were measured at different degradation time points.  
Figure 5-13 and Table 5-4 summarize the mechanical properties for the PCL/PAH composite at 
various degradation times. During degradation, the Young’s modulus steadily decreased, from a 
starting modulus of 7.5 MPa ± 0.9 MPa to its lowest at 2.2 MPa ± 0.8 MPa at 48 h. The modulus 
did not significantly change between 48 h and 96 h. After 8 d, it began to steadily increase and 
recover to that of electrospun PCL. By 14 days, the modulus was not significantly different than 
electrospun PCL, with a modulus of 7.7 MPa ± 3.0 and 7.1 MPa ± 3.0, respectively. The strain-
to-failure of the composite was initially significantly lower than that of electrospun PCL at 80% 
± 40% compared to 1300% ± 140% and approached this value during degradation. The strain-to-
failure was similar to that of PCL after 14 days at around 1200% ± 30%.   
The mechanical properties of the PVAc/PAH composite shown in Figure 5-14 could not 
be studied beyond 48 h of degradation due to poor mechanical integrity. The average value 
calculated for the Young’s modulus and strain-to-failure at 48 h reported in Table 5-5 was based 
on two samples instead of five since the remaining samples were unable to be tested. 
5.4.6 In Vitro Drug Release 
 
The in vitro cumulative drug release profiles of both PCL/PAH and PVAc/PAH 
composites loaded with 0.5% RhB entrapped in the fibers are summarized in Figure 5-15. The 
release profile for the PCL/PAH shown in Figure 5-15B did not follow a two stage pattern, with 
 
178 
an initial burst release of approximately 9% within 6 h; this was followed by a period of steady 
release between 6 h and 5 d, which released another 10%. At this point, a second burst release 
was observed between 5 d and 8 d, which released the greatest amount of drug at an additional 
~50%. This was followed by another period of steady release that liberated an additional 7% 
drug over the next 7 d. The total drug release was approximately 65% for 15 d, with no 
significant change after 15 d. In comparison, the RhB-loaded PCL fibers with no matrix (control 
sample), as shown in Figure 5-15A, exhibited a two-step release profile, with a single release at 
2 h that released 60% of the drug, and a short, steady release until approximately 48 h, with 67% 
total released.  
 Unlike the PCL/PAH composite, the PVAc/PAH sample, as shown in Figures 5-15A 
and 5-15C, exhibited biphasic drug release with an initial burst release of approximately 20% 
within 6 h, followed by a steady additional 30% release of RhB over 30 d. As shown in Figure 
5-15C, RhB release increased with additional degradation of the PAH matrix.  In contrast, the 
RhB-loaded PVAc fibers alone, without the PAH matrix, showed an initial burst release of 
approximately 18% after 6 h, followed by an additional 12% of RhB released steadily for a 
period of approximately 7 d, where no significant RhB release was observed between 7 days and 
17 days. A total of approximately 31% of RhB was released from the PVAc fiber mat without 
PAH (control sample), whereas a total of approximately 52% of RhB was released from the 
PVAc/PAH composite, which appeared to continue to release past 30 days.  
5.4.7 Shape Memory  
The qualitative and quantitative shape memory properties of the PVAc/PAH composite 
are shown in Figures 5-16 and 5-17, respectively. The fixing and recovery ratios are summarized 
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in Table 5-6 and were calculated using Eqns. 5-4 and 5-5. The PVAc/PAH exhibited excellent 
shape fixing for all cycles, with 99% retention of the induced strain following load release. The 
shape programming temperature was 40 C, which was above the PVAc/PAH composite 
temperature and below the reconfiguration temperature for PAH. The shape recovery improved 
from 74% in the first cycle to 90% for the second cycle. The qualitative shape memory in Figure 
5-16 revealed that the PVAc/PAH composite showed good shape fixing and recovery 
performance, with a fixing ratio of 92% and a recovery ratio of 100%. The shape memory results 
are not shown for the PCL/PAH composite, as these samples exhibited poor shape memory since 
the shape fixing and recovery mechanism is by way of the PCL melting transition of ~55 – 60 C 
and overlaps the temperature range at which the PAH crosslinks are rearranged, as discussed in 
Chapter 4. As a result, the composite can only be remolded into new permanent shapes. 
5.4.8 Fixed Shape Preservation during Degradation 
  
The PCL/PAH composite demonstrated the ability to retain a temporary shape during 
degradation, as shown in Figure 5-18. The composite was deformed into three different arbitrary 
shapes and showed excellent shape fixing after four months of immersion in PBS at 37 C. It 
was observed that within the first 24 h of in vitro degradation, some slight retraction of the shape 
occurred and no further change in the shape dimensions occurred between 24 h and 4 months. 
The PCL/PAH composite became more opaque as degradation of the PAH matrix progressed, 
leaving a solid white sample, which is characteristic of pure PCL.  
 
 
180 
5.5. Discussion 
 
 To compose a biodegradable elastomeric shape memory composite, crosslinked PAH and 
semicrystalline PCL were combined using commercially available materials. This study 
examined the degradation of the PCL/PAH composite and the effect of the composition of the 
fibrous component on degradation and drug release of a model compound by substituting PCL 
with PVAc.  
 The mass loss data reveal that changing the fiber composition from PCL to PVAc, both 
hydrophobic polymers, had influenced the degradation of the surrounding PAH matrix. Although 
PAH is also hydrophobic, it is composed of moisture-sensitive anhydride linkages that 
hydrolytically cleave into water-soluble products with a relatively high hydrolysis rate on the 
time scale of hours-to-days compared to other polyanhydrides.
35 
By shifting the relative 
hydrophobicities of the fibers percolating through the PAH matrix, we hypothesized that this 
would affect PAH degradation due to differences in water accessibility within the internal 
structure of the composite, where the more hygroscopic PVAc would readily attract water 
compared to PCL. It is for this reason that PVAc was selected as an alternative material to PCL 
as the fibrous phase since its relatively polar carboxyl groups impart more moisture-sensitivity 
than PCL, with the ability to sorb ambient water, which would also impact its Tg  and thus chain 
mobility.
36,37
  PVAc has been reported by others to absorb up to 4 wt% water, whereas PCL is 
known to absorb less than 0.5 wt% water after 12 days immersed.
38,39  
 
Interestingly, the gravimetric data revealed that degradation of the PCL/PAH composite 
occurred much faster than the PVAc/PAH sample, losing approximately 55% percent of its 
original mass within 10 h, compared to PVAc/PAH, which took 5 – 6 times longer to attain a 
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similar result. Overall, the degradation of the PCL-based composite appeared to occur in two 
main stages, beginning with crater formation at the surface that progressed into pores by 24 h, 
which coincided with a rapid loss of mass and the majority of the composite erosion. During the 
second stage, the mass loss rate drastically decreased between 24 h and 14 days, while the pores 
at the surface appeared to develop into channels through the thickness of the sample, as shown in 
Figure 5-6; these channels continued to enlarge and evolve into the free space between the PCL 
fibers during this secondary stage of erosion. Here, a drastic increase in the strain-to-failure of 
the composite also occurred, which is consistent with removal of a substantial mass of the PAH 
matrix to liberate PCL fiber mobility. This type of degradation is an alteration from the surface 
erosion that is characteristic of the PAH matrix, which then advanced to bulk degradation. The 
crater morphology during the first stage enabled direct contact and thus concentration of the 
buffer solution into the volume of the composite, establishing a route for the degradation front to 
advance through the sample bulk. As the degradation of PAH proceeded, the crystallization 
endotherm of PCL became more prominent in the DSC thermograms shown in Figure 5-8. 
Between the mass loss and morphological micrographs, it appeared that degradation of 
PCL/PAH was complete and matrix-free by 4 days; however, an evaluation of the relative 
crystallization enthalpies of PCL revealed that residual PAH remained in the composite, with 
approximately 4% remaining after 14 days. This extended degradation suggests that there may be 
regions of PAH that begin to degrade later and are likely in the form of a sheath surrounding the 
PCL fibers, which would be consistent with the fibrous morphology at this stage. The tensile 
Young’s modulus and strain-to-failure do not fully recover before 14 days of degradation, further 
indicating the presence of PAH within the composite not detected gravimetrically or visually by 
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SEM, as it is continuing to restrict PCL fiber mobility. There is no contribution from PCL 
erosion since it degrades considerably slower.
4
 
 Unlike the PCL/PAH composite, we contemplated that the PVAc fibers were plasticized 
by PAH based on macroscopic observations during fabrication, where a thermal treatment was 
necessary to relieve residual stresses incurred during electrospinning to prevent shrinkage, 
coupled with the observed apparent dissolution of the non-heat treated PVAc fibers into the PAH 
monomer (Figure 5-1). The thermal characterization at different degradation times further 
supported this postulation, showing that the glass transition (Tg ) of PVAc in the composite was 
significantly decreased by almost 15 C prior to the degradation study, suggesting a molecular 
interaction between the heat-treated PVAc fibers and the PAH matrix.  
 The degradation of the PVAc/PAH composite appeared to proceed in three regimes, and 
unlike the PCL/PAH composite, the glass transition did not positively correlate with degradation 
time. Phase I occurred between 0 and 10 h, and degradation was rapid and dominated by the 
erosion of PAH at the surface, since there was no substantial change in Tg  of PVAc or surface 
morphology. Phase II ensued from 10 h to 72 h, and is marked by a significant drop in Tg and the 
formation of larger pores and channels. The continued shift in the Tg of PVAc was most likely 
due to the plasticizing effect of absorbed water as more fibers were exposed to the buffer 
solution through the growing population of pores and channels during this period. We 
hypothesized that the PAH as a matrix is severely interrupted, as was the case with PCL/PAH 
composite at this degradation time; here, the remaining material was likely PVAc fibers 
containing plasticizing PAH. It is during Phase III that we postulated that the degradation of 
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PAH continued mostly within the fibers, albeit at a much slower rate and limited by diffusion, 
which would explain the continuing decrease in mass and the recovery of the PVAc Tg .  
 Although initially the PVAc/PAH composite showed similar mechanical properties as 
that of PAH film, the tensile Young’s modulus displayed a recovering trend toward that of 
electrospun PVAc during degradation. Interestingly, the strain-to-failure was substantially 
increased such that it was approximately six-fold greater than either the PAH or PVAc 
components individually, which we postulated may be due to rubber toughening by the PAH. As 
the PVAc/PAH samples degraded, excessive shrinkage occurred, which made it difficult to study 
the mechanical properties beyond 48 h. This shrinkage was likely caused by additional relaxation 
of the fibers during plasticization by water, where amorphous PVAc enabled greater access of 
water through the structure. 
 The drug release of the PCL/PAH composite did not follow a typical biphasic pattern and 
instead manifested as two burst release intervals with periods of sustained release following each 
burst. The small initial burst release was likely due to the liberation of RhB molecules adsorbed 
previously to the surface that stemmed from migration during composite fabrication, when the 
PCL fibers were wetted by the PAH monomer. During this early burst release, 15% of the mass 
of the composite had eroded; however, given that only 9% of drug released, compared to ~60% 
from the control (PCL fibers without PAH) during the same time frame, we surmised that there 
was sufficient PAH shielding underlying fibers. The second and final burst release occurred 
beginning at 4 d and lasted for 3 d; it was at this point that a very high rate of drug release 
commenced, and during when most of the drug was released. This drug release behavior 
correlated with the disappearance of the continuous PAH matrix through the structure which led 
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to near full exposure of the PCL fibers, as visualized by SEM, and signified that the drug release 
here was primarily erosion-mediated rather than diffusionally controlled. The period of 
continual, steady RhB release that followed the second burst release, beginning at 8 d, was slow 
and likely due to diffusion of RhB from the fibers to the media. Since this release was controlled, 
unlike that of original PCL fiber control, this further suggested that there remained a PAH 
coating around the fibers. This observation was consistent with the degradation thermal 
properties (Table 5-2) and mechanical data (Table 5-4), which indicated that residual PAH 
remaining after 4 d, as the behavior of the material during this time was not that of pure 
electrospun PCL. A total of 67% of RhB was released from the PCL/PAH composite and this 
was likely due to drug trapped in the fibers, as has been previously observed by others.
40,41  
 
Amorphous polymers offer an advantage over semicrystalline polymers in that there are 
no crystallites that can possibly impede drug loading.
42
 Unlike the PCL/PAH composite, the 
PVAc/PAH sample exhibited biphasic drug release with the initial burst release of 20% of RhB, 
followed by a slow, steady release at a slower rate, beyond when significant PAH has degraded. 
The initial burst release was likely due to a combination of eroded PAH (15% mass reduction) 
and diffusion of surface adsorbed drug. The drug release appeared to continue to steadily release 
past 30 d, a further indication that residual PAH remained in the composite imparting an 
additional diffusional barrier to RhB; this is consistent with our hypothesis that additional PAH 
remained in the fibers beyond 14 d. 
 One-way shape memory was possible for the PVAc/PAH composite due to the 
plasticization of the PVAc fibers by the PAH monomer during composite fabrication. This 
resulted in a decrease in the glass transition temperature to ~ 45 C and thus enabled the shape 
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fixing and recovery temperature triggers to occur sufficiently below the shape reconfiguration 
regime of PAH, which would have inhibited the recovery of the original shape due to the 
rearrangement of the  PAH cross-links during shape fixing.
43 
It is for this very reason that the one 
way shape memory performance was poor for the PCL/PAH composite, since the required 
thermal trigger was above 55 C and resulted in overlapping permanent and fixed shapes; a 
modification would be necessary to the PCL thermal transition, which was further discussed in 
Chapter 4. The macroscopic shape memory of the PVAc/PAH composite is demonstrated in 
Figure 5-16, and also showed excellent shape fixing and recovery properties, with 92% of the 
induced curve retained upon release of the applied load and full recovery of its length upon 
heating. The shape memory measured thermomechanically in tension revealed consistent Rf 
values of 99% over three consecutive cycles. The shape recovery ratio of the initial cycle was 
mediocre at 76%, but improved to 90% after the first cycle. This difference between the first and 
second cycle may be due to relaxation effects of PVAc.  Since the elastomeric component was 
composed of crosslinked PAH, this composite would also be capable of reprogramming its 
permanent shape, as discussed in Chapter 4. Unlike other fiber reinforced shape memory 
systems, complex geometries could be fabricated without requiring a new sample to be 
manufactured each time, as had been proposed by others.
20
 
 Finally, the PCL/PAH composite offered a way to maintain a fixed, temporary shape 
during degradation. This was possible since the fibrous PCL framework was remained following 
PAH degradation, serving as structural support. This feature may be useful in situation-specific 
applications where a customized, complex geometry is essential, even after significant 
degradation. Shape retention during degradation was previously studied by Knight et al., where a 
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biodegradable copolymer of poly(lactide) and glycolide was synthesized with polyhedral 
oligosilsesquioxane (POSS) in the backbone.
44
 In their study, it was found that the samples had 
to be annealed to enable sufficient crystallization for good shape fixing. The samples, however, 
began recovering slowly during degradation, with approximately 20% recovered length within 
two weeks and 50% recovered by four weeks. In contrast, by isolating the fixing mechanism to a 
separate phase with a significantly slower degradation rate, our composite was capable of 
maintaining a high degree of deformation over a significant period of time; it is likely that this 
shape retention could extend on the order of two years, when the PCL fibers begin to degrade.  
5.6. Conclusions 
 A fully biodegradable shape memory elastomeric composite was developed using 
electrospun fibers embedded in a degradable, crosslinked polyanhydride matrix. The degradation 
of the polyanhydride matrix was dependent on the composition of the fibrous phase, where 
erosion proceeded more rapidly when the composite contained the more hydrophobic PCL fibers 
compared to hygroscopic PVAc, since PVAc competed with the degrading PAH for water. The 
presence of a fibrous structure permeating through the PAH film altered the erosion dynamics 
from heterogeneous to homogenous. PAH continued to remain on the fibers as a protective 
sheath for both composite compositions. It was found that the PVAc fibers were plasticized by 
the PAH, which remained in the fibers, and this resulted in prolonged degradation and enhanced 
the duration of sustained drug delivery of a hydrophilic model drug. The addition of a drug to a 
material would be advantageous for infection management following surgical intervention or 
minimizing thrombosis on the surface of an implant. This composite has the potential to possess 
these properties in addition to tailorable degradation, reconfigurable shape memory, and long-
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term shape retention and can provide an enabling technology with broad biomedical applications 
such as smart implants and tissue engineering scaffolds. 
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Scheme 5-1. (A) Synthesis of polyanhydride elastomer, and chemical structures of (B) poly(ε-
caprolactone) and (C) poly(vinyl acetate). 
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Figure 5-1. Effect of thermal treatment implemented to minimize shrinkage of electrospun.  
PVAc fibers prior to composite fabrication. (A) The resulting composite (right) when no thermal 
treatment or PAH pre-cure is used in comparison to its original geometry (left) (B) Pre-curing 
the PAH monomer enabled the PVAc to maintain its fibrous phase within the composite, 
however significant shrinkage occurred (right). Distinct regions of excess PAH denoted by the 
blue arrow. (C) Comparison of the effect of heat treatment on electrospun PVAc following 
hydration in DI water revealed significantly less shrinkage for samples previously treated. The 
foil substrate shows the original size of the fiber mat. (D) The addition of a heat treatment and 
pre-cured PAH resulted in a composite with minimal shrinkage and conservation of its original 
geometry. The excess PAH is trimmed as part of the fabrication process. 
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Figure 5-2. (A) Thermal and (B) thermomechanical characterizations of the (i) PAH elastomer, 
(ii) electrospun PVAc (heat treated), (iii) PVAc/PAH composite (iv) PCL/PAH composite, (v) 
electrospun PCL, and (vi) electrospun PVAc (untreated). 
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Figure 5-3. Scanning electron microscopy micrographs of (A) electrospun PCL and (B) 
electrospun PVAc following thermal treatment. The surface and cross-section of PCL/PAH are 
shown in (C) and (D). The surface and cross-section of PVAc/PAH are shown in (E) and (F). 
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Figure 5-4. Representative tensile engineering stress-strain curves of both the composite and 
individual components for PCL/PAH and PVAc/PAH composites showing (A) the strain-to-
failures and (B) the linear elastic regions for (i) electrospun PVAc (heat treated), (ii) electrospun 
PVAc (untreated), (iii) electrospun PCL, (iv) PCL/PAH composite, (v) PAH, and (vi) 
PVAc/PAH composite. 
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Table 5-1. Summary of tensile engineering stress-strain curves for the PCL/PAH and 
PVAc/PAH composites and individual components. 
  
 
Young’s Modulus 
(MPa) 
Strain-to-Failure 
(%) 
PAH 4.5 ± 0.4 30 ± 5 
Electrospun PCL 7.1 ± 3.0 1300 ± 140 
Electrospun PVAc (Untreated) 63.5 ± 11.3 30 ± 10 
Electrospun PVAc (Heat Treated) 157.1 ± 15.2 40 ± 10 
PCL/PAH Composite 7.5 ± 0.9 80 ± 40 
PVAc/PAH Composite 2.9 ± 0.5 60 ± 7 
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Figure 5-5. Mass loss during in vitro degradation in PBS at 37 C for the PCL/PAH and 
PVAc/PAH composites. 
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Figure 5-6. Morphological changes during degradation of  the PCL/PAH composite in PBS at 37 
C at the A) surface and B) cross-section, revealed using scanning electron microscopy (SEM). 
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Figure 5-7. Morphological changes during degradation of the PVAc/PAH composite in PBS at 
37 C at the A) surface and B) cross-section, revealed using scanning electron microscopy 
(SEM). 
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Figure 5-8. Thermal properties of the PCL/PAH composite during degradation. The dotted line 
indicates the crystallization temperature for electrospun PCL. 
Temperature (
o
C)
-40 -20 0 20 40 60 80
H
e
a
t 
F
lo
w
 (
E
x
o
 U
p
)
0.5 W/g
1st Cooling
10
o
C/min
t = 0
t = 5 h
PAH
t = 10 h
t = 24 h
t = 48 h
PCL
t = 74 h
t = 100 h
t = 14 days
 
201 
 
 
Figure 5-9. Fraction of PCL in the PCL/PAH composite as a function of degradation time. 
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Table 5-2. Fraction of PCL in the PCL/PAH composite as a function of degradation time. 
 
Degradation Time (h) H
c
 (J/g) T
c
 (C) Amount of PCL(%) 
0 9.4 28.8 18.3 
5 11.3 27.9 21.9 
10 13.7 27.3 26.5 
24 32.1 28.7 62.2 
48 41.1 31.9 79.7 
74 38.7 38.7 74.9 
100 47.5 31.8 92.1 
336 49.5 32.0 95.8 
PCL Fiber Mat 51.6 31.9 100.0 
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Figure 5-10. Thermal characterization by DSC of the PVAc/PAH composite following different 
degradation times. The dotted lines denote the glass transitions for PAH and PVAc. 
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Table 5-3. Fraction of PVAc in the PVAc/PAH composite as a function of degradation time. 
 
Degradation Time (h) Tg
 (PVAc) C
p
 (PVAc) % PVAc 
Electrospun PVAc 44.7 0.473 100 
0 30.1 0.076 16 
5 38.8 0.081 17 
10 37.4 0.074 16 
24 20.3 0.159 34 
48 13.0 0.145 31 
72 0.9 0.182 38 
96 29.5 0.282 60 
150 30.4 0.240 51 
192 30.9 0.350 74 
336 36.7 0.314 66 
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Figure 5-11. Evolution of the glass transition temperature of the PVAc component of the 
PVAc/PAH composite at different stages of PAH degradation. 
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Figure 5-12. Comparison of PCL and PVAc content during degradation of the PCL/PAH and 
PVAc/PAH composites, respectively. The fiber composition was calculated based on the relative 
melting or glass transition temperatures as determined by DSC. 
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Figure 5-13. Representative engineering stress-strain plots of PCL/PAH at various degradation 
points of (i) as fabricated, t = 0, (ii) 10 h, (iii) 48 h, (iv) 72 h, (v) 96 h, (vi) 8 days, (vii) 14 days, 
and (viii) as-fabricated electrospun PCL for reference. 
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Table 5-4. Mechanical properties of PCL/PAH composite after different degradation times. 
 
Degradation Time Young’s Modulus 
(MPa) 
Strain-to-Failure 
(%) 
0 7.5 ± 0.9 80 ± 40 
10 h 4.6 ± 0.9 150 ± 25 
48 h 3.0 ± 0.5 1000 ± 170 
72 h 2.2 ± 0.8 950 ± 170 
96 h 2.2 ± 1.5 900 ± 190 
8 days 4.2 ± 1.5 640 ± 85 
14 days 7.7 ± 3.0 1200 ± 30 
Electrospun PCL 7.1 ± 3.0 1300 ± 140 
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Figure 5-14. Representative engineering stress-strain plots of PVAc/PAH at various degradation 
points of (i) as fabricated, t = 0, (ii) 10 h, (iii) 48 h, (iv) PAH for reference, and (v) as-fabricated 
heat-treated electrospun PVAc for reference. 
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Table 5-5. Mechanical properties of PVAc/PAH composite after different degradation times. 
 
Degradation Time Young’s Modulus  
(MPa) 
Strain-to-Failure  
(%) 
0 2.9 ± 0.5 60 ± 7 
10 h 45.3 ± 3.2 140 ± 45 
48 h 49.2 ± 22.5 300 ± 220 
Electrospun PVAc (Heat Treated) 157.1 ± 15.2 40 ± 10 
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Figure 5-15. In vitro release of hydrophilic model drug Rhodamine B from the PCL/PAH and 
PVAC/PAH composites with comparisons to (A) Rhodamine B release from fibers without the 
PAH matrix, and with mass loss results in (B) and (C). 
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Figure 5-16. Qualitative demonstration of one way shape memory of the PVAc/PAH composite. 
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Figure 5-17. Shape memory stress-temperature-strain plot for the PVAc/PAH composite. 
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Table 5-6. One way shape memory fixing and recovery ratios for the PVAc/PAH composite. 
 
Cycle Rf (%) Rr (%) 
1 99 76 
2 99 90 
3 99 ND 
*ND denotes no data available. 
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Figure 5-18. Preservation of arbitrarily deformed shapes during in vitro degradation of the 
PCL/PAH composite in PBS at 37 C. 
ORIGINAL FIXED 24 h 72 h 4 months
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Chapter 6   
Latent Mechanical Programming of a Shape Memory Composite  
with Reversible Anisotropic Actuation 
 
6.1 Synopsis 
In this chapter, the design, fabrication, and characterization of a polymeric composite 
composed of oriented semicrystalline polymeric fibers embedded within a crosslinked epoxy 
matrix is presented. While this composite inherently exhibits triple shape memory, as our group 
has presented in the past, we observed that introducing anisotropy enabled the construction of 
complex three dimensional geometries featuring latent mechanical programming. Rather than 
relying on specific molds to manipulate a new shape, this system instead capitalized on an 
induced strain to influence a new structure attained by strain conditioning above a transition 
temperature followed by cooling. The new geometry was then activated by strain-free exposure 
to this temperature, which was dictated by the orientation of the fibers across the bilayer cross-
section. We investigated the effect of programming these new shapes by varying the fibrous 
phase orientation through multilayer laminates and studied the curvature, thermomechanical, 
shape memory, and microstructural properties of the composites. Additionally, we found that by 
compressing the oriented fibers of each ply during composite cure, the composites constructed 
from such plies exhibited actuation into anisotropically induced shapes. The new composite 
materials can have broad applications in artificial muscles, hinges, sensors, and robotics, to name 
a few.  
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6.2 Introduction 
 Anisotropy is found in both natural and synthetic materials and can have significant 
effects on material properties. In the construction, automotive and aerospace sectors, anisotropy 
is engineered into laminated composites in order to tailor load bearing properties, typically by 
specific layering of oriented laminates.
1-4
 In nature, biological materials such as wood,
5
 tendons,
6
 
blood vessels,
7
 sea shells,
8
 and cortical bone
9
 contain hierarchical structures that exhibit 
anisotropy that serve to maximize mechanical functionalities. As a result, incorporating oriented 
properties into composite materials has served as a great inspiration for composite material 
design as evidenced by the abundance of review articles, with only a few referenced here.
10-14
 Of 
particular interest to many are the natural anisotropic architectures within botanical materials that 
form complex 3D geometries.
15
 One specific example is the curling of pine cone scales in 
response to dehydration, which has been artificially mimicked by constructing bilayers 
containing materials that respond anisotropically to humidity.
16
 In another example, the twisting 
of orchid seed pods as a result of fibrous layers oriented ~45 relative to the long axis had been 
imitated by orienting stretched latex sheets at a diagonal.
17
  
 Active materials such as shape memory polymers have broad applications in many fields 
due to the low cost and ease of being able to create and retain articles that undergo simple 
temporary shape changes, yet can be returned to their original form by environmental trigger.
18,19
 
These materials are seemingly a natural candidate for developing complex 3D geometries 
resulting from anisotropy; however only few studies have used this approach to produce such 
complex shapes. Lee et al. formed a variety of coil-based shapes by orienting the nematic 
domains within a crosslinked liquid crystalline polymer that are then thermally triggered.
20
 In the 
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Mather research group, Robertson et al. introduced mechanically programming complex shapes 
from anisotropic soft, elastomeric shape memory composites.
21 
This was accomplished by 
layering amorphous composites composed of oriented electrospun poly(vinyl acetate) embedded 
within a Sylgard 184 silicone matrix. The composite laminates were fabricated into bilayers at 
differing orientations relative to each other. By uniaxially straining the bilayer composite, 
spontaneous room temperature curling of the samples resulted upon release of the load. While 
that system was capable of attaining 3D shape changes by mechanical (rather than thermal) 
programming, circumventing one way shape memory cycling, it was limited to immediate 
curling upon load release. The present investigation combines thermal triggering with 
mechanical programming.  
 We were interested in not only producing both complex shapes but also controlling when 
this spontaneous shape change occurred. As such, our goal was to introduce anisotropy into a 
similarly fibrous thermoset composite system, where the mechanically programmed shape 
remained dormant at room temperature until thermally prompted. We theorized that a composite 
material exhibiting thermal transitions above room temperature would serve to suspend a 
mechanically programmed shape until ready for deployment. Accordingly, we also hypothesized 
that these dormant mechanically programmed shapes could be tailored by the lay-up design 
wherein distinct layers featured orientation differences relative to each other and to the direction 
of mechanical programming.  In order to design such a material, we turned to a versatile material 
combination where electrospun semicrystalline PCL was embedded within a crosslinked epoxy 
matrix, which had been previously developed for triple shape memory in the Mather research 
group.
22
 This particular composite was attractive due to an easily tunable glass transition 
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temperature through the addition reaction blend of two diepoxides, aromatic bisphenol A 
diglycidyl ether (DGEBA) and aliphatic diepoxide (neopentyl glycol diglycidyl) (NDGE), with a 
flexible diamine, Jeffamine D230.
23 
Additionally, we observed that incorporating compressive 
stresses into the fibrous phase during fabrication led to unique reversible actuation that was 
unanticipated based on prior studies that demonstrated the effect for crystallizable networks
24
 of 
which this is not one. 
6.3 Methods 
6.3.1 Materials 
Poly(ε-caprolactone) (70,000 – 90,000 g·mol–1), bisphenol A diglycidyl ether (DGEBA), 
neopentyl glycol diglycidyl (NDGE), Jeffamine 230, tetrahydrofuran (THF), and 
dimethylformamide (DMF) were purchased from Sigma Aldrich and used as received. 
6.3.2 Electrospinning 
Fibers were electrospun using a solution of 20 w/v % PCL dissolved in a 4:1 THF:DMF 
solvent mixture. The PCL solution was then transferred to a 10 ml syringe fitted with a blunt 
22G needle tip. A syringe pump was used to supply a steady flow rate of 1.0 ml
.
h
-1
, which was 
electrospun onto a grounded 50 mm drum using a distance of 7 cm between the needle tip and 
the drum (-500 V), and an applied voltage of 11.5 kV. To achieve oriented fibers, the drum was 
rotated at 5000 rpm. Typically drum rotations below 800 rpm result in randomly oriented fibers. 
Following electrospinning, all fiber mats were dried at room temperature under vacuum (-30 mm 
Hg) for 48 h to remove any residual solvent prior to further use. 
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6.3.3 Anisotropic Composite Fabrication 
The epoxy monomers were prepared by melting DGEBA at 80 C followed by vigorous 
mixing with NDGE and Jeffamine D230 (Scheme 6-1), which resulted in a low viscosity fluid. 
The weight fractions of the NDGE and DGEBA were selected to achieve a target glass transition 
temperature of ~35C,according to the Gordon-Taylor equation and prior model-fitting for this 
same system.
22
 The nomenclature used herein to refer to the epoxy formulation is DXNYD230. 
This refers to the weight percentage of DGEBA relative to NDGE as DX, and NDGE as NY, X 
and Y summing to 100. The designation “D230” denotes the Jeffamine 230 crosslinker with 
stoichiometric equivalence of amine protons (4 per D230 molecule) and epoxide rings (two each 
for DGEBA and NGDE). For example, D41N59D230 refers to crosslinked epoxy synthesized 
using 41 wt% DGEBA and 59 wt% NDGE.  
The cross-ply bilayer composite was prepared by layering two electrospun PCL fiber 
mats, one on top of the other as depicted in Scheme 6-2. The assembly was arranged with the 
aligned fibers orthogonal between top and bottom layers, yielding a “cross-ply” porous 
construction. Once this was arranged, the fiber mats were secured together using binder clips and 
infiltrated with the epoxy monomer as an assembly, followed by vacuum infiltration at RT to 
remove any trapped air within the fiber mats. This assembly was then clamped between two 
glass slides using a  spacer with variable thickness, arranged as a frame defining the composite 
perimeter, as shown in Scheme 6-3. The composite was next cured for four days at 45 C. This 
relatively low cure temperature was selected to preserve the PCL fiber morphology, as it is 
below the PCL melting transition. A spacer was used to control the sample thickness and a 
compression factor was quantified (CF), using a range from 1 to 2.6, according to: 
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𝐶𝐹 =  
𝑛 ∗ (𝑡𝐹𝑖𝑏𝑒𝑟 𝑚𝑎𝑡 )
𝑡𝑆𝑝𝑎𝑐𝑒𝑟
,   (6-1) 
where t is the thickness of the individual fiber mat or the thickness of the spacer and n is the 
number of fiber mats or plies used. 
In a similar manner, single-ply laminae were prepared by infiltrating aligned PCL fiber 
mats with the epoxy monomer, followed by vacuum infiltration at RT to remove any trapped air 
within the fiber mats. This was then clamped between two glass slides with a spacer and cured 
for four days at 45 C.  
6.3.4 Thermal Analysis 
 Differential scanning calorimetry (DSC) was performed using a Q200 manufactured by 
TA Instruments, Inc. Samples weighing 2.5 – 4.0 mg were sealed in Tzero aluminum pans and 
heated from -60 C to 120C at 10 C ∙ min
-1
. The melting enthalpy was calculated from the 
second heating cycle by integrating the melting peak, and was used to determine the fraction of 
PCL in the elastomeric composite by comparing the melting enthalpies according to: 
𝑊𝑃𝐶𝐿 (%) =  
∆𝐻𝑚
∆𝐻𝑚,0
 × 100 % (6-2) 
where Hm  is the melting enthalpy of the composite measured by DSC and Hm,o is the melting 
enthalpy of  pure electrospun PCL, which was 48.0 J g
-1
, as determined by DSC. 
6.3.5 Morphology 
 Scanning electron microscopy (SEM) was used to determine the study the morphology of 
the composite. All samples were sputter coated with gold for 45 s prior to SEM. A JEOL JSM-
5600 SEM was used with an accelerating voltage of 4 – 6 kV. ImageJ software (version 1.46, 
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National Institutes of Health) was used to measure PCL fiber diameter. Fiber diameter 
measurements were determined by taking a minimum of 50 measurements at 5 different 
locations well separated in the composites. The average diameter and standard deviation were 
calculated using a minimum of 250 total measurements.  
 The cross-sections of the samples were obtained by cryogenically fracturing then solvent-
etching the composites. A dogbone shaped sample prepared by punching with a die, followed by 
immersion in liquid nitrogen (to embrittle the specimens), followed by fracturing of the narrow 
section by manual flexure. The cross-section surface was then treated with THF overnight to 
remove the PCL phase so that the morphology of the oriented PCL fibers could be clearly 
distinguished – as cavities – from the epoxy matrix. 
6.3.6 Thermomechanical Characterization 
 A TA Instruments Q800 dynamic mechanical analyzer (DMA) was used in 
multifrequency strain mode to measure the storage and loss moduli and tan delta. Samples were 
cut into rectangular strips from the cross-ply composite orientation, maintaining a ratio of length 
to width of 5:1. All samples were first cooled to -60 C, followed by heating at 10 C min
-1
 to 90 
C as the tensile storage and loss moduli were measured at a frequency of 1 Hz. 
6.3.7 Quantitative Triple Shape Memory 
The triple shape behavior of the anisotropic composite was quantified using the DMA. 
Samples were similarly prepared as those for thermomechanical characterization in Section 
6.3.6. The DMA was used in controlled force mode to stretch a dog bone sample at 75 C to a 
10% strain (or 5% for the cross-ply sample) by ramping the force at 0.05 N min
-1
; this 
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temperature was above both the PCL melting and epoxy glass transitions. The temperature was 
then decreased at 3 C min
-1
 to 0 C and held isothermal for 10 min to fix the first temporary 
shape. The sample was then heated at 3 C min
-1
 to 45 C (below PCL Tm and above epoxy Tg) 
and held isothermal for 5 min. The force was then unloaded at 0.25 N min
-1
 until it reached the 
preload force of 10
-3
 N. The second temporary shape was programmed by then ramping the force 
at 0.05 N min
-1
 to a strain of 30% (or 10% for the cross-ply sample), followed by cooling at 3 C 
min
-1
 to 0 C and held isothermal for 10 min to fix the second temporary shape. The force was 
then unloaded at 0.25 N min
-1
 until it reached the preload force of 10
-3
 N. Finally, the permanent 
shape was recovered by heating at 1 C min
-1
 to 80 C (or to 60 C for the cross-ply sample), and 
holding isothermal for 10 min. The cross-ply samples utilized a reduced strain and melting 
temperature protocol due to failure at larger values.  
The degree of shape fixing (Rf) and the degree of shape recovery (Rr) were quantified for 
each sample using the following equations: 
𝑅𝑓(%) =  (
𝜀𝑓𝑖𝑥𝑒𝑑
𝜀𝑑𝑒𝑓𝑜𝑟𝑚𝑒𝑑
) × 100 % (6-3) 
𝑅𝑟(%) =  (
𝜀𝑓𝑖𝑥𝑒𝑑 −  𝜀𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑
𝜀𝑓𝑖𝑥𝑒𝑑 −  𝜀0
) × 100 % (6-4) 
 
where ε0 is the original strain (at the beginning of each cycle), εdeformed is the deformed strain that 
occurred after cooling while still under a load, εfixed is the fixed strain that resulted following 
unloading, and εrecovered is the recovered strain following heating. 
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6.3.8 Latent Triggering of Mechanically Programmed, Anisotropic Shape Change 
Rectangular samples of 2.5 cm by 0.3 cm were cut from the cross-ply composite 
fabricated using a CF of 1.1; i.e., with minimal compression. The samples were cut at different 
angles according to Scheme 6-4, resulting in a variation of the cross-ply fiber orientation relative 
to the long dimension of the sample. For example, samples were cut such that a cross-ply(0) 
sample contained one surface with fibers oriented longitudinally and the opposing surface with 
fibers perpendicular to the long dimension. Samples cut with a 45 angle contained a cross-hatch 
pattern of fibers, relative to the rectangular cut out shape, and is hereafter referred to as cross-
ply(45). The thermomechanically activated shape changed proceeded by securing the sample 
onto a custom manual stretcher and placing in an isothermal oven at 70 C for 10 min to melt the 
PCL phase. While the PCL was melted, the sample was then stretched to strains of 10 %, 20 %, 
30 %, or 40 % and immediately placed in an isothermal oven at 45 C to recrystallize PCL above 
the epoxy Tg for 30 min, followed by cooling to room temperature. The sample was then 
unclamped and a temporary shape (generally flat) was observed. The mechanically programmed 
shape change was then activated by heating to a temperature between Tg of the epoxy but below 
Tm of PCL. This was accomplished by placing the unconstrained sample in an isothermal oven at 
45 C for 10 min, followed by room temperature cooling to observe the programmed shape 
change. Shape recovery was then triggered heating above both Tg of the epoxy and Tm of PCL. 
This was accomplished by placing the unconstrained sample in an isothermal oven at 70 C for 
10 min. The radius of curvature and pitch were measured at each stage to characterize the latent 
shape change and its dependence on the magnitude of strain during shape programming for a 
strain of 10% to 50%. 
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6.3.9 Reversible Anisotropic Actuation 
Rectangular samples from the cross-ply composite were fabricated using a CF of 2.6 and 
prepared at differing cutting angles according to Scheme 6-4. Reversible actuation was activated 
by placing the unconstrained sample into a heated water bath at 75 C until a shape change 
appeared and had completed. The sample was then removed from the water bath and cooled to 
room temperature (~ 21.8 C to 22.5 C) on the bench top, in response to which that samples 
were observed to reverse the heat-induced shape change to a great extent. This was repeated for 
10 consecutive cycles and the radius of curvature was measured for each cycle.  
The thermal expansion and contraction of a single-ply composite was quantified using the 
DMA of rectangular strips containing fibers oriented either parallel (0) or perpendicular (90) to 
the tensile axis. The DMA was used in controlled force mode to heat a rectangular sample to 75 
C at a rate of 3 C min
-1
 followed by an isothermal hold for 3 min. The sample was then cooled 
to 0 C at a rate of 3 C min
-1
 and then held isothermally for 5 min.  
6.4 Results 
6.4.1 Composite Fabrication and Morphology 
The electrospun fibers were generally oriented in the same direction, as shown in Figure 
6-1A, with an average fiber diameter of 1.3 μm ± 0.5 μm. Following infiltration of the epoxy 
matrix, the surface of the composite appeared to contain a smooth layer of epoxy as shown in 
Figure 6-1B. Two cross-sections of the single-ply composite, taken perpendicularly from each 
other, are shown in Figures 6-1C and D. These micrographs verified both complete infiltration 
of the epoxy matrix, and fiber orientation relative to each ply. The PCL phase had been 
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successfully removed by solvent etching, leaving behind a “negative” morphology within the 
epoxy phase. The circular cavities shown in the micrographs are indicative of the fibers aligned 
in the direction toward the observer, while horizontal channels are a result of the fibers parallel 
to the surface. The cross-ply morphology is similarly shown in Figure 6-1E, confirming good 
coupling of the fibrous bilayers with complete epoxy infiltration with no epoxy rich layer 
between the two fiber mats to interfere with the anisotropic shape effect discussed later. 
Moreover there was no surface rich material observed that could potentially introduce bias any 
resulting programmed shapes in the bilayer.  Superimposing the fiber mats prior to the addition 
of the epoxy matrix served to reduce the interface between the two layers. This allowed both 
fiber mats to be secured within a single epoxy matrix rather than gluing both laminates together, 
which can interfere with the composite properties or provide a site for delamination. 
6.4.2 Thermal Analysis 
Figure 6.2 and Table 6-1 summarize the data obtained by DSC for the crosslinked epoxy 
with different targeted glass transitions temperatures, as well as the cross-ply composite in 
comparison with its individual components. The DSC results in Figure 6-2A show that by 
systematically decreasing the DGEBA weight fraction in the epoxy formulation, the Tg of the 
crosslinked epoxy decreased accordingly and was consistently within 8 C of the predicted Tg 
from the Gordon-Taylor equation.
22
 As shown in Figure 6-2B, the epoxy Tg and the PCL Tm 
remained unchanged when combined in composite form, indicating minimal mixing of the two 
components. The addition of epoxy to the PCL fiber mat did not significantly alter the properties, 
which was consistent with a prior report from the Mather Research Group.
22
 Based on the 
relative enthalpies, the D41N59D230_PCL composite contained 15 % PCL. The PCL Tg was not 
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measured but is known to be ~ -60 C.
25 
The D41N59D230 epoxy formulation was selected in 
order to maximize the temperature interval between the epoxy Tg and PCL Tm, while maintaining 
the former above room temperature. 
6.4.3 Thermomechanical Properties 
 The thermomechanical properties of the D41N59D230_PCL cross-ply(0) composite were 
characterized using dynamic mechanical analysis (DMA) and shown in Figure 6-3. The 
composite exhibited a much lower glass transition than measured by DSC of 12.0 C, though the 
melting transition was 58.1 C, as based on the loss modulus maxima. The storage modulus of 
the cross-ply(0) composite was approximately 100 MPa at 25 C. 
 6.4.4 Quantitative Triple Shape Memory 
The triple shape memory properties of the cross-ply(0) and the individual oriented single-
ply samples were quantified using the DMA and the results are shown in Figure 6-4. The 
samples were temporarily fixed into two elongated shapes with different lengths, as indicated by 
the letters “F1” and “F2” in Figure 6-4, where F2 was more elongated than F1. The recovered 
shape is denoted by the letter “R” in Figure 6-4. These results validated that the oriented 
composites maintained their triple shape memory properties. The cross-ply(0) samples utilized a 
reduced strain and melting temperature protocol due to failure at larger values. The shape fixing 
and recovery ratios were calculated according to Eqns. 6-3 and 6-4 and summarized in Table 6-
2. Overall, the single-ply composite, whether unidirectional or cross-ply, exhibited good shape 
fixing, with excellent shape fixing results for the single layer samples with the fibers oriented in 
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the tensile direction. The recovery ratio was slightly lower than expected, albeit still good 
(~90%), and was slightly lower when the fibers were oriented longitudinally.  
6.4.5 Latent Anisotropic Shape Change 
The mechanical shape programming of the epoxy/PCL composite was the result of a 
mismatched alignment of fiber oriented laminae constructed in a cross-ply arrangement relative 
to the long dimension of a rectangular sample strip, where an external tensile mechanical stress 
was directed parallel to the long dimension. This mechanical programming and shape memory 
cycle sequence are outlined in Figure 6-5 and the resulting programmed shapes are summarized 
in Figure 6-6. The sense of curvature and twisting actuation relative to fiber alignment 
distribution (top and bottom layers) was made possible by labeling of the samples with indication 
of fiber orientation of the top and bottom layers. Following recrystallization of PCL and 
vitrification of epoxy, the cross-ply samples remained elongated and flat upon release of the 
uniaxial tensile load. Upon heating to 45 C, which was above the epoxy Tg and below the PCL 
Tm, the sample activated to the mechanically programmed shape of a circular bend, with the outer 
radius containing the longitudinally oriented fibers (capable of holding a PCL-fixed strain), and 
the inner radius comprising the fibers oriented perpendicular to the long dimension (relatively 
less capable of holding a PCL-fixed strain). A left-handed twist was formed for the cross-
ply(45). When the cross-ply alignment was rotated 67.5cross-ply(67.5)), an angle between the 
cross-ply and the twist, the result was a hybrid shape comprising a twisted bend, where, similar 
to the cross-ply, the outer radius was composed of fibers oriented parallel to the long dimension. 
The effect of the magnitude of strain on the resulting programmed shape is summarized 
in Figure 6-7 for the cross-ply(0) oriented bilayer composite. It was observed that increasing the 
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magnitude of strain resulted in larger curvature, as expected from the increasing strain gradient, 
as recovered, through the thickness of the specimens. Programming strains beyond 40% could 
not be obtained due to fracture of samples. The cross-ply(45) samples showed a similar trend, 
where the degree of twisting increased with increased magnitude of strain, however the degree of 
pitch was difficult to characterize since the samples did not undergo complete twisting for the 
lengths tested. The pitch was estimated by extrapolating to a full rotation of the programmed 
shape and was estimated as 40 cm for a 10% strain and 11 cm for a strain of 40%. These pitch 
approximations were based on samples with an original width of 0.3 cm; the sample widths were 
reduced following tensile straining to approximately 0.25 cm for a 10% strain, and 0.21 cm for a 
40 % strain. 
6.4.6 Reversible Anisotropic Actuation 
The method for controlling the clamping force during composite fabrication, as outlined 
in Scheme 6-3, following fiber infiltration with epoxy monomer, was postulated to increase fiber 
stress, volume fraction, orientation, or all of these. By using a spacer to control the thickness of 
the composite during curing, any lateral gradients of the factors postulated above were 
minimized. Further, decreasing the spacer height introduced compressive forces onto the layered 
fiber mats, which were wetted by the epoxy monomer; this was easily observable by the ensuing 
increase in area occupied by the fibers mats during clamping and described by the CF value (Eq. 
6-1). Consequently, decreasing the thickness beyond that already occupied by the fiber mats led 
to an increase in the PCL content of the composites, which was quantified by comparing the 
relative melting endotherms using Eq. 6-2, measured by DSC. Figure 6-8 further shows that as 
the CF value of the composite increased, the peak corresponding to the PCL melting endotherm 
 231 
increased, indicating an increase in the PCL composition. These results are summarized in Table 
6-3, which show that the PCL content ranged from 4% to 28% for the lowest to high CF values 
tested. It was also observed that when increasing the CF value to 2.6, samples deformed (curling, 
twisting or both) immediately upon being cut into a narrow rectangular strip from the larger 
parent composite sample. This is shown in Figure 6-9, which reveals that this behavior did not 
occur at a lower CF value. This deformed original shape was dependent on the orientation of the 
fibers across the bilayers, as observed in Section 6.4.5 above, with the exception that a bend or 
twist formed in the opposite direction as that of the programmed shape, and to a substantially 
smaller degree. For example, the as-cut strip was curled such that the inner radius comprised of 
fibers oriented longitudinal to the long dimension, rather than perpendicular. This slightly 
distorted original shape remained as the recoverable shape during actuation. We attribute this 
phenomenon to tensile stresses that exist in the constituent fibers during cure (which transpired 
below Tm) whose through-thickness gradient can distort slender samples for which the stresses 
are off-axis from principle directions of the specimen. 
We suspected that reversible curvature and twisting actuation in the laminated 
composites might occur due to through-thickness gradients of anisotropic thermal expansion 
coefficient. Thus, free-standing thermal expansion/contraction measurements were conducted on 
single-ply composites oriented in the longitudinal and transverse directions and over a 
temperature range spanning both Tg and Tm. The results are presented in Figure 6-10, which was 
conducted for the first heating cycle. The longitudinally (0) oriented sample exhibited a 6% 
tensile contraction upon melting of the PCL phase, which was mostly recovered with a slight 
elongation upon cooling that was likely due to PCL crystallization. This elongation may be due 
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to the preload tension of the clamps on the samples that is released upon melting of the PCL 
phase. In contrast, the orthogonally oriented sample (90) exhibited a 3.7% expansion in tensile 
strain over a small temperature change, which then slowly returned upon cooling. As shown in 
Figure 6-10, these changes in tensile length occurred above the melting transition for PCL, 
indicating that this observed tensile contraction or elongation may be the result of the relieving 
of PCL stresses during melting.  A future study should also measure the changes in tensile strain 
during the second heating cycle, since this initial influence of PCL tensile stresses would only 
occur in the first heating cycle and any anisotropic thermal expansion effects would be isolated 
in the subsequent heating cycles. 
The actuation of the bilayer composite was conducted by cyclically exposing the sample 
to isothermal water-baths held at temperatures above (Thigh = 75 
o
C) and below (Tlow = 21 
o
C) the 
PCL melting transition and is portrayed in Figures 6-11 for the cross-ply(0) and in Figure 6-12 
cross-ply(45) samples. Following an initial exposure to heat (> PCL Tm, the cross-ply sample 
began to bend in the direction opposite that which occurred during cutting of the specimens as 
described in reference to Figure 6-9 above. In particular, heating caused curling toward the 
longitudinally oriented layer. Then, upon cooling to room temperature, the sample cooled away 
the longitudinally oriented layer.  Successive actuation cycles advanced with the sample quickly 
bending in the inverted, as-cut shape upon re-immersion in a hot bath (> PCL Tm), and returning 
to the mechanically programmed shape at room temperature. In each cycle, the sample curled 
toward the longitudinal layer upon heating and in the opposite direction – toward the 
perpendicular layer upon cooling.  
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Reversible twisting was observed during thermal cycling of the cross-ply(45) sample. 
The sample began the cycle with an as-cut inverted left-handed (flattened) twist at room 
temperature that reversed in its twisting sense to an right-handed twisted ribbon after one cycle 
of heat heating (> PCL Tm) and cooling back to room temperature. Thereafter, this shape 
remained the equilibrium, “return” shape at room temperature. Actuation proceeded by the 
sample reversibly twisting between a right-handed ribbon in hot water (> PCL Tm), and the left-
handed ribbon (as mechanically programmed) upon cooling to room temperature. Both the cross-
ply(0) and cross-ply (45) were observed to reversibly actuate for at least 10 consecutive cycles, 
which was counted as beginning after the initial heat exposure (Cycle 0), which was distinct 
from all subsequent cycles. The radius of curvature was measured for the cross-ply sample for 10 
cycles and is summarized in Figure 6-13, where no significant loss of shape was observed by the 
tenth cycle, although more repetitions should be conducted. The reversible twisting was not 
quantified due to technical limitations related to characterizing the complex shapes formed. 
6.5 Discussion 
In this chapter, we systematically altered the microstructure of an epoxy/PCL bilayer 
composite to influence the shape change outcome. The newly generated shapes were investigated 
and their dependences on the introduced strain and relative fiber orientations between laminae 
were studied. Additionally, an apparently new  mechanical actuation mechanism for reversible 
curling and twisting of strips was discovered and characterized in a proof-of-concept manner. 
To introduce anisotropy into a reinforced shape memory composite aligned electrospun 
PCL fibers were embedded within a crosslinked epoxy matrix. Two fiber mats were layered with 
orthogonal orientations between the plies prior to infiltration with the epoxy monomer. This 
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yielded bilayer composites with anisotropic properties in each layer and orientational 
orthogonality through the thickness. Further, variation in the principle axis of a parallelepiped 
strip and the orientation directions was accomplished. By assembling fibrous preforms before 
epoxy infiltration (rather than assembling plies already infiltrated with epoxy) use of an adhesive 
tie layer between the two laminae was obviated. This, in turn, prevented delamination and 
preserved pristine shape changing mechanics unaltered by the intervening layer. The angle 
formed between the fiber direction of the top and bottom fiber layers was systematically varied. 
The crosslinked epoxy was customized to target a glass transition temperature between room 
temperature and the PCL melting transition by adjusting the weight fractions of the reactants 
according to the Gordon-Taylor equation previously used to fit data for the same system, similar 
to prior work studied within the Mather research group.
22
 We hypothesized that positioning the 
glass transition within this range would enable typical temporary shape fixing of the composite, 
while the mechanically programmed shape remained dormant. The resulting thermal properties 
revealed distinctly separate thermal transitions without overlap of the thermal regimes.  
The mechanical shape programming of the epoxy/PCL composite was the result of a 
mismatched alignment of oriented laminae constructed in a cross-ply arrangement relative to the 
long dimension of the a rectangular sample strip, where an external tensile mechanical stress was 
directed parallel to the long dimension. The phenomena of introducing mismatched strain into e 
bending or wrinkling is well known
.26 
This mismatching was maximal for the cross-ply(0) and 
triggered under a temperature change, where differences in the coefficient of thermal expansion 
(CTE) led to reversible bending or twisting of the composite. By introducing a uniaxial stress 
into two or more mismatched layers restricted by each other, residual stresses are introduced in 
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the layers that are then relieved by morphing into non-flat, 3D structures.
27 
Possessing this shape 
change provides an advantage over previous approaches in that it broadens the applicability to 
include on-demand usability.  
Unlike other anisotropic bilayer systems, the mechanical shape change in the PCL/epoxy 
composite remained dormant until thermally triggered and was also capable of retaining an 
arbitrary temporary shape until such activation, in part due to its inherent triple shape memory 
property.
22
 A temporary shape was established by first melting the fibrous phase and uniaxially 
straining the composite. Subsequent slow recrystallization of the fibers while maintaining the 
epoxy above its Tg was then followed by room temperature vitrification of the matrix to stabilize 
the fixed shape. In this temporary fixed state, the crystallized PCL fibers and vitrified epoxy 
(mainly the latter) maintained an arbitrary temporary shape, which was an elongated strip in this 
study; however, unlike traditional shape memory, internal directional stresses were stored in the 
composite as a result of the orthogonal anisotropy between the laminae. A mechanically 
programmed bend was then activated by thermally triggering the epoxy phase at a temperature 
between Tg and Tm in order to maintain the crystallized form of PCL. By doing so, we postulated 
that the compliant state of the epoxy, which was the abundant weight fraction of the composite, 
permitted relief of the internal stresses by allowing a curl to form preferentially toward the layer 
containing fibers perpendicular to the long axis. We surmised that this fiber arrangement caused 
local shrinkage of the epoxy near the fibers on the inside of the bend, through biased recovery of 
the epoxy strain, and that the outer surface exerted tensile strain. The extent of this bending was 
found to depend on the magnitude of strain imposed during temporary shape fixing, as 
manifested in the radius of curvature, where increasing the strain increased the curvature. Upon 
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further heating to temperature above both the epoxy Tg and fiber Tm, the sample recovered back 
to its original flat 2D shape and length, as was expected of a shape memory polymer.  
In addition to the bending behavior of the composite, mechanical programming of a twist 
was also achieved. Twisting of the bilayer composite was the result of orienting the cross-ply 
fiber arrangement 45 relative to the long axis of the sample. The twist shape was mechanically 
programmed in the same manner described above for the bend shape, and remained dormant 
until heat exposure. Upon thermal activation, the top and bottom lamellar residual stresses were 
relieved in opposing orthogonal directions, thus forming a twist.
28
 Additional angles were also 
investigated (Figure 6-6), where an angle between the 90 and 45 relative to the long axis of the 
sample showed an evolving shape hybrid of a bend and twist, revealing the potential for other 
complex shapes such as helices or combinations of bends and twists, which will be further 
studied in the future. Although not investigated in this study, we surmised that the handedness of 
the twist can be switched by mirroring the cutting angle of the cross-ply relative to the sample 
dimensions. 
The reversible actuation behavior of the mechanically programmed geometries was 
achieved by incorporating additional internal stresses into the anisotropic bilayer composite 
during fabrication. More specifically, external compressive forces, as defined by CF (Eqn. 6-1), 
were imposed on the fibrous laminae by increasing the clamping force used to construct the 
composite (Scheme 6-4). A slip condition between the PCL fiber/epoxy monomer liquid 
assembly and the mold surfaces was evident, facilitating stretching of the PCL fibers while the 
assembly was squeezed and prior to the crosslinking reaction. Furthermore, we postulated that 
the residual stresses incurred during the epoxy crosslinking reaction likely contributed to 
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additional compression at the fiber interface due to chemical shrinkage.
29
 We hypothesized that 
the epoxy CTE was greater in the direction orthogonal to the PCL fibers, with no strong 
dependence on PCL melting or crystallization. These combined effects on the fibrous phase 
promoted the internal stresses that served to further strain and align the percolating channels 
occupied by the fibers within the epoxy matrix. Consequently, the restricted geometry of these 
channels  likely supported the crystal orientation recovery, and may even serve as a template for 
oriented recrystallization during thermal cycling.
30
 Moreover, it has been reported in the 
literature that polymer crystal nucleation tends to proceed parallel to the surface of the substrate, 
which would be the strained anisotropic channels, in our case.
31
 We attributed the cyclic melting 
and cooling of the PCL crystalline domains within the anisotropic channels as driving the 
actuation, where upon melting of the PCL crystals, directional contraction occurred, whereas 
during cooling, the confined recrystallization induced anisotropic expansion. This 
recrystallization within conflicting pathways among the bilayers led to reversible restoration of 
the mechanically programmed bend or twist observed in the non-actuating samples above.  
The concept of reversible actuation directed by anisotropic crystallizable domains was 
previously investigated by Behl et al. in semicrystalline copolymers exhibiting very broad 
melting transitions (~Tm over 65 C);
32
 however, in contrast to our system, the actuation in 
those copolymers was controlled by polymer chain expansion during melting and contraction 
during crystallization. Bothe et al., on the other hand, developed a polyurethane elastomer that 
exhibited this very phenomena in the crystalline domains, which was applied to thermally 
triggered actuation.
33 
That system, however, was limited to simple bidirectional shape change 
and required thermomechanical training of the polymer before actuation can be stimulated. Other 
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examples using this type of driving mechanism use shape memory materials that are also limited 
to simpler shape changes.
34
 Unlike other systems, the PCL used in this composite was not 
crosslinked,
35
 and complete melting of the fibrous phase was established through exposure well 
above Tm. This provision further confirmed that partial melting was not driving actuation as had 
been observed in other crystallizable thermosets exhibiting reversible actuation.
36
 The reversible 
actuation for the PCL/epoxy composite was found to proceed over multiple cycles without 
diminishing curvature and appeared to be limited by the elected the number of testing cycles 
(Figure 6-12). Additional studies on the crystalline morphologies and actuation properties 
should be investigated in future work. 
6.6 Conclusions 
 In this work, mechanically programmable 3D shapes were produced by introducing 
anisotropy into an epoxy/PCL bilayer composite. These mechanically programmed shapes 
remained dormant until thermally triggered. The prominence of these shapes depended on the 
magnitude of the imposed strain used to program these shapes. We also demonstrated reversible 
thermal actuation of the composite between its equilibrium and mechanically programmed 
shapes around the PCL melting transition. This actuation behavior was activated upon the 
increase of stored stresses of the fibrous phase imparted during composite fabrication. We 
hypothesized that this actuation was driven by the melt-induced expansion and oriented 
recrystallization generated contraction of the PCL crystalline domains within the composite. 
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Scheme  6-1.  The chemical structures of the epoxy components and PCL used to fabricate the 
PCL/epoxy composite. 
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Scheme 6-2.  Fabrication of the bilayer anisotropic epoxy-PCL composite by (A) first 
electrospinning aligned PCL fibers followed by (B) infiltration of aligned PCL fiber mats in the 
cross-ply(0) orientation. 
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Scheme  6-3. Method for controlling clamping force by varying the spacer thickness during 
epoxy/PCL composite fabrication. 
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Scheme 6-4. Various cutting angles (top row) of rectangular samples (bottom row) used to 
mechanically program 3D shapes. The blue lines correspond to the fiber direction of the top layer 
and the red lines were maintained on the bottom layer.  
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Figure 6-1. Representative SEM micrographs of the (A) aligned electrospun PCL fibers, (B) 
PCL/epoxy composite surface, (C) cross-section of the single-ply composite with fibers aligned 
longitudinally (0 to long dimension), (D) cross-section of the single-ply composite with fibers 
aligned perpendicular (90 to long dimension), and (E) cross-section of the cross-ply(0) bilayer 
composite. The micrographs in (B) – (E) were visualized following removal of the PCL phase. 
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Figure 6-2.   DSC thermograms of (A) the crosslinked epoxy using different relative weight 
fractions of DGEBA and NDGE, and (B) the PCL/epoxy composite and its individual 
components. 
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Table 6-1.  Thermal transitions of the different crosslinked epoxy formulations, the epoxy/PCL 
composite and the electrospun PCL component. All measurements were taken from the second 
heating cycle. NM denotes not measured and N/A means not applicable. 
 
Formulation Target T
g
 (C) T
g
 (C)  T
m
 (C) 
D55N45D230 45 38.2 N/A 
D48N52D230 40 31.9 N/A 
D41N59D230 35 27.2 N/A 
D41N59D230_PCL (Cross-ply(0)) 35 27.9 55.7 
Electrospun PCL N/A NM 56.1 
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Figure 6-3.  Thermomechanical characterization of the D41N59D230 epoxy/PCL cross-ply(0) 
composite fabricated using a compression factor of 1.1 showing (A) the storage modulus and (B) 
the loss modulus and tan delta. 
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Figure 6-4.  Triple shape memory quantification of the epoxy/PCL composite (A) single-ply 
with fibers oriented parallel to the uniaxial strain (0), (B) single-ply with fibers oriented 
perpendicular to the uniaxial strain (90), and (C) the cross-ply(0) bilayer composite. The 
annotations denote the first fixed shape (F1), second fixed shape (F2) and the recovered shape 
(R). 
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Table 6-2.  Fixing and recovery ratios for the triple shape memory quantification of the 
epoxy/PCL composite as single-ply with fibers oriented parallel to the uniaxial strain (0) or  
perpendicular to the uniaxial strain (90), and the cross-ply(0) bilayer composite. 
 
 
Sample Rf,1 (%) Rf,2 (%) Rr (%) 
0 Fiber Alignment (Single-ply) 99.8 99.6 79.0 
90 Fiber Alignment (Single-ply) 90.8 97.1 87.4 
Cross-ply(0)  (Bilayer) 92.8 95.6 87.8 
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Figure 6-5.  Example of mechanical shape programming sequence with shape recovery (shown 
for the cross-ply(0) composite)., where 0 refers to the layer containing longitudinally oriented 
fibers. 
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Figure 6-6. Various fiber orientations between the top and bottom fibrous phases within the 
composite and resulting shapes. (Row A) original shape with fiber orientation depiction (blue = 
top layer/red = bottom layer) (Row B) and original shapes (Row C) temporary fixed shape 
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Figure 6-7. Effect of strain during mechanical shape programming on the cross-ply(0) 
composite. 
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Figure 6-8. DSC thermograms for epoxy/PCL cross-ply(0) composites fabricated using different 
compression factors. 
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Table 6-3. Thermal characterizations for epoxy/PCL composites fabricated using different 
compression factors. NM denotes not measured and N/A means not applicable. 
 
Compression Factor Tg (C) Tm (C) H (J/g) Amount of PCL (%) 
0.29 27.8 55.6 1.8 4% 
1.12 27.9 55.7 7.6 15% 
2.60 29.5 55.7 13.7 28% 
Epoxy 27.1 N/A N/A N/A 
PCL Fibers NM 56.1 49.7 100% 
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Figure 6-9.  Upon increasing the compression factor (CF) of the fiber mats within the 
composites, the samples begin to immediately change shape when strips are cut from the parent 
composite batch. The fiber orientation is depicted such that the blue vertical lines are the top 
layer and the red horizontal lines indicate the bottom layer)  
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Figure 6-10. Stress-free strain of single-ply oriented epoxy/PCL composites in response to 
heating and cooling for fiber alignment oriented (A) longitudinal and (B) perpendicular to the 
long axis. 
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Figure 6-11. Actuation behavior of the epoxy/PCL bilayer composites upon thermal cycling with 
the cross-ply(0) sample showing the (A) testing set-up and (B) magnification of the samples 
during actuation. 
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Figure 6-12. Actuation behavior of the epoxy/PCL bilayer composites upon thermal cycling with 
the cross-ply(45) sample showing the (A) testing set-up and (B) magnification of the samples 
during actuation. 
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Figure 6-13. (A) Curvature of the cross-ply(0) bilayer epoxy/PCL composite after 10 
consecutive actuation cycles for the shape at room temperature (cooled) and the shape upon 
heating. (B) Representative photos of the shape change under cooling (left column) and heating 
(right column) conditions. The curvature of the heated activated shape was opposite to that of the 
cooled shape, as indicated by the negative curvature value. 
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Chapter 7   
Conclusions & Future Work 
 
7.1 Overall Conclusions  
 This dissertation examined the design, development and characterization of electrospun 
shape memory polymeric composites with tailorable properties for various applications. Several 
features were designed into these composites including one way shape memory, controlled drug 
delivery, reconfigurable shape memory, degradation, latent mechanical programming and 
reversible actuation.  
 In Chapters 2 and 3, a drug molecule was combined with PCL and then electrospun into 
fibers that were then embedded within a PDMS matrix. The in vitro controlled release 
characteristics of two different hydrophilic drugs in PBS under physiological conditions were 
investigated. In both chapters, the addition of the PDMS elastomer served to control the initial 
burst release as well as extend and improve overall drug release. Chapter 2 demonstrated 
controlled release of a hydrophilic model drug, Rhodamine B, and it was ascertained that the 
crystallinity of the fibers had a greater effect on the drug release than did the size of the fibers, 
such that the crystallization mechanism guided drug release. We attributed this behavior to phase 
separation of the hydrophilic drug within the hydrophobic PCL fiber that either expelled the drug 
to the fiber surface during fiber formation or toward the fiber core during post-electrospinning 
crystallization. Furthermore, we postulated that the addition of the PDMS elastomer displaced air 
occupying the voids within the fiber mats, thus enabling further release of buried drug due to 
additional aqueous contact with the fibers. The tensile mechanical properties of this composite 
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demonstrated usefulness for soft material applications owing to its elasticity, low modulus, and 
multi-stage load bearing response typically associated with native soft tissues. 
 Encouraged by the results in Chapter 2, the work in Chapter 3 extended the 
development of the PCL/PDMS composite for use as a small diameter synthetic vascular graft. A 
nitric oxide (NO) releasing donor compound was added to the PCL fibrous phase and controlled 
release of NO was demonstrated for over ten weeks. Here, it was observed that increasing the 
concentration of the hydrophilic NO donor molecule reduced drug release on a percentage basis, 
which we attributed to the phase separation effect between the drug and the PCL fiber carrier. 
This composite exhibited good suture retention characteristics that were comparable to native 
blood vessels, and a burst pressure strength that exceeded commercially available options. The 
NO-releasing composite also demonstrated good cytotoxicity when using a reduced 
concentration of the tin catalyst employed to crosslink the PDMS matrix, with no impact on the 
tensile mechanical properties. The addition of the NO donor compound counteracted both the 
catalytic activity and cell toxicity caused by the catalyst. The NO-releasing composite also 
promoted significant endothelial cell migration, which was revealed using an in vitro chemotaxis 
assay. We expect that this composite material is a good candidate for blood vessel prosthetics 
such as AV or bypass grafts where long term mechanical and anti-thrombogenic properties are 
desired. 
 In Chapter 4, a new shape memory composite was developed by substituting the PDMS 
component with a crosslinked PAH to make a fully degradable and biocompatible composite. 
We determined that coupling these materials in this manner gave rise to reconfigurable shape 
memory such that the original shape can be permanently altered due to dynamic covalent 
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exchange between the anhydride groups. The use of a PCL thermoplastic urethane enabled one 
way shape memory to be implemented without interference with the permanent reconfiguration 
programming, owing to its relatively low melting point. Additionally, since shape memory 
occurs at physiological temperatures, the potential exists for many biomedical applications such 
as degradable implants with deploying mechanisms, self-healing applications, and dynamic 
surfaces for tissue engineering. 
 The degradation properties of the reconfigurable composite developed in Chapter 4 were 
explored in Chapter 5, where two different electrospun fiber compositions were separately 
embedded in crosslinked PAH. The degradation of the polyanhydride matrix was dependent on 
the composition of the fibrous phase, where erosion proceeded more rapidly when the composite 
contained the more hydrophobic PCL fibers compared to hygroscopic, amorphous PVAc, since 
PVAc competed with the degrading PAH for water. The presence of a fibrous structure 
infiltrating through the PAH film altered the erosion dynamics from heterogeneous to 
homogenous. PAH continued to remain on the fibers as a protective sheath for both composite 
compositions. It was determined that the PVAc fibers were plasticized by the PAH, which 
remained in the fibers, and this resulted in prolonged degradation and enhanced the duration of 
sustained drug delivery of hydrophilic model drug Rhodamine B. The drug releasing properties 
of this composite would be advantageous for infection management following surgical 
intervention or minimizing thrombosis on the surface of an implant. This composite possesses 
tailorable degradation, reconfigurable shape memory, controlled drug release, and long-term 
shape retention and can thus provide an enabling technology with broad biomedical applications 
such as smart implants and tissue engineering scaffolds. 
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 Lastly, in Chapter 6, mechanically programmable 3D shapes were produced by 
introducing anisotropy into an epoxy/PCL bilayer composite. These mechanically programmed 
shapes remained dormant until thermally triggered. The distinction of these shapes depended on 
increasing the magnitude of the imposed strain used to program these shapes. Reversible thermal 
actuation of the composite was also demonstrated between its equilibrium and mechanically 
programmed shapes around the PCL melting transition. This actuation behavior was activated 
upon the increase of stored stresses of the fibrous phase imparted during composite fabrication. 
We hypothesized that this actuation was driven by the melt-induced expansion and oriented 
recrystallization-generated contraction of the PCL crystalline domains within the composite. The 
new composite materials can have broad applications in artificial muscles, hinges, sensors, and 
robotics. 
7.2 Future Directions  
7.2.1 Shape Memory Elastomeric Composite with Controlled Drug Release of a Hydrophilic 
Drug Model 
 The drug releasing SMEC system developed and characterized in Chapter 2 focused 
only on release of a hydrophilic model drug. This particular composite system lends itself well to 
studying other types of drug molecules by mixing with PCL prior to electrospinning. The drug 
releasing capabilities of this composite can be expanded to include release of other water-soluble 
drugs with varying hydrophilicities such as acetaminophen, an anti-inflammatory agent. 
Additional work can also be conducted using hydrophobic drugs such as dexamethasone and 
ketoprofen, both of which are useful anti-inflammatory agents. Even more interesting would be 
the ability to release two drugs, each with independent release. This can be achieved by co-
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spinning two PCL solutions, each containing a different drug followed by imbibing with the 
siloxane matrix. This approach would promote controlled mixing of the drug populations and 
even mediate gradient concentrations through the fiber mat cross-section. For example, a 
combination of two anticancer drugs, doxorubicin hydrochloride and paclitaxel can provide an 
enhanced therapeutic effect.
1
 We anticipate slower or more incomplete release of hydrophobic 
drugs in the PCL/PDMS composite due to the greater solubility between the drug and the 
composite materials. To account for this, the hydrophilicity of the fibrous phase can be adjusted 
by substituting with electrospun PCL copolymerized with poly(ethylene glycol) (PEG) and a 
chain extender to create a PCL-PEG multi-block copolymer thermoplastic polyurethane (TPU). 
This TPU has been previously developed in the Mather Research group for shape memory.
2
 PEG 
is a widely studied hydrophilic biocompatible polymer that can be used to conduct a series of 
PCL-PEG compositions with gradually increasing PEG content until a desired drug release rate 
is reached. Considering that PEG is also crystalline, competing crystallization patterns between 
PCL and PEG may yield interesting interactions with the encapsulated drug than was reported in 
Chapter 2. Furthermore, more than one fibrous composition can be co-spun such that 
differences in hydrophobicity would gate drug release such that in the case of a single drug, one 
polymer can provide immediate drug release while the other can engage in late stage drug 
release. 
 Alternatively, co-spinning of PCL with Pellethane 5863−80A (Lubrizol), an aromatic 
polyether thermoplastic polyurethane elastomer could allow for a variety of drug releasing 
options. This SMEC was previously developed for its shape memory properties, however, drug 
release was not studied.
3
 Here, Pellethane would replace PCL as the fibrous phase while 
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electrospun PCL would become the matrix following hot pressing the fiber mat above the PCL 
melting transition. Some initial work was conducted that supported the feasibility of this system, 
as shown in Figure 7-1, where controlled release of RhB was observed. Additional work is 
required to study the weight fraction, microstructural and morphological effects of this 
composite composition in comparison to the PDMS-based one. Pellethane was determined to 
absorb considerably more water than PDMS, as shown in Figure 7-2. As such, we expect that 
RhB release would be quicker; however, the crystalline PCL matrix could counter that quicker 
release by providing a physical barrier to water uptake to the Pellethane channels due to its poor 
water absorption properties. In a separate study, the drug can be added to the Pellethane phase 
rather than the PCL matrix. Additionally, another way to combine Pellethane with PCL would be 
by coaxial electrospinning of these polymers, which to our knowledge, has not been done before. 
In this arrangement, PCL can contain RhB and serve as the core that is encapsulated in a 
Pellethane sheath, rather than in a non-porous matrix. Beyond drug release, this composite 
morphology can potentially lead to interesting mechanically properties since it would retain a 
fully fibrous format and thus be a good candidate for tissue engineering applications.  
7.2.2 Nitric Oxide Releasing Shape Memory Elastomeric Composite for Vascular Graft 
Applications 
 The application of the drug release SMEC system in Chapter 2 was also studied specific 
to vascular graft development. As suggested in Section 7.2.1, dual spinning of an additional 
fibrous population containing another drug can yield some useful effects. Specific to this 
endeavor, other drugs shown to aid in preventing thrombosis such as heparin or an antiplatelet 
agent such as aspirin can be electrospun in combination with electrospun DETA-NO/PCL or 
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similar material to extend drug release benefits. Aspirin has been studied for this application in 
combination with electrospun PCL and demonstrated a promising reduction in  platelet adhesion, 
however, the effect was short term of up to ~ 2 d.
4
 Additional application specific evaluations 
could be considered for the DETA-NO/PCL/PDMS composite such as hemocompatibility 
assessment. An initial study was conducted in collaboration with Dr. Eric Finkelstein and REU 
student Emily Mihalko. PCL/PDMS samples both with and without DETA-NO were placed in 
contact with whole human blood and the clotting time and hemolysis assays were evaluated 
according to established protocols.
5
 Figure 7-3 reveals promising results, where the NO 
releasing samples showed a slight reduction in clotting compared to the control groups. This 
work can be expanded by adjusting the DETA-NO concentration and conducting a platelet 
adhesion assay according to methods prescribed in the literature.
6,7
 Lastly, further optimization 
of the in vitro chemotaxis study in Chapter 3, can be conducted utilizing a co-culture of both the 
smooth muscle cells and endothelial cells to better simulate in vivo conditions and capture any 
synergistic effects between the two cell populations and NO releasing materials. Also, 
considering that NO is a natural antimicrobial, the antimicrobial activity of the NO-releasing 
PCL/PDMS composites can be studied to assess the infection resistant potential of this 
composite.
8
 
7.2.3 Anhydride-Based Reconfigurable Shape Memory Elastomeric Composite 
The results in Chapter 4 indicated that the reconfigurable nature of the PAH anhydride 
groups may be exploited for developing re-moldable thermoset materials and self-healing of 
cracks or fractures through heating of select PAH surfaces. Figure 7-4A shows the potential of 
remolding crosslinked PAH cubical pellets into a larger object. This was accomplished by 
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applying a force and heat above the reconfiguration temperature in a mold substrate. Additional 
work to further this concept would include optimizing the molding process to improve the 
moldability of small features as well as characterization of the material properties following 
molding. Similarly, in Figure 7-4B, the PAH/PCL Re-SMEC exhibited similar abilities, with the 
ability to be recycled following grinding into a film. The resulting morphology would no longer 
contain percolating fibers. The newly blended, molded material morphology would need to be 
investigated alongside the post-molding mechanical and shape memory properties. The effect of 
the volume fraction of PCL should be determined, where it is anticipated that an upper limit 
could be reached such that the presence of PCL may interfere with shape memory if the PAH 
continuity through the sample volume is significantly disrupted. Figure 7-5 further shows 
healing potential of a composite containing PAH, where two fragmented pieces of the PCL/PAH 
composite are repaired following coupling of the pieces under pressure and heat. The reverse 
plasticity shape memory should be quantified and optimized by varying the relative fractions of 
the composite constituents or composition of the fibrous phase. Additionally, the shape memory 
of an embossed surface can be studied to determine the minimum resolution and its dependence 
on the PAH fraction in the composite. The degradability of an embossed feature in the surface 
may be useful for studying cell-material interactions under dynamic surfaces or even altered drug 
releasing properties through the increased macroscopic surface areas. 
7.2.4 Biodegradable Shape Memory Elastomeric Composites with Controlled Model Drug 
Release of a Model Drug 
Additional degradation work can be conducted to complete the degradation of the 
PCL/PAH composite through enzymatic degradation of PCL, which would also liberate any 
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remaining drug molecules. The substitution of Pellethane as the fibrous phase in combination 
with the PAH matrix could prompt a different type of shape memory effect in a fully elastomeric 
composite. Specifically, the PAH matrix can be used to fix a temporary shape through the 
thermally reconfigurable bond exchange mechanisms, while the Pellethane fibers would serve to 
remember the original/permanent shape. Shape recovery would then proceed by degradation of 
the PAH using methods described in Chapter 5. A feasibility study was conducted, in 
collaboration with Tackla S. Winston, that revealed the possibility of this type of shape memory, 
as depicted in Figure 7-6, where a rectangular strip of electrospun Pellethane imbibed by PAH 
was shaped into a curl and the original flat geometry was recovered following degradation of the 
PAH matrix. While immersed in PBS at 37 C, the curled shape unfolded back into the 
rectangular strip within 24 h, while the composite visually reverted to the original opaqueness of 
the electrospun Pellethane fiber mat. SEM of the degraded composite verified the preservation of 
the Pellethane fibrous morphology as well as the absence of the PAH matrix following a 24 h 
degradation induced shape recovery cycle. Additional work to complete this investigation 
includes quantification of a temporary shape over degradation time (i.e. radius of curvature 
evolution for a curled shape), effect of fiber volume fraction, mechanical and thermal 
characterizations as well as thermomechanical quantification of the new composite and 
controlled drug release can be explored. We also anticipate that quick drug release for a 
hydrophilic drug would occur due to the combined effects of PAH degradation and the greater 
water absorption properties for Pellethane, as described in Section 7.2.1. 
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7.2.5 Latent Mechanical Programming of a Shape Memory Composite with Reversible 
Anisotropic Actuation 
 The programmed shapes studied in Chapter 6 were fabricated using a bilayer composite 
containing a cross-ply orientation that was varied relative to the direction of mechanical strain. 
Future work can include varying the orientations of the fibers with respect to each other as well 
as combining additional anisotropic lamina for multilayer composites with a goal of producing 
latent programming of complex shapes.  Complex shapes can also result from gradient 
mechanical programming of the bilayer composites at different orientations. With the innate 
delayed shape triggering only activated by temperature, a temperature gradient can also be 
introduced such that the hotter end of a strip will express a tighter curl or twist that would 
gradually decrease in magnitude until it reaches the position below the thermal activation 
temperature. Since the epoxy/PCL composite is a tough material (Appendix A1), it has the 
potential to apply a force and manipulate an external object such as by pushing or lifting. We 
would expect the direction and range of motion to depend on the programmed shape. Figure 7-7 
demonstrates the ability of a flat strip to lift a 20 mm x 20 mm glass cover slip upon thermal 
activation into the bend shape. Further studies are needed to quantify the mass ratio limit that this 
composite can displace an object and the ability to tune that limit. Moreover, the thermally 
reversible actuation mechanisms can also be engaged to manipulate external objects. The 
development of more complex shapes as described above will also enable more complex 
actuation movement. Lastly, the shape dependence on the fiber orientations and mechanical 
programming can be modeled to predict the resulting shapes. 
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Figure 7-1. Cumulative release of RhB from PCL/Pellethane composite. RhB diffusion 
originated from the PCL matrix. 
  
Time (days)
0 2 4 6 8 10 12 14
C
u
m
u
la
ti
v
e
 R
e
le
a
s
e
 (
%
)
0
5
10
15
20
25
30
 275 
 
 
Figure 7-2. Water uptake comparison between electrospun Pellethane and crosslinked silanol-
terminated PDMS film following 24 h immersion in water. Sample size of three per group was 
used. The water uptake was calculated by dividing the difference in the mass of the wet and dried 
samples by the mass of the dried sample. 
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Figure 7-3. Results of hemolysis assay showing (A) photos of human blood clot formation over 
time comparing blood exposure to no samples (blood alone), the PCL/PDMS composite without 
drug, and the DETA-NO/PCL/PDMS composite, and (B) lysate absorbance values from the 
clotting assay. 
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Figure 7-4. Feasibility of remolding PAH-based materials following grinding. (A) A crosslinked 
PAH film is cut into small cubes that are then compression molded into a single object, and (B) 
the PAH/PCL composite is grinded and then compression molded into a film. 
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Figure 7-5. Healing potential of the PAH/PCL composite. A rectangular sample is fragmented 
into two pieces and then repaired back into a single piece following applying heat and pressure to 
the fractured surfaces under constant contact. 
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Figure 7-6. Sequence for attaining degradation-induced shape recovery for the electrospun 
Pellethane fibers imbibed in PAH composite showing: (A) original shape, (B) arbitrarily 
thermally programmed shape, (C) degradation of the newly shaped composite (D) recovery of 
the original shape following PAH matrix degradation, and (E) retention of fibrous morphology 
following degradation of the PAH matrix. 
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Figure 7-7.  Time-lapsed mechanically programmed displacement of an object by the 
anisotropic PCL/epoxy composed of oriented PCL arranged orthogonally. A rectangular strip 
was topped with a glass cover slip and placed on a hot plate at 45 C. As the mechanically 
programmed shape was thermally activated, the sample began to curl and lift the glass slide in 
under 30 s. The schematic above demonstrates the thermally activated sequence of free-standing 
object displacement by the sample shown below. 
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Appendix 1 
Properties and Ballistic Performance of Epoxy-Based  
Thermoset-Thermoplastic Composites 
 
A1.1 Background       
An epoxy/(poly(ε-caprolactone) (PCL) composite previously developed by the Mather 
research group for triple shape memory properties has the potential to provide suitable 
mechanical properties with self-healing ballistic damage.
1-3 
We contemplated that the addition of 
the more ductile, semicrystalline PCL phase to a brittle epoxy matrix may support energy 
dissipation during high strain rate impact, thus improving fracture resistance. Moreover, the 
temperature dependent moduli of this composite can be tuned through facile adjustment of the 
glass transition temperature of the epoxy phase was considered a practical utility.  We were 
interested in studying the method of integrating PCL into the epoxy matrix as it can institute 
profoundly diverse structural characteristics. Given these possibilities, we were motivated to 
study the effect of varying the microstructural properties of the epoxy/PCL composite by altering 
the formulation and fabrication scheme such as by polymerization-induced phase separation 
(PIPS) or fibrous PCL coupled with epoxy imbibing. 
A1.2 Experimental Methods 
Materials 
Poly(ε-caprolactone) (43,000 – 50,000 g·mol–1) was purchased from Polysciences. 
Jeffamine D230 was purchased from Huntsman. Diglycidyl ether of bisphenol A (DGEBA) and 
neopentyl glycol diglycidyl (NDGE), poly(propylene glycol) bis(2-aminopropyl ether) 
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(Jeffamine® 230), tetrahydrofuran (THF), and dimethylformamide (DMF) were purchased from 
Sigma Aldrich. All materials were used as received.  
 
Fabrication of Polymerization-Induced Phase Separation (PIPS) Composite 
The mass ratios of the epoxy components were calculated according to a targeted glass 
transition temperature guided by the Gordon Taylor relation and prior model-fitting for this same 
system.
2
 The Jeffamine D230 was calculated for stoichiometric equivalence of amine protons 
(four per D230 molecule) and epoxide rings (two each for DGEBA and NGDE). The PIPS 
composite was prepared by first melting DGEBA at 80 C in an isothermal oven and combined 
with NDGE and PCL in a three-neck flask. The components were then stirred using an overhead 
motorized mixer (~150 rpm) at 60 C under a nitrogen purge until a homogenous transparent 
mixture was observed. This was followed by degassing of the mixture under vacuum before 
cooling to 40 C under continuous stirring. At this stage, the Jeffamine 230 was added and 
allowed to continue stirring under vacuum until homogenous, for approximately 10 min. The 
mixture was then immediately casted in stainless steel molds (6 in. x 6 in. x 0.25 in.) previously 
treated with Frekote 55NC release agent and pre-heated to the selected cure temperature; this 
was immediately followed by degassing under vacuum. The epoxy/PCL mixture was then cured 
at either 80 C for 4 h, 90 C for 4 h, 100 C for 4 h, 130 C for 2 h, 150 C for 30 min. All 
batches were then post-cured at 120 C for 2 h followed by 150 C for 2 h. The nomenclature 
used herein to refer to the PIPS formulation is DXNYD230/PCLMWk(Z), X and Y summing to 
100. This describes the weight fraction of DGEBA relative to NDGE as DX, and NDGE as NY. 
The designation “D230” denotes the Jeffamine 230 crosslinker. The terms “MW” and “Z” denote 
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the molecular weight and wt% of PCL relative to the epoxy. For example, 
D41N59D230/PCL45k(20) refers to crosslinked epoxy synthesized using 41 wt% DGEBA, 59 
wt% NDGE and 20 wt% PCL. The chemical structures are presented in Scheme A1-1. 
 
Fabrication of Laminated Electrospun PCL/Epoxy Composite 
 PCL fibers were electrospun (Scheme A1-2A) using a customized electrospinning system 
(Spraybase®, Profector Life Sciences, Dublin, Ireland). A 35 w/v % solution was prepared by 
dissolution of PCL in THF:DMF (4:1) and then transferred to the syringe ejection system 
equipped with three emitters, each fitted with blunt 22G needle tips. The needle tips were 
adjusted to a distance of 7 cm from the receiving drum and the PCL was electrospun at a rate of 
1 ml h
-1
 onto the drum rotating at 250 rpm with an applied voltage of 6.5 kV. Following 
electrospinning, the fiber mats were dried at room temperature under vacuum overnight to 
remove any residual solvents. The dried fiber mats were then cut into two squares of 5.375 in. x 
5.375 in. and separately imbibed with an epoxy monomer mixture prepared using 55 wt % 
DGEBA, 45 wt % NDGE and stoichiometric Jeffamine D230 (described above), followed by 
exposure to vacuum at room temperature to complete infiltration of the monomer within the fiber 
mats by air removal (Scheme A1-2B). Excess monomer was manually removed from the 
surfaces and the two fiber mats were superimposed and fitted in an unheated stainless steel 
molds (6 in. x 6 in. x 0.25 in.) pre- treated with Frekote 55NC release agent. The sample was 
cured then at 40 C for 48 h (below PCL melting transition) followed by a post cure of 90 C for 
24 h.  
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Cryogenic Treatment 
 Small-scale samples for x-ray diffraction and thermal characterizations were 
cryogenically treated by exposure to -60 C for 5 min. Larger samples prepared for ballistics 
testing were cryogenically treated to induce crystallization of the PCL phase by placing in a 
freezer at -30 C, which is above the PCL glass transition temperature, for approximately 72 h.  
 
Scanning Electron Microscopy (SEM) 
 The morphology of the various formulations and cure conditions were assessed using 
SEM. All samples were sputter-coated (Denton Desk-5) with gold-palladium for 45 s using a 
current of 45 mA. A Hitachi S-4700 SEM was used to visualize the surfaces using an 
accelerating voltage of 1.0 kV. ImageJ software (version 1.46r, National Institutes of Health) 
was used to measure PCL fiber diameter. Fiber diameter measurements were determined by 
taking a minimum of 50 measurements at five different sites. The average diameter and standard 
deviation were calculated using a minimum of 250 total measurements. 
 The cross-sections of the samples were obtained by cryogenically fracturing then solvent 
removal of the PCL phase from the composite. A dogbone shaped sample was prepared and 
immersed in liquid nitrogen followed by fracturing of the narrow section. The cross-section 
surface was then treated with THF overnight to remove the PCL phase by molecular dissolution.  
 
Thermal Characterization 
 Differential scanning calorimetry (DSC) was performed using a Discovery DSC 
manufactured by TA Instruments, Inc. Samples weighing 2.5 – 4.0 mg were sealed in Tzero 
aluminum pans and heated and cooled from -60 C to 120 C at 10 C ∙ min
-1
 for each cycle. 
 
 285 
 
Thermomechanical Characterization 
 A TA Instruments Q800 dynamic mechanical analyzer (DMA) was used in the 
multifrequency strain mode to measure the storage and loss moduli and tan delta. Samples were 
cut into rectangular strips, maintaining a 5:1 ratio of length to width. All samples were first 
cooled to -60 C and held isothermally for 5 min followed by heating at 3 C min
-1
 to 100 C. 
 
X-Ray Diffraction 
 The crystalline structural properties of the composites were studied using both wide angle 
and small angle x-ray scattering (WAXS and SAXS). Wide-angle (WAXS) and small-angle 
(SAXS) x-ray scattering experiments were conducted to ascertain the molecular and nano-scale 
ordering and orientation of the various crosslinked polymeric samples. For this purpose, a 
Rigaku S-MAX3000 pinhole camera system was utilized, with a Micromax-007HF rotating 
anode source operating with Cu Kα emission (λ = 1.5406), voltage of 40 kV and current of 20 
mA. Wide-angle scattering patterns were collected at a sample-detector distance of 117 mm, as 
calibrated using corundum (NIST SRM 676a) and using Fujifilm image plates (CR HR-V) with a 
Raxia-Di Image Plate reader at a scan resolution of 100 μm. Small angle scattering patterns were 
collected at a sample-detector distance of 1525 mm, as calibrated using silver behenate, on a 2D 
Multiwire Area Detector. Exposure times were 900 s for WAXS patterns and 600 s for SAXS 
patterns. 
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Ballistics Testing 
 Ballistic testing was conducted according to a previously established protocol.
4
 The 
sample was cut into squares of 62.5 mm x 62.5 mm x 6.4 mm (total of 12 per test group) and 
clamped between two aluminum plates with a circular aperture diameter of 50.8 mm. A witness 
plate composed of aluminum foil with a 0.0108 mm thickness was placed at a distance of 50.8 
mm behind the target. A stainless steel ball bearing (Type 302) with a diameter of 5.56 mm and a 
mass of 0.69 g was discharged from a 22 caliber gas gun. The speed of the projectile was 
measured using a Doppler radar (BR-3502, Infinition, Inc.). Ballistic failure was defined as 
either when the projectile or a fraction of the sample penetrated the witness plate; therefore, 
ballistic failure can manifest without projectile penetration. The impact velocities were recorded 
and used to calculated the V50 ballistic limit, which represents the projectile velocity at which 
there is a 50 % probability for target failure. This value was calculated by taking the average of 
the top three highest passing and lowest failed impact velocities. The kinetic energy was then 
calculated from the V50 value (KE = 0.5 m 𝑉50
2 , where m is the mass of the projectile) and is 
reported.  
A1.3 Preliminary Results 
The morphological effect of increasing the PCL concentration in the PIPS blend 
composite was examined in Figure A1-1.  At PCL concentrations of 20% and below, the 
microstructure comprised of a percolating epoxy rich matrix with regularly dispersed PCL 
droplets, which appeared to generally increase in diameter as the PCL fraction was increased. 
This microstructure was substantially altered when the PCL concentration was increased to 25 
%, where the morphology of both phases became heterogeneous such that both the PCL and 
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epoxy mutually formed droplets and interconnected capillaries.  At 30 % PCL, the epoxy 
transitioned into regularly dispersed spheres embedded within a continuous PCL matrix.  
A cure study was conducted by varying the initial curing profile and maintaining the 
same post-cure conditions and formulation (D55N45D230/PCL45k(20)). The resulting PIPS 
composites exhibited increasing optical clarity as the cure temperature was increased, with 
apparent translucence occurring for cure temperatures of 100 C to 150 C (Figure A1-2).  Cure 
temperatures greater than 150 C resulted in visual degradation of the samples and were not 
studied further. This change in opacity was accompanied by a shift in morphology shown in 
Figure A1-3, from a distinct two phase microstructure containing spherical particles, which then 
appeared to coalesce when the cure temperature was increased to 100 C and above. At higher 
cure temperatures, the morphology was smooth and homogenous, with no clear difference 
between curing at 130 C and 150 C. This was suggestive of PCL arrest in the amorphous state 
during higher epoxy crosslinking temperatures.  This postulation was further supported by the 
thermal analyses in Figure A1-4, where PCL was markedly more crystalline for the cooler 
curing conditions below 100 C; this microstructural state persisted even pursuant to a second 
heating cycle (FigureA1-4C), where the melting endotherm was substantially smaller and 
broader for the amorphous PCL, asserting that PCL may be suppressed from fully recrystallizing. 
Consequently, we hypothesized that a more aggressive crystallization protocol would enable 
PCL recrystallization and initiate nanoscale domains for high performance impact protection. A 
cure temperature of 130 C was thus selected for further study due its ease of fabrication and 
reproducibility, with no significant difference in properties compared to the composite cured at 
higher temperatures. Figure A1-5 summarizes the thermomechanical analyses, exposing that the 
 288 
glass transition temperature decreased as the curing temperature was increased. The target Tg was 
45 C, which was attained using the original cure profile (80 C). We attributed this 
plasticization effect to the highly dispersed PCL within the epoxy matrix, which while in an  
amorphous state, mediated greater epoxy chain mobility. 
Cryogenically treating the D55N45D230/PCL45k(20) PIPS samples cured at 130 C 
corroborated our hypothesis when a significant increase in crystallization materialized, as 
revealed by the DSC thermograms in Figures A1-6 and A1-7. This observation demonstrated 
high reproducibility across several synthesis batches. A comparison of the samples by WAXS 
(Figure A1-8) verified the amorphous nature of PCL at greater curing temperatures which then 
became more crystalline following cryogenic exposure by observing that the ring pattern 
becomes sharper and additional peaks are liberated in the scattering profile (Figure A1-9). The 
SAXS data in Figures A1-10 and A1-11 similarly confirm these elucidations, indicating long 
range order of the cryogenically induced PCL lamellae formation. 
The ballistic performance presented in Figures A1-12 and A1-13 was significantly 
improved by the addition of PCL to the epoxy matrix, in comparison to the neat epoxy, which 
resulted in complete penetration of the projectile with radial cracks. A comparison of the 
epoxy/PCL PIPS compositions showed that increasing glass transition, by addition of the 
aromatic diepoxide (DGEBA), aided in withstanding greater impact; however, this gain in KE50 
was also made by simply curing the composite at a higher temperature. Interestingly, these 
higher cure samples had a tendency to capture the projectile without crack initiation. The highest 
KE50 value (V50 of 293 m s
-1
) of this series was attained by the cryogenically treated, high cure 
sample, though this provided only a marginal improvement beyond the untreated samples. 
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Further investigation is warranted to gain additional insight into the fraction mechanism 
differences relative to the microstructural properties observed in this work. 
Lastly, a fiber reinforced epoxy matrix was prepared by combining two layers of 
electrospun non-woven PCL fibers within the crosslinked epoxy. The electrospun PCL fibers 
were randomly oriented with an average fiber diameter of 2.4 μm ± 0.8 μm (Figure A1-14) and a 
resulting thickness of ~ 2.8 mm. Preliminary ballistics testing conducted on a limited number of 
samples revealed complete penetration of the projectile with radial cracking and fragmental 
delamination between the fiber mats (Figure A1-15); we postulated that this failure was likely 
due to entrapped air pockets between laminae, which can be improved through optimization of 
the fabrication process. The estimated KE50 value was 16 kg m
2
 s
-2
 (based on a V50 ~ 215 m s
-1
), 
though more trials were needed to support this calculation. These results were a slight 
improvement over the neat epoxy samples, though not as resilient as those prepared by PIPS.  
A1.4 Conclusions & Future Directions 
 
In this work, the effect of the microstructural properties of an epoxy/PCL composite on 
ballistic performance was investigated. Increasing the weight fraction of PCL in the PIPS blend 
was shown to impart significant morphological changes. We determined that increasing the 
temperature of the cure of this epoxy/PCL PIPS composite affected optical clarity and 
considerably inhibited the formation of crystalline domains, while also having a plasticizing 
effect.  The addition of PCL to the crosslinked epoxy significantly improved ballistic 
performance, where samples formulated with a greater glass transition temperature, and those 
processed with highly dispersed PCL cryogenically induced crystallized domains showing 
greatest improvements. The ballistic results for electrospun PCL imbibed within crosslinked 
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epoxy were not as satisfactory as the blended samples; however, additional process optimization 
is merited. The thermally triggered self-healing of the blends can be studied to ensure 
preservation of mechanical properties following impact by a ballistics projectile. The cure effect 
described here can also be investigated for other PIPS formulations, with determination of 
rheological constraints. Transmission electron microscopy can be employed to examine the 
morphological transitions affected by curing parameters in greater detail. Finally, 
characterization of the mechanical properties such as tensile stress-strain and fracture toughness 
can be conducted. 
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Scheme A1-1.  Chemical structures used to synthesize epoxy-PCL composites. 
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Scheme A1-2.  (A) Electrospinning of PCL and (B) subsequent preparation of epoxy imbibed 
laminated PCL fiber mats . 
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Figure A1-1. Microstructure of varying PCL concentration in D
62
N
38
D230/PCL45k as revealed 
by SEM of both (A) as fabricated and (B) post-etching of PCL, for (i) 10 %, (ii) 15 %, (iii) 
20  %, (iv) 25 %, (v) 30 %. The scale bar represents 5 μm. 
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Figure A1-2. Photographs of cure temperature effect on appearance of D55N45D230/PCL45k(20)  
for an initial cure temperature  of (A) 80 °C, (B) 90 °C, (C) 100 °C, (D) 130 °C.   
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Figure A1-3. Microstructure of D
55
N
45
D230/PCL45k(20) cross-sections as revealed using SEM 
for initial cure temperature  of: (A) 80 °C, (Bi) 90 °C, (C) 100 °C, (D) 130 °C, (E) 150 °C . The 
scale bar represents 50 μm. 
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Figure A1-4. DSC characterization of D55N45D230/PCL45k(20) at various cure temperatures 
demonstrating that PCL becomes more amorphous with increased cure temperature for the (A) 
first cool, (B) first heat, (iii) second heat cycles. 
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Figure A1-5. DMA characterization of D55N45D230/PCL45k(20) showing (A) the storage 
moduli, (B) loss moduli at various cure temperatures. The plot is (C) shows that the glass 
transition temperature decreased with increased cure temperature.  
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Figure A1-6. DSC first and second heat characterizations of D55N45D230/PCL45k(20) (A) 
before and (B) after cryogenic treatment and demonstrating reproducibility across synthesis 
batches. 
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Figure A1-7. DSC first cooling characterizations of D55N45D230/PCL45k(20) (A) before and 
(B) after cryogenic treatment and demonstrating reproducibility across synthesis batches. 
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Figure A1-8. Microstructure of D
55
N
45
D230/PCL45k(20) as revealed using WAXS for the 
composite (A) as-cured and (B) cryogenically treated, for an initial cure temperature of: (i) 80 
°C, (ii) 90 °C, (iii) 100 °C, (iv) 130 °C, (v) 150 °C.   
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Figure A1-9. WAXS diffractograms revealing crystalline peaks for the 
D55N45D230/PCL45k(20) the composite comparing both as-cured (black trace) and cryogenically 
treated (red trace), for an initial cure temperature of: (i) 80 °C, (ii) 90 °C, (iii) 100 °C, (iv) 130 
°C, (v) 150 °C.   
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Figure A1-10. Effect of post-cure cryogenic treatment of D
55
N
45
D230/PCL45k(20) as revealed 
using SAXS for the composite (A) as-cured and (B) cryogenically treated, for an initial cure 
temperature of: (i) 80 °C, (ii) 130 °C.   
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Figure A1-11. WAXS diffractograms comparing crystalline peaks for the 
D
55
N
45
D230/PCL45k(20) before and after cryogenically treatment. 
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Figure A1-12. Ballistic results of the D
55
N
45
D230 D
62
N
38
D230 formulations synthesized with 
and without 20 % PCL at two different cure temperatures. The cryogenically treated sample is 
also included for comparison.  
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Figure A1-13. Photographs following ballistic testing of D55N45D230/PCL45k(20) for cure at 
(A) at 130 °C, (B) 130 °C post-cryo, (C) 80 °C, and (D) untreated neat epoxy, cured at 80 °C. 
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Figure A1-14. SEM micrograph of  (A) electrospun PCL45k and (B) resulting fiber diameter 
distribution. 
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Figure A1-15. Photographs following ballistic testing of laminated epoxy/PCL composites 
prepared using electrospun PCL fibers for the same sample group with the reverse side of the top 
row shown in the bottom row. 
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